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ABSTRACT
CYP3A4 is usually the major cytochrome P450 enzyme in adult human liver. It is 
known to metabolise a wide variety of xenobiotic and endogenous compounds. 
Substantial inter-individual variation in hepatic levels of CYP3A4 has been observed 
and although polymorphic mutations have been reported in both the 5' regulatory and 
coding regions of the CYP3A4 gene, those investigated so far do not appear to make a 
major contribution to CYP3A4 variation in the population as a whole.
To determine whether regulatory mutations might occur in more distal regions of the 
promoter, I have performed a new population screening on a panel of 101 human 
DNA samples. 1141 bp of the proximal 5' regulatory region of the CYP3A4 gene and 
300 bp of the distal enhancer region at -7.9 kb, both containing numerous regulatory 
motifs, were amplified from genomic DNA. Screening for mutations in the resulting 
PCR products was carried out using non-radioactive single strand conformation 
polymorphism (SSCP) followed by confirmatory sequencing of both DNA strands. 
In addition to detection of the previously reported CYP3A4"^1B allele in nine subjects, 
three novel alleles were found: CYP3A4^1E (having a T-^A transversion at -369 in 
one subject), CYP3A4^1F (having a C ^ G  transversion at -747 in 17 subjects) and 
CYP3A4^15B having a nine-nucleotide insertion between -845 and -844 linked to an 
A-^G transition at -392 and a G->A transition in exon 6  (position 485 in the cDNA) 
in one subject. No mutations were found in the distal enhancer region indicating 
strong conservation of sequence in this region of the promoter.
Functional analysis of the regulatory region mutants was performed in vitro using 
reporter DNA constructs in which the whole 1141 bp proximal promoter region from 
each mutant allele was inserted between a single copy of the 300 bp core distal 
enhancer sequence and the cDNA for human secreted alkaline phosphatase (SEAR). 
The individual reporter constructs were co-transfected with an hPXR expression 
vector into human liver (HepG2, HuH7) and intestinal (Caco-2) cell lines, in the 
presence or absence of classical xenobiotic inducers of CYP3A4. Modulation of 
transcriptional activation, as indicated by SEAP expression, was measured by 
chemiluminescent SEAP assay of the culture medium. Significant variation in
promoter strength was found between the mutant CYP3A4 promoter alleles depending 
on the inducer used and the recipient cell line. While there was close similarity 
between the xenobiotic induction patterns for wild type and mutant promoters in 
HepG2 and HuH7 cells, the pattern in Caco-2 cells was substantially different. 
Identification of novel regulatory and coding region alleles of CYP3A4 will assist 
detailed investigation of the mechanistic basis of CYP3A4 regulation and help 
elucidate the relationship between genotype, xenobiotic metabolism and toxicity in 
the CYP3A family of isoenzymes.
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AR Androgen receptor
ABCBl ATP-binding cassette B1
AF Activation function
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NR Nuclear receptor
OCT-1 octamer 1
PAH Polycyclic aromatic hydrocarbon
Pal Palindromes
PB Phénobarbital
PBS Phosphate buffered saline
PCN Pregnenolone 16a-carbonitrile
PCR Polymerase chain reaction
PP Peroxisome proliferators
PPAR Peroxisome proliferator activated receptor
PPRE Peroxisome proliferator response element
PR Progesterone receptor
RXRa Retinoid X receptor a
RAR Retinoid acid receptor
RIF Rifampicin
RXR Retinoid X receptor
SEAP Secreted alkaline phosphatase
SEM Standard error of mean
SF-1 Steroidogenic factor 1
V
SMRT Silencing mediator of retinoid and thyroid receptors
SNP Nucleotide polymorphisms
SPl specificity protein
SPAP Secreted placental alkaline phosphatase
SRC Steroid receptor co-activator
SSCP Single strand conformation polymorphism
SXR Steroid and xenobiotic receptor
SWl/SNF Switch/sucrose non-fermentable
TAD Transactivating domain
TAB Tris acetate EDTA buffer
TBE Tris borate EDTA buffer
TCDD Tetrachlorodibenzo-p-dioxin
TE Tris EDTA buffer
TEMED Tetramethylethylenediamine
TIE Transcription intermediary factor
TR Thyroid receptor
USFl upstream stimulatory factor 1
XRE Xenobiotic response element
XREM Xenobiotic responsive enhancer module
YYl ying yang 1
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CHAPTER ONE 
INTRODUCTION
One of the most challenging research areas in pharmacotherapy is to understand why 
individuals respond differently to drugs and to what extent individual variability in 
drug metabolism is responsible for observed differences in therapeutic efficacy and 
adverse reactions. Understanding such variation at the molecular level would be very 
valuable because it would allow provision of more specific therapies to meet the 
specific needs of the individual (Lu, 1998).
Inter-individual variations in the oxidative metabolism of many drugs have been 
identified and are due in part to polymorphism in the cytochrome P450 enzymes. 
These polymorphisms invariably contain a strong genetic component and, in addition 
to predisposing individuals to potential drug toxicities or inefficiencies, may also 
contribute to the influence of host factors in carcinogenesis, since the P450s are 
involved in the biotransformation of a variety of environmental pollutants, pesticides, 
and cancer-causing agents (Guengerich et al, 1986).
1.1 Drug metabolism
All organisms are exposed constantly and unavoidably to foreign chemicals 
(xenobiotics) which include both man-made and natural chemicals, e.g. drugs, 
industrial chemicals, pesticides, pollutants, chemical products in cooked food, 
alkaloids, secondary plant metabolites, and toxins produced by moulds, plants and 
animals (Correia, 1998). Pharmacologically active organic molecules including 
drugs tend to be lipophilic and remain non-ionised or only partially ionised at 
physiological pH and often bind strongly to plasma proteins. Such substances are not 
readily filtered in the renal glomerulus. The lipophilic nature of the renal tubular 
membrane also facilitates the reabsorption of hydrophobic compounds following their 
glomerular filtration. Consequently, most drugs would have a prolonged duration of 
action if termination of effects dependent solely on renal excretion. An alternative 
process that may lead to the termination of biological activity is metabolism (Correia, 
1998). The enzymes involved in the metabolism processes are of considerable
current interest in pharmaceutical discovery, development and in environmental 
health (Guengerich, 2000). An exception to this general rule is the elimination of 
volatile compounds by exhalation, in which case metabolism to non-volatile, water- 
soluble chemicals can retard their rate of elimination (Klaassen, 1996).
In general lipophilic xenobiotics are transformed (via metabolism) to more polar and 
hence more readily excretable products. Metabolic products are often less 
pharmacodynamically active than the parent drug and may even be inactive. 
However, some biotransformation products have enhanced activity or even 
toxic properties including mutagenicity, teratogenicity and carcinogenicity. Most 
metabolic biotransformations occur at some point between absorption and its renal 
elimination (Correia, 1998). A few transformations occur in the intestinal lumen or 
intestinal wall (Gibson et al, 1999). In general all of these reactions can be assigned 
to one of the two major categories of metabolism called phase I and phase II reactions 
(Correia, 1998).
Phase I reactions (Table 1.1) usually convert the parent drug to a more polar 
metabolite by introducing or unmasking a functional group (-OH, -NH 2 , -SH). 
Often these metabolites are inactive, though in some instances activity is only 
modified. If phase I metabolites are sufficiently polar, they may be readily excreted. 
However, many phase I products are not eliminated rapidly and undergo a subsequent 
reaction in which an endogenous substrate such as glucuronic acid, sulfuric acid, an 
amino acid or glutathione combines with the newly established functional group to 
form a highly polar conjugate. Such conjugation or synthetic reactions are hallmarks 
of phase II metabolism (Table 1.2). A great variety of drugs undergo these sequential 
biotransformation reactions, although in some instances the parent drug may 
already possess a functional group that may form a conjugate directly. This 
conjugate may be either eliminated or undergo a phase I type reaction (Correia, 1998; 
Gibson et al, 1999).
A further phase of metabolism, phase III, has also been proposed by some workers 
(Gibson and Skett, 1994) which involves the processing of glutathione conjugates. 
Subsequent to glutathione conjugation, a glutamyltranspeptidase can metabolise the
Table 1.1 Phase I reactions of drug metabolism (adapted from Correia, 1998)
R ea ctio n  c la ss Structural ch an ge D ru g  substrates
Oxidations
i) Cytochrome P450- 
dependent oxidations;
R R
Ô—0
Ù
Acetanilide, amphetamine, benzopyrene, 
17a-ethinylestradiol, naphthalene, 
phénobarbital, phenylbutazone, 
phenytoin, propranolol, warfarin.
Aromatic hydroxylations
Aliphatic hydroxylations
RCH2CH3 RCH2CH2OH 
RCH2CH3 RCHCH3
OH
Amobarbital, chlorpropamide, digitoxin, 
glutethimide, ibuprofen, meprobamate, 
pentobarbital, phenylbutazone, 
secobarbital
Epoxidation RCH=CHR-> R-C-C-R Aldrin
Oxidative dealkylation 
N-dealkylation RNHCH3 -^RN H 2 + CH2O
Aminopyrine, benzphetamine, caffeine, 
ethylmorphine, morphine, theophylline
0 -dealkylation ROCH3 -^RO H  + CH2O Codeine, p-nitroanisole
S-dealkylation RSCH3-^RSH + CH 2 0 6 -methylthiopurine, methitural
N-oxidation 
Primary amines
RNH 2 - ^ R N H 0 H Aniline, chlorphentermine
Secondary amines ^ N H  p N G H  
Ri R2
2 -acethylaminofluorene, paracetamol
Tertiary amines
Ri Ri
R i^N  “>  Ri— N^O 
R3 Rs^
Methaqualene, nicotine
S-oxidation
Ri Ri
^ 8 = 0  
R2 R%
Chlorpromazine, cimetidine, thioridazine
Deamination
OH
RCCH3 R-C-CH3 R-CCH3 +NH3 
NH2  NH2  0
Amphetamine, diazepam
Désulfuration
R. R,
pc=s -»■ pc=o
R2 R2
\  R, 
/ P = s  P= 0
Rz ^2
Thiopental, parathion
Dechlorination CCI4  [CCI3I  CHCI3 Carbon tetrachloride
Table 1.1 Phase I reactions of drug metabolism (Continued)
ii) Cytochrome P450-
independent
oxidations:
Flavin monooxygenase 
(Ziegler’s enzyme)
R3N R3N+O + H+ R3N+OH Amitriptyline, benzphetamine, 
chlorpromazine
R C H zN -C H zR '-^R C H zN -C H zR ' 
H OH 
- >  RCH=N^-CH2R'
0 “
Desipramine, nortriptyline
Amine oxidses RCH2NH2 ^  RCHO + NH3 Adrenaline, phenylethylamine
Dehydrogenations RCH2OH RCHO Ethanol
Reductions
Azo reductions RN=NR'-> RHN-NHR'-^RNH2+ R'NH2 Prontosil, tartrazine
Nitro reductions RNO2 - >  RNO RNHOH-^ 
RNH2
Chloramphenicol, clorazepam, 
dantrolene, nitrobebzene
Carbonyl reductions
RCR '-^RCH R'
II 1
0  OH
Methadone, metyropane, 
naloxone
Hydrolysis
Esters
RCOOR' RCOOH + R'20H Aspirin, clofibrate, procaine, 
methylphenidate, succinycholine
Amides RCONHR' RCOOH + R'NH2 Indomethacin, lidocaine, 
procainamide
Table 1.2 Phase II reactions of drug metabolism (adapted from Correia, 1998)
Type of 
Conjugation
Endogenous
reactant
Transferase
(location)
Types of 
substrates
Examples
Glucuronidation
UDP glucuronic 
acid
UDP glucuronosyl
transferase
(microsomes)
Alcohols, 
carboxylic acids, 
hydroxylamines, 
sulfonamides
Diazepam, digitoxin, 
digoxin, meproabamte, 
morphine, 
N-hydroxydapsone, 
nitrophenol, paracetamol 
sulfathiazole
Acétylation Acetyl-CoA
N-acetyl transferase 
(cytosol) Amines
Clonazepam, dapson, 
isoniazid, mescaline, 
sulfonamides
Glutathione
conjugation
Glutathione GSH-S-transferase 
(cytosol, microsomes)
Arene oxides, 
epoxides, 
hydroxylamines, 
nitro groups
Bromobenzene. 
ethacrinic acid
Glycine
conjugation
Glycine Acyl-CoA glycine
transferase
(mitochondria)
Acyl-CoA 
derivatives of 
carboxylic acids
Benzoic acid, cholic acid, 
cinnamic acid, deoxy- 
cholic acid, nicotinic acid, 
salicylic acid
Sulphate
conjugation
Phosphoadenosyl
phophosulphate
Sulphotransferase
(cytosol)
Alcohols, 
aromatic amines, 
phenols
Aniline, estrone,
3-hydroxy-coumarine,
methyldopa
Méthylation S-Adenosyl-mthionine
Transmethylases
(cytosol)
Amines,
catecholamines,
phenols
Adrenaline, dopamine, 
histamine, pyridine, 
thiouracil
Water
conjugation Water
Epoxide hydrolase 
(microsomes)
Arene oxides, cis- 
distributed and 
monosubstituted 
oxiranes
Benzopyrene 7,8-epoxide, 
carbamazepine epoxide, 
styrene 1 ,2 -oxide
(cytosol)
Alkene oxides, 
fatty acid- 
epoxides
Leukotriene A4
conjugate yielding the cysteine conjugate of the xenobiotic which can then be 
N-acetylated to N-acetylcysteine or mercapturic acid conjugates. Depending on the 
substrate and species involved the glycylcysteine, cysteine or mercapturic acid 
conjugates may occur as excretion products. Sulphur-containing conjugates can also 
be further metabolised by C-S lyase (or cysteine conjugate (3-lyase).
It should be noted that the dose and the frequency of administration of a drug 
required to achieve effective therapeutic blood and tissue levels in different patients 
will vary because of individual differences in drug distribution and rates of drug 
metabolism and elimination. These differences are determined by genetic factors and 
non-genetic variables such as age, sex, liver function, circadian rhythm, body 
temperature, nutrition and environmental factors such as concomitant exposure to 
inducers or inhibitors of drug metabolism (Correia, 1998).
The major organ of drug metabolism is the liver. In some cases extrahepaic tissues, 
frequently the sites of absorption or excretion (e.g. the gastrointestinal mucosa, lung 
or kidney), are also important in the metabolism of xenobiotics (Correia, 1998). 
Cytochrome P450 enzymes play the central role in xenochemical metabolism, as 
members of the haem-thiolate monooxygenase gene superfamily. By increasing the 
capability for metabolic detoxification and elimination, induction of cytochrome 
P450 is an integral part of the defence mechanism against xenobiotics (Sueyoshi and 
Negishi, 2001).
A change in pharmacokinetic behaviour is not the only consequence of xenobiotic 
metabolism nor, in some cases, is it the most important outcome. In many instances, 
chemical modification of a xenobiotic by metabolism alters its biological effects. 
The importance of this principle to pharmacology is that some drugs must undergo 
metabolism to exert their pharmacological effect. The importance of this principle to 
toxicology is that many xenobiotics must undergo metabolism to exert their 
characteristic toxic or tumorigenic effect (i.e. the metabolite is more toxic than 
the parent compound). In most cases, however, metabolism terminates the 
pharmacological effects of a drug and lessens the toxicity of xenobiotics (Paolini 
etal, 1999).
1.2 Role and mechanism of action of cytochrome P450 enzymes in 
drug metabolism
Cytochrome P450 enzymes are important in the oxidative, peroxidative and reductive 
metabolism of numerous and diverse endogenous compounds as well as a wide range 
of man-made xenobiotics including drugs, environmental chemicals and pollutants. 
The original name cytochrome P450 represents a hangover (related to its absorbance 
at 450 nm) from the time when the protein was first given its name by Omura and 
Sato in 1964. These proteins are not, in fact, cytochromes in the true sense of the 
word. The Nomenclature Conunittee of the International Union of Biochemistry and 
Molecular Biology (NC-IUBMB) prefers the term “ haem-thiolate protein” instead of 
cytochrome for these enzymes (Nelson et al, 1996).
The cytochrome P450 enzyme system consists of three essential components.
(1) Cytochrome P450 as the terminal oxidase component of the system that is 
classified as a haemoprotein with iron protoporphyrin DC as the prosthetic group 
(Gibson and Skett, 1996). The active site of cytochrome P450 contains an iron 
protoporphyrin IX moiety in a large, relatively open hydrophobic cleft or 
depression in the surface of the apoprotein. The haem is bound, apparently 
somewhat loosely, by a combination of hydrophobic forces, coulombic 
attractions, and one or two coordinate-covalent bonds to the central metal iron 
(White and Coon, 1980).
(2) NADPH-cytochrome P450 reductase that is a flavoprotein responsible for 
transferring reducing equivalents from NADPH+H^ to cytochrome P450. It 
exists in close association with cytochrome P450 in the endoplasmic reticulum 
membrane.
(3) Phospholipids, mainly phosphatidyl choline that embeds the other two 
components and may be required for substrate binding, facilitation of electron 
transfer or providing a "template" for the interaction of cytochrome P450 and 
NADPH-cytochrome P450 reductase molecules (Gibson and Skett, 1996).
Primarily, cytochrome P450 functions as a mono-oxygenase by catalysing the 
cleavage of molecular dioxygen and subsequent insertion of a single oxygen atom 
into the substrate, with concomitant production of a water molecule. The overall 
catalytic process of mono-oxygenation of substrate (RH) can be represented as below, 
where it can be seen that the input of two reducing equivalents is required:
2H^ , 2 e “
RH + O2 --------------------> ROH + H2O
(substrate) P450 (metabolite)
The source of the reducing equivalents (2fT ,^ 2e~) is either NADPH or NADH and the 
transfer is mediated by a flavoprotein and, in some cases by an iron-sulfur redoxin 
(Lewis and Pratt, 1998]. Microsomal drug oxidations require cytochrome P450, 
cytochrome P450 reductase, NADPH and molecular oxygen. Catalytic mechanism of 
cytochrome P450 3A4 is presented in Figure 1.1 as an example from a general 
paradigm. What is not particularly clear is what steps are rate-limiting in various 
reactions (Guengerich, 1999 and references therein).
Step [1] is a relatively well characterised and involves drug binding to the oxidised 
(Fe^ "^ ) form of cytochrome P450 to form a substrate-cytochrome P450 complex. Step
[2] involves the first electron reduction of substrate-bound ferric cytochrome P450 to 
the ferrous form (Fe^ "^ ) of the haemoprotein. The reducing equivalent necessary for 
this reduction is originally derived from NADPH-bH^ and is transferred by the 
flavoprotein, NADPH-cytochrome P450 reductase. Step [3] involves the binding of 
molecular oxygen to the binary ferrous cytochrome P450-substrate adduct. Steps 
[4-9] involve putative electron rearrangement, introduction of the second electron and 
subsequent oxygen insertion and product release. The precise oxidation states of iron 
and oxygen in these intermediates are not exactly known (Gibson and Skett, 1996). 
However, it can be briefly explained that a second electron introduced from NADPH 
via the same flavoprotein reductase, serves to reduce molecular oxygen and forms an 
“activated oxygen-cytochrome P450-substrate” complex. This complex in turn 
transfers “activated” oxygen to the drug substrate to form the oxidised product. The 
potent oxidising properties of this activated oxygen permit oxidation of a large 
number of substrates. Substrate specificity is very low for this enzyme complex.
ROH
3+
NADPH-P450 reductase''®'^
FeROH
NADPH-P450 reductase®^
Fe'^-Oi RH
Fe-OOH
RH
NADPH-P450 reductase'^®'^ NADPH-P450 reductase®^
Figure 1.1 Catalytic cycle of the cytochrome P450 (adapted from Guengerich, 
1999). RH: drug, e: electron, bs'. cytochrome and ROH: oxidised drug
1.3 The Cytochrome P450 isoenzyme superfamily
Cytochrome P450s are classified as haem-containing enzymes (haemoprotein) with 
iron protoporphyrin IX as the prosthetic group present in prokaryotes and eukaryotes. 
These enzymes are members of a family of closely related isoenzymes. In eukaryotes 
they are embedded in the membrane of the endoplasmic reticulum and exist in 
multiple forms of monomeric molecular weight of approximately 45000-55000 
Daltons. The haem is non-covalently bound to the apoprotein and the name 
cytochrome P450 is derived from the fact that the cytochrome (or pigment) exhibits a 
spectral absorbance maximum at 450 nm when reduced and complexed with carbon 
monoxide. The concept of cytochrome P450 multiplicity has now been firmly 
established and has had a profound influence on drug metabolism studies. This was 
initially discovered following the development of techniques enabling the 
cytochrome P450 isoenzymes to be solublised and purified from liver endoplasmic 
reticulum fragments such that structural and functional comparisons of highly 
purified cytochrome P450 preparations could be assessed (Gibson et al, 1999).
Over the past fifteen years gene cloning and the elucidation of P450 sequences have 
resulted in a dramatic increase in known P450 isoenzymes. Currently, the number of 
P450s known from cDNA and other sequencing procedures has been reported to be 
about 1200 or more (Lewis and Sheridan, 2001). The classification of P450 enzymes 
into families and subfamilies based on amino acid sequence comparison has proved 
to be useful for the construction of phylogenetic trees and for other forms of analysis 
that study evolutionary relationships between genes. The basis of assignment for 
individual P450s into families and subfamilies requires a primary amino acid 
sequence homology of >59% for P450s being placed within the same gene family, 
whereas P450s within the same subfamily should be -70% similar. Orthologous 
P450 genes generally exhibit similarities of between 71% and 80%, and it is found 
that one gene family is usually <36% similar to P450s in other families (Lewis et al,
1998).
In any one mammalian species up to 60 isoforms of cytochrome P450 may be 
present, representing the majority of the 18 mammalian CYP gene families 
(http://dmelson.utmem.edu/famcount.html). This number is rising steadily with the
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completion of the various genome-sequencing projects (Nelson, 1999). On the basis 
of crystal structures of mainly bacterial P450s, molecular modelling and site directed 
mutagenesis, the overall structure of manunalian membrane-bound P450 has been 
deduced and residues required for substrate binding, electron transfer and haem 
binding have been identified (Honkakoski and Negishi, 2000).
There is a conserved structural fold among cytochrome P450s even though the amino 
acid sequence identity among proteins may be less than 20% and with only 3 
absolutely conserved amino acids across the superfamily (Hasemann et al, 1995). 
Within the structural fold there appears to be a highly conserved core, as determined 
from the comparison of the structures of the six crystallised, soluble cytochrome 
P450s. However, while the cytochrome P450 structural fold is the same for all 
determined structures, they have enough diversity in the primary, secondary and 
tertiary sequences to accommodate specific substrates. Structural diversity also is 
important regarding redox partners and additionally to the cellular location of the 
protein (e.g. whether soluble or membrane associated, mitochondrial or microsomal) 
(Graham and Peterson, 1999).
All cytochrome P450s sequenced to date exhibit a so-called ‘P450 signature m otif of 
1 0  amino acid residues, which includes the invariant cysteine residue that ligates the 
haem iron. This generally takes the form: FxxGxxxCxG where F is phenylalanine, G 
is glycine, C is cysteine and x is any amino acid. The occurrence of this signature 
sequence is indicative of haem-thiolate proteins of the cytochrome P450 superfamily 
and no other protein sequence have been found which display this motif, and it is 
probably essential for haem-binding proteins that possess cytochrome P450-like 
catalytic activity (Lewis et al, 1998).
An evaluation of the mechanism for the metabolic clearance of 315 different drugs 
revealed that 56% of them were primarily cleared through the action of the 
cytochrome P450 enzymes. CYP3A4 was by far the most important isoenzyme 
(50%) followed by CYP2D6 (20%), CYP2C9 and CYP2C19 (15%), and the 
remaining metabolism carried out by CYP2E1, CYP2A6, CYP1A2 and other 
cytochrome P450s (Bertz and Granneman, 1997). All of these enzymes are inducible 
except CYP2D6 (Ingelman-Sundberg et al, 1999).
11
1.3.1 Subcellular localisation of cytochrome P450s
The cytochrome P450 enzyme system is found in the membranes of certain 
organelles in the cell. The most important and most abundant of them are embedded 
in the lipophilic membrane of the endoplasmic reticulum (Gibson and Skett, 1996). 
High solubility in lipids is the only common structural feature of the wide variety of 
structurally unrelated drugs and chemicals that serve as substrates in this system. All 
the electron transport components of the liver microsomal P450 system are localised 
toward the cytoplasmic side of the endoplasmic reticulum. This provides rapid 
recovery of the oxidised flavoproteins recruited in the metabolic reactions (Ortiz de 
Montellano, 1995).
This enzyme system also is present in mitochondria (Wang et al, 2000). All 
steroidogenic organs and some non-steroidogenic organs including liver and kidney 
contain cytochrome P450 in mitochondria, and mitochondrial cytochrome P450s are 
distinct from their microsomal counterparts in the same cell. Mitochondrial 
cytochrome P450s are involved in the metabolism of steroids and related 
physiological substrates, e.g. vitamin Dg, and in contrast with many microsomal types 
of cytochrome P450, they do not have significant activities towards xenobiotic 
compounds. These enzymes are bound to the inner membrane and receive electrons 
from NADPH in the matrix (Schenkman and Greim, 1993).
1.3.2 Nomenclature and categorisation of P450 genes or enzymes
The system of classification is based on percentage amino acid sequence similarity 
between cytochrome P450s and, therefore, facilitates the construction of a 
phylogenetic tree for the enzyme superfamily which can be related to the 
development of biological species over time on the basis of the specific mutation 
rates for the cytochrome P450 genes (Lewis and Sheridan, 2001). This categorisation 
and nomenclature system results in their classification into gene families and gene 
subfamilies. A cytochrome P450 sequence from one gene family is defined as 
usually having less than 40% resemblance to that from any other family. In other 
words, members of different families exhibit 40% or less amino acid sequence 
similarity whilst members within families show more than 40% amino acid sequence 
similarity. Any two cytochrome P450 proteins belong to the same gene subfamily, if
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they have approximately 70% (or greater) similarity in their sequence (Nelson et al, 
1993).
The recommendation for naming a P450 gene includes the italicised root symbol CYP 
(Cyp for the mouse and Drosophilia), denoting cytochrome P450, an Arabic number 
designating the P450 family, a letter indicating the subfamily when two or more 
subfamilies are known to exist within that family, and an Arabic numeral 
representing the individual gene (e.g. CYP1A2). The same letters and numbers are 
recommended for the corresponding gene products (mRNA, cDNA and enzyme): 
non-italicised and all capital letters (e.g. CYP1A2) in all species including mouse and 
Drosophilia (Nelson et al, 1996).
Currently, there are about 265 families and the number is growing with time. The 
large number of families is beginning to make the nomenclature cumbersome. One 
way to alleviate some of this is to recognise that the families naturally group into 
higher order clusters (‘clans’). Naming these clusters would automatically reduce the 
need to keep abreast of all the P450 families. Nelson began the process of naming 
consistent clusters of P450 in 1999 (http://dmelson.utmem.edu/famcount.html).
1.3.3 Cytochrome P450 gene families
Over 1200 individual cytochrome P450s have had their protein sequences defined to 
date (Lewis & Sheridan, 2001). Of 265 gene families so far described, 75 families 
belong to bacteria (CYP101-CYP174+CYP51), 72 families belong to lower 
eukaryotes (CYP51-CYP69 + CYP501-526), 52 families belong to plants (CYP71-99 
+ CYP701-726 + CYP51 minus four discontinued family names CYP91, CYP95, 
CYP713, and CYP717), and 69 families belong to animals [{CYP1-CYP49 minus two 
discontinued/not used CYP16 and CYP40) + CYP301-CYP320 + CYP51]. CYP51 is 
present in all four groups so it is counted four times. Full details have not been 
published but are available at the Nelson’s laboratory website (http.V/dmelson.utmem. 
edu/famcount.html).
In mammals, CYPl, CYP2 and CYP3 appear to be primarily associated with the 
metabolism of exogenous compounds, although they are able to metabolise some
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endogenous chemicals such as steroids (Waxman, 1988). In contrast, members of the 
other cytochrome P450 families, especially those in manunalians, have been shown 
to possess specific metabolic functions. For example, some enzymes of the CYP4 
family are responsible for the end-chain hydroxylation of long-chain fatty acids, 
whereas some others are associated with the co-hydroxylation of certain 
prostaglandins and leukotrienes (Harder et al, 1995). Cytochrome P450s belonging 
to gene families 5 and 8 A are involved in thromboxane and prostacyclin synthesis 
(Lewis and Lake, 1996). Cytochrome P450s from families 11,17,19, and 21 are 
required for steroid hormone biosynthesis (Nelson et al, 1996). Cytochrome P450s 
from families 7, 8 B, 24, 27, 46, and 51 catalyse reactions in the pathways leading to 
the biosynthesis of bile acid, vitamin Dg and cholesterol and CYP26 is involved in 
retinoid metabolism, a step that may be important during development (Nelson,
1999). These cytochrome P450s usually have selective substrate specificities and 
they are subject to tight tissue-specific and hormone-dependent regulation 
(Honkakoski and Negishi, 2000). The nomenclature of cytochrome P450 families 
involved in the biosynthesis of steroid hormones is derived from the various positions 
in the steroid nucleus where metabolism occurs (CYP7, CY Pll, CYP17, CYP19 and 
CYP21) (Lewis and Lake, 1996).
The involvement of individual cytochrome P450s in the metabolism of a given drug 
may be screened in vitro by means of selective functional makers, selective chemical 
inhibitors and antibodies. In vivo, such screening may be accomplished by means of 
relatively selective non-invasive markers, which include breath tests or urinary 
analyses of specific metabolites after administration of a cytochrome P450-selective 
substrate probe (Correia, 1998). However, most of these marker drugs are not truly 
non-invasive and sometimes are too complex or expensive for widespread use, and 
many available probes lack desired safety and/or sensitivity. For example, study of 
midazolam metabolism usually requires intravenous administration and preparation 
of several blood samples, and erythromycin breath test uses [^"^C]N-methyl- 
erythromycin (Streetman et al, 2000). Important human GYP isoenzymes in families 
1-3 are shown in table 1.3 with substrates (drugs), inducers and drugs used for 
metabolic screening (non-invasive markers).
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Table 1.3 Some important human liver drug metabolising CYPs (adapted from 
Correia, 1998)
CYP Substrates Inducers
Non-invasive
markers
1A2 Antipyrine
Caffeine
Clomipramine
Paracetamol
Phenacetin
Tamoxifen
Theophylline
Warfarin
Smoking, charcoal- 
boded foods, Cruc­
iferous vegetables
Caffeine
2A6 Coumarin None Coumarin
2C9 Hexobarbital Phenytoin Trimethadione Barbiturates MephenytoinIbuprofen Tolbutamide S-Warfarin Rifampicin
2C19 Diazepam
^'-Mephenytoin
Naproxen
Omeprazole
Propranolol None Omeprazole
Amitriptyline Guanoxan Paroxetine
2D6 Clomipramine
Clonazepam
Codeine
Debrisoquine
Desipramine
Dextrometorphan
Encainide
Flecainide
Fluoxetine
Haloperidol
Hydrocodone
Imipramine
4-methoxyam-
phetamine
Metoprolol
Mexiletine
Nortriptyline
Oxycodone
Phenformin
Propafenone
Propoxyphene
Selegilene
Sparteine
Thioridazine
Timolol
None Debrisoquine
Dextrometorphan
2E1 Chlorzoxazone
Enflurane
Ethanol (minor) 
Halothane
Paracetamol
* Chlorzoxazone
3A4
Alfentanil
Amiodarone
Astemizole
Felodipine
Gestodene
Lidocaine
Quinidine
Rapamycin
Sufentanil
Barbiturates
Glucocorticoids
Erythromycin
Midazolam
Cocaine Lovastatin Sulfamethoxazole Macrolid antibiotics
Cortisol
Cyclosporine
Dapsone
Diazepam
Dihydroergotamine
Diltiazem
Erytheromycin
Ethinyl estradiol
Miconazole
Midazolam
Nifedipine
Niludipine
Nitendipine
Paclitaxel
Paracetamol
Progestrone
Tacrolimus
Tamoxifen
Terfenadine
Testosterone
Triazolam
Troleandomycin
Verapamil
Rifampicin
* 2E1 is induced by diabetes, starvation, ethanol, acetone, pyrazole, isoniazid and 
dimethylsulfoxide (Honkakoski and Negishi, 2000).
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1.3.4 Species differences in xenobiotic metabolism
Although a substantial number of both endogenous and exogenous P450 substrates 
are metabolised in a similar fashion by mammalian species, there are also examples 
where differences occur which may be due to either the same chemical being 
metabolised by different isoforms or by orthologous cytochrome P450s within the 
same family/subfamily (Lewis et al, 1998). For example, phénobarbital treatment 
increases the toxicity of paracetamol in rat and mouse, but decreases the toxicity of 
this chemical in the hamster (Boobis et al, 1990). Apparently, this is due to an 
increase in the detoxifying glucuronidation pathway in hamster as opposed to the 
cytochrome P450-mediated activation which is predominant in the mouse and rat. 
There is also a marked difference between the metabolism of coumarin in rat and 
mouse which results in activation in the rat {via 3-hydroxylation), but detoxification 
in the mouse involving the 7-hydroxylation pathway (Lewis and Lake, 1995). It is 
hkely that this is due to the variation between CYP2A orthologues in the rodent 
species.
There is, moreover, an interesting species difference between cytochrome P450 
complements in New and Old World primates, which may well be explained in terms 
of continental drift and changing habitat. Apparently, New World monkeys possess 
relatively high levels of CYP1A2 but virtually no CYP2A, whereas the opposite is 
found for Old World primates. Homo sapiens would appear to represent a 
combination of each type of primate species as both CYP1A2 and CYP2A6 are 
constitutively expressed in human liver (Lewis and Lake, 1996).
As far as the CYP2B subfamily is concerned, there are species differences in the 
sterio-selectivity of steroid metabolism (Oguri et al, 1994). For example, both rat 
and dog CYP2B orthologues hydroxylate androgens in the 16a and 16p positions, 
whereas the guinea pig and monkey orthologues hydroxylate solely at the 16p 
position and the rabbit form exhibits 16a-hydroxylation primarily. This is likely to 
be due to subtle differences in amino acid residues in the enzyme active sites, as it 
has been demonstrated that site-directed mutagenesis at two positions can alter the 
stereoselectivity of CYP2B1 (Aoyama etal, 1989).
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The CYP2C subfamily also shows marked variation in regio- and stereoselectivity of 
steroid metabolism between different species and also exhibits differences between 
CYP2C-mediated testosterone metabolism for male and female, which can be 
ascribed to gender-specific isoforms (reviewed in Lewis and Lake, 1996). In the 
CYP2D subfamily, there are also species variations in substrate metabolism. For 
example, unlike rat and human CYP2D enzymes, none of the mouse CYP2D 
orthologues is able to metabolise debrisoquine, but mouse CYP2D9 can carry out 
16a-hydroxylation of testosterone, which is metabolised in the 6p position by both 
rat and human CYP2D isoforms (Funae and Imaoka, 1993). Furthermore, there are 
species differences in metabolic pathways carried out by the CYP2E subfamily 
enzymes (Duescher and Elfarra, 1994) which, as with other examples mentioned 
previously, suggest that considerable care must be exercised in using small rodents as 
surrogates for man in chemical safety evaluation.
Other differences between species reflect the alteration in cytochrome P450 
complements together with variability of expression and regulation of the cytochrome 
P450 genes which can be subject to alteration depending on not only species, sex and 
strain differences but also variations between organs and tissues. Thus, it is found 
that the anticancer agent tamoxifen is carcinogenic in both rat and mouse due to 
cytochrome P450-dependent pathways, but is readily detoxified via CYP3A4 in 
human (Wiseman and Lewis, 1996). Consequently, the preferred experimental 
animal species for the screening of chemicals that are destined for human exposure 
will vary depending on the nature of the compound itself and the relevant pathways 
of metabolism.
1.3.5 Regulation of cytochrome P450 gene expression
DNA in the nucleus of a eukaryotic cell is found in the form of chromatin where both 
histone and non-histone proteins are bound to the genetic material. For a gene to be 
available for expression, it must be in the activated state so that transcription can take 
place. The transcribing molecule, RNA polymerase II, is then able to synthesise a 
pre-mRNA copy of the gene, including both the coding (exon) and non-coding 
(intron) regions. The introns of this pre-mRNA are removed by splicing and mature 
mRNA is produced. This is then transported to the cytoplasm where it is translated
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by ribosomes into the polypeptide apoprotein. The modification of this apoprotein 
yields active enzyme. Any of these stages (Figure 1.2) can be a site of regulatory 
control (Goldfarb, 1989; Lewis and Lake, 1996). The cytochrome P450 enzymes 
responsible for the metabolism of xenobiotics are generally present at low cellular 
levels, but are substantially induced in response to specific xenobiotics. This 
induction process makes biological sense because the xenobiotic inducers are 
generally substrates for the induced cytochrome P450. Induction of cytochrome 
P450 enzyme(s) then continues until the inducer is lowered to a threshold level 
(Dogra et al, 1998). In addition to induction, the level of catalytic activity of 
cytochrome P450s can be lowered (or down-regulated) by a variety of other factors 
such as inhibition and post-translational loss of functionality (Lewis and Lake, 1996). 
There is also some evidence that pre-transcriptional steps can affect the induction of 
some liver CYPs by phénobarbital e.g. extracellular matrix, disruption of the 
cytoskeleton and activation of cAMP-dependent protein kinase (Brown etal, 1997).
1.3.5.1 Transcriptional regulation
Induction of cytochrome P450 enzymes occurs predominantly at the level of 
transcription (Dogra et al, 1998). Regulation at the level of mRNA synthesis is 
dependent on two factors: the presence of cis-acting regulatory DNA sequences 
adjacent to or within the gene and the synthesis or activation of gene-specific DNA- 
binding proteins. The DNA-binding proteins dock specifically with their target 
regulatory DNA sequences and facilitate the entry of RNA polymerase 
molecules into the promoter site of the gene. These DNA-binding proteins or 
trans-acting factors, which are present in both the nucleus and cytoplasm, can 
be activated by ligand binding (drugs or hormones), by phosphorylation (second 
messenger signalling systems) or in some instances, by metabolite-induced 
dimerisation/dissociation (Goldfarb, 1989).
Each ligand interacts with its cognate receptor to induce conformational changes in 
the tertiary protein structure, enabling productive interactions between the ligand- 
bound receptor and its target response element DNA sequences (Kumar and 
Thompson, 1999). Steroid hormones, some chemicals such as dioxin and related 
agents or the peroxisome proliferators bind stereospecifically to their cytoplasmic
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Haem pool
Cytochrome P450 gene
Transcription and processing 
(Nucleus)
mRNA
Translation
(Endoplasmic reticulum)
Apoprotein
Cytochrome P450 enzyme
Specific inactivation
Cytochrome P420 (inactive)
Degradation and catabolism
Figure 1.2 Stages in cytochrome P450 gene expression (modified from Lewis and 
Lake, 1996).
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xenobiotic receptors in the process of stimulating expression of some cytochrome 
P450 genes (Brown et al, 1997). Depending on the chemical nature of the ligand 
(xenobiotic), CYP isozymes belonging to a particular subfamily are predominantly 
induced (Figure 1.3).
Several types of agents have been found to down-regulate CYPlAl transcription 
by inhibiting the binding of ligand-receptor complex to DNA. For example, 
transcriptional regulation of CYPlAl and CYP1A2 by TCDD requires protein kinase 
C-dependent phosphorylation and inhibitors of protein kinase activity, such as 
2-aminopurine or phorbol esters, inhibit CYPlAl mRNA induction by TCDD as 
well as the concomitant increase in CYPlAl enzyme activity (Berghard et al, 1993). 
Formation of DNA-protein complexes between the Ah receptor and its AhRE target 
is also inhibited by 2-aminopurine (Carrier et al, 1992; Okino et al, 1992; Berghard 
et al, 1993). Treatment of in vivo or in vitro ligand-activated dioxin receptor with 
potato acid phosphatase significantly reduced or abolished its specific binding 
activity. This effect was inhibited in the presence of sodium phosphate. These 
results suggest that phosphorylation may regulate the DNA binding activity of the 
ligand-occupied dioxin receptor (Pongratz et al, 1991).
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PAH AhR
Arnt
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CAR
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Figure 1.3. A general model for the transcriptional activation of CYP genes by 
various chemicals (modified from Dogra et al, 1998).
PAH, polycyclic aromatic hydrocarbon; PP, peroxisome proliferators; PB, 
phénobarbital; RIF, rifampicin; AhR, arylhydrocarbon receptor; hsp90, heat-shock 
protein 90; PPAR, peroxisome proliferator activated receptor; GR, glucocorticoid 
receptor; Arnt, AhR nuclear translocator protein; RXRa, retinoid X receptor a; 
XRE, xenobiotic response element; PPRE, peroxisome proliferator response 
element; HRE, hormone responsive element; PXR, Pregnane X receptor; CAR, 
constitutively active receptor.
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1.3.5.2 Post-transcriptional regulation
Post-transcriptional regulation includes the mechanisms that may affect the splicing, 
transport, stability (time until degradation) and translatability of mRNA. In the 
cytochrome P450s, post-transcriptional mechanisms have been reported to operate in 
the induction of CYP1A2 (and possibly CYPlAl) by 3-methylcholanthrene or 
TCDD, the induction of CYP3A2 by troleandomycin or dexamethasone (Goldfarb,
1989) and, the induction of CYP2E1 by triiodothyronine (Peng and Coon, 1998). In 
all these instances, there appears to be a stabilisation of the mRNA by some unknown 
mechanism e.g. alternative mRNA splicing in the 3’ UTR as has been demonstrated 
in the case of CYP4A1 (Goldfarb, 1989). Increased translational efficiency has been 
reported for CYP2E1 induction by pyridine (Kim et al, 1993). Insulin may decrease 
CYP2E1 mRNA stability (Peng and Coon, 1998).
1.3.5.3 Post-translational regulation
Regulation of cytochrome P450 activity at the level of enzyme activity or stability 
has been shown to operate in a number of instances. The availability of haem is 
clearly an important factor and haem synthesis is readily induced following 
administration of TCDD or phénobarbital (Goldfarb, 1989). Some organochloride 
insecticides have been reported to stabilise CYP3A1 protein (Yaun et al, 1994) and 
ethanol has been shown to protect CYP2E1 from catalytic degeneration (Hu et al, 
1995). DMSG increased CYP3A protein levels as a result of decreased protein 
degradation (Zangar and Novak, 1998).
Inactivation or inhibition of cytochrome P450 can also occur by formation of a 
chemical complex between substrate or inhibitor and enzyme protein. Inactivation of 
cytochrome P450 by thiono-sulfur compounds occurs during their biotransformation 
and results in the binding of atomic sulphur to the cytochrome P450 apoprotein 
(Chang etal, 1997).
The mechanism of cytochrome P450 inactivation is generally classified into two 
groups: one involves covalent binding of a reactive intermediate to the enzyme 
protein and/or haem, which leads to irreversible inhibition of catalytic function; the 
second involves a quasi-irreversible coordination of a reactive intermediate to the
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cytochrome P450. The major classes of chemical entities that form cytochrome P450 
complexes include methylenedioxybenzene derivatives, alkylamines, macrolide 
antibiotics, and hydrazines. Compounds such as piperonyl butoxide, isosafrole and 
alkylamine functions undergo cytochrome P450-catalysed oxidation to form 
intermediates that coordinate tightly to the prosthetic haem iron (Chiba et al, 1998). 
Also, grapefruit juice has been found to inhibit cytochrome P450 3A4 enzymatic 
activity and decrease the content of intestinal P450 3A4 (He et al, 1998). The 
mechanism of the inactivation appears to involve modification of the CYP3A4 in the 
active site of the enzyme. Bergamottin, a constituent of grapefruit juice appears to be 
responsible for this inhibition.
1.4 The CYP3A subfamily
1.4.1 Hepatic CYP3A enzymes
CYP3A enzymes are found in different tissues but liver is usually considered as the 
major organ for drug metabolism. These enzymes are the most abundantly expressed 
P450s in human liver, accounting for up to 60% of total cytochrome P450 in some 
liver specimens (Nelson et al, 1996). In contrast, in rats, a CYP3A, designated 
CYP3A2 is expressed only in adult females and represents about 25% of total hepatic 
cytochrome P450. The enzyme is apparently absent in males (Emi and Omura, 
1988). This sexual dimorphism has not been found in humans (Guengerich, 1995). 
Another rat hepatic cytochrome P450, CYP3A1, is not appreciably expressed in 
either sex but is highly inducible by certain steroids (Gonzalez, 1993).
The human CYP3A subfamily consists of four members CYP3A4, CYP3A5, 
CYP3A7 (Li et al, 1995) and recently identified CYP3A43 (Domanski et al, 2001). 
CYP3A7 is expressed only in foetal liver. Two main adult isoforms (3A4 and 3A5) 
display largely overlapping substrate specificity, although clear differences have also 
been demonstrated (Domanski et al, 2001). For example, the primary route of 
erythromycin metabolism appears to be by N-demethylation mediated exclusively by 
CYP3A4 but cortisol 6P-hydroxylation have been shown to be catalysed variably by 
both members of the subfamily (Watkins et al, 1989). It has been suggested that 
CYP3A43 might have substrate specificity different from the other human CYP3A 
enzymes. CYP3A43 has a valine at position 370, whereas a conserved alanine is
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seen in the other CYP3A enzymes (Westlind et al, 2001). Alanine-370 has been 
shown to be important for the interaction of CYP3A4 with many of its substrates 
(Khan and Halpert, 2000).
Understanding the role of CYP3A isoforms in the metabolism of drugs, and the 
factors influencing their activity is of major clinical importance. Studies of the 
content of various cytochromes in large numbers of human liver specimens (Shimada 
et al, 1994) indicate that CYP3A isoforms on average constitute the largest 
component of identified cytochrome P450s (Figure 1.4).
The CYP3A isoforms are partially or entirely responsible for biotransformation of 
many drugs in humans including many psychotropic agents, cardiovascular drugs, 
antineoplastic and immunosuppressive agents, the Hi-antihistamines and various 
analgesics. A number of endogenous hormones are also metabolised by these 
isoforms. Extensive studies of drug metabolism in humans have established a 
number of important characteristics of CYP3A subfamily and its metabolic activity 
(von Moltke et al, 1995).
As indicated above, the CYP3A subfamily is variably expressed in the liver at 
different ages. High levels of CYP3A7 and low levels of CYP3A5 exist during foetal 
life. CYP3A7 ceases to be the principal hepatic CYP3A soon after birth as CYP3A4 
comes on line. CYP3A4 reaches 30% to 40% of adult activity by the first postnatal 
month and is the predominant CYP3A during adulthood (Oesterheld, 1998).
In adults, CYP3A7 is variably expressed at low levels. CYP3A5 is more commonly 
expressed in children and teenagers, as compared with adults, but it is not present in 
all children, nor is it gender specific. The mRNA of CYP3A5 has been located in 
about 23% of adult livers without gender specificity. Hepatic P450 activity declines 
with age and it is likely that the CYP3A subfamily specific activity also declines with 
age but there is some disagreement on this issue (Oesterheld, 1998). CYP3A43 has 
been reported to be expressed in relatively low amounts in the liver where it can be 
induced by rifampicin (Gellner et al, 2001) but there is no strong evidence for its 
contribution to drug metabolism at the moment (Westlind et al, 2001).
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Figure 1.4 Mean relative amounts of identifiable human CYPs determined 
immunologically in a study of 60 human liver samples (von Moltke et al, 
1995).
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1.4.2 Expression of CYP3A enzymes in other tissues
Expression of the CYP3A subfamily has been found in many tissues throughout the 
body with the highest levels in the liver, villus epithelium of the small intestine, 
kidney and to some extent in the lung (Haehner et al, 1996; Anttila et al, 1997; Paine 
et al, 1997).
On average, CYP3A, as mentioned above, composes 25% to 30% of total hepatic 
cytochrome P450s and an even larger percentage of total small intestinal cytochrome 
P450s. In addition, CYP3A content in both organs is highly variable among 
individuals (>11 fold) (Lown et al, 1994). Due to the anatomical arrangement of the 
small intestine and liver, drugs may encounter sequential CYP3A-mediated first pass 
metabolism when taken orally. Historically, the liver was considered the major site of 
CYP3A-dependent first pass metabolic extraction. Recent in vitro and in vivo 
studies, however, suggest that metabolism by the mucosal villi of the small intestine 
can be of equal or greater importance for some drugs such as cyclosporine and 
verapamil. Studies conducted on midazolam metabolism revealed large inter­
individual differences in hepatic and intestinal extraction ratios. Hepatic extraction 
ranged from 22% to 76%, whereas intestinal extraction ranged from -0% to 77% in 
healthy volunteers and 14% to 59% in anhepatics (e.g. following liver failure due to 
hepatitis) (Paine etal, 1997).
In the human kidney, based on immunohistochemical studies, CYP3A appears to be 
located in the proximal tubule, thin limb of Henle, the cortical collecting ducts and 
the cells lining the renal pelvis (Haehner et al, 1996). It has been well established 
that both human CYP3A4 and CYP3A5 catalyse the conversion of cortisol to its 
6|3-hydroxy metabolite. Consequently, the pathophysiological role of renal CYP3A 
has been suggested to be the intrarenal conversion of excess cortisol to 
6|3-hydroxycortisol. In contrast to hepatic tissue, CYP3A5 is the ubiquitously 
expressed member of CYP3A subfamily in renal tissue (Haehner et al, 1996).
In the lung and kidney, CYP3A5 appears to be the predominant CYP3A isoform. 
CYP3A4 is expressed in this tissue in only about 20% of individuals. There are 
considerable variations of pulmonary expression in both CYPs among individuals
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(Anttila et al, 1997). There is also evidence that CYP3A5 is the only member of 
CYP3A subfamily that is expressed in human blood cells (Janarden et al, 1996).
The CYP3A7 protein appears to be expressed mainly in foetal liver but also in adult 
endometrium and placenta. The highest level of CYP3A43 mRNA is observed in the 
prostate, an organ with extensive steroid metabolism and it can be speculated that the 
enzyme has a physiological role in this organ (Westlind et al, 2001).
1.4.3 The Human CYP3A4 enzyme
Human CYP3A4 is usually the major cytochrome P450 enzyme in the human liver 
and is known to metabolise a large variety of xenobiotics and endogenous 
biochemicals (Li et al, 1995 and references therein). Multiple metabolic pathways 
are catalysed by CYP3A4. The major pathways are C- and N-dealkylation and 
C-hydroxylation. Others include dehalogenation, dehydration and nitroreduction (Li 
et al, 1995). It is now known that CYP3A4 is highly inducible and this may account 
for a major mechanism in known cases of drug interactions. It is also plausible that 
CYP3A4 induction may be a key determinant of inter-individual variation in 
susceptibility to chemical toxicants. The abundance of CYP3A4 in the human liver, 
the large number of substrates of diverse chemical structures it metabolises, the 
multiple metabolic pathways involved and its inducibility are all reasons suggesting 
that CYP3A4 is one of the most interesting CYP enzymes to be studied (Li et al, 
1995).
Considering the capability of CYP3A4 to metabolise structurally diverse chemicals, 
ranging in molecular weight of 151 for paracetamol to 1202 for cyclosporine A, the 
active site of the enzyme would be expected to be relatively large and open in order 
to accommodate very large substrates. In fact, it has been reported that the CYP3A4 
active site may be large enough to allow the simultaneous binding of two similar or 
different molecules (Lewis et al, 1996).
The clinical significance of CYP3A4 stems from both its ability to metabolise a large 
number of therapeutic agents and its high expression level in the liver of most 
humans. Moreover, intestinal CYP3A4 expression accounts for significant first pass
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metabolism of orally administered medication. Consequently, stmcture-function 
analysis of this enzyme can help to elucidate the exact mechanism of many 
drug interactions during drug development (Szklarz and Halpert, 1997). Thus 
considerable attempts have been made to construct molecular models of CYP3A4 to 
rationalise the binding of a broad range of substrates and possibly to predict the routs 
of metabolism and enzyme specificity for novel development compounds (Lewis 
et al, 1996; Szklarz and Halpert, 1997).
As mentioned above although CYP3A4 can metabolise a wide variety of structurally 
diverse substrates, it still exhibits remarkable regio- and stereoselectivity with many 
compounds. For example, the enzyme catalyses the 2p, 6p- and 15p-hydroxylation 
of testosterone, the 6p- and 16a- hydroxylation of progesterone, the 1- and 
4-hydroxylation of midazolam, and M l-, M l7- and M21-oxidation of cyclosporine A 
(Harlow and Halpert, 1997).
The enzyme has a very broad substrate specificity, with >100 substrate now 
identified. Approximately half of the therapeutic drugs currently on the market are 
substrates. The ability of a single protein to catalyse so many reactions has been 
confirmed in studies with recombinant proteins (Ueng et al, 1997).
CYP3A4, like other CYP3A subfamily enzymes, tends to lose catalytic activity 
during purification, and many of its reactions require special conditions for 
reconstitution of optimal activity. Some of the reactions are very sensitive to 
particular reconstitution components (e.g. cytochrome bs, Mg^^ , and negatively 
charged phospholipids) while others are not. In addition, some reactions appear to 
show auto-activation or homotropic cooperativity, at least as judged by sigmoidal 
V versus S plots reported in studies with microsomes. Also, the effects of 
a-naphthoflavone and natural flavonoids vary, yielding stimulation (heterotropic 
cooperativity), no effect or inhibition depending on the reaction (Ueng et al, 1997; 
Halpert et al, 1998).
Autoactivation is observed particularly with substrates such as aflatoxin and 
progesterone resulting in sigmoidal kinetics. The mechanism of stimulation is not
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well understood, but a number of hypotheses have been proposed, including the 
possibility that activators bind to the same site as the substrate or at a separate site, 
causing an allosteric effect on substrate binding (Halpert et al, 1998). Some 
investigators have tried to explain such properties using site directed mutagenesis in 
the CYP3A4 DNA to produce mutant forms of the enzyme with altered active sites. 
These studies have provided the first evidence for the active site location of residues 
that influence flavonoid stimulation of P450 3A4 (Harlow and Halpert, 1997; He 
etal, 1997; Szklarz and Halpert, 1998).
Although much progress has been made toward understanding the substrate 
specificity of CYP3A4, the detailed mechanism of activation is not clear. A broad 
study of multiple mutants with a range of substrates and activators is the next step 
toward defining this process. There is still much to be learned about the function of 
CYP3A4 (Harlow and Halpert, 1997; Halpert et al, 1998).
1.4.4 CYP3A xenobiotic substrates in humans
CYP3A4 probably has the broadest catalytic activity of any cytochrome P450. The 
substrates vary in size from smaller molecules such as paracetamol (Mr 151) to 
cyclosporine A (Mr 1201) (Guengerich, 1999). An updated list of about 100 known 
human drug substrates is presented in Table 1.4. The list of substrates includes not 
only drugs but also synthetic steroids and carcinogens. Although an extensive list of 
other xenobiotic substrates such as pesticides (e.g. parathion, aldrin) has not been 
compiled, undoubtedly the number of substrates is larger. Studies are also in 
progress to determine whether the oxidation of certain peptides is catalysed by 
CYP3A4 (Guengerich, 1999).
CYP3A4 and CYP3A5 catalyse the 6p-hydroxylation of the steroid hormones 
testosterone, progesterone, hydrocortisone, and androstenedione, although CYP3A4 
exhibited several fold higher expressed activity than CYP3A5 (Aoyama et al, 1989; 
Haehner et al, 1996). CYP3A5 shows roughly the same substrate preference pattern 
but the turnover rates are lower. However, exceptions appear to exist, since aflatoxin 
Bi and 1-nitropyrene are both activated by CYP3A4 but not by CYP3A5. However, 
both CYP3A4 and CYP3A5 are active in the metabolism of benzo(a)pyrene and some
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Table 1.4 Drug substrates of CYP3A4 (modified from Guengerich, 1999)
*
Acetaminophen (quinoneim ine formation) Lovastatin (6'P, 6'-exo-m ethylene,
Albendazole (S-oxide) 3",3',5'-dihydrodiol)
Alfentanil (noralfentanil formation) M eloxicam
Alprazolam M ethadone (N-demethylation)
Amiodarone (N-deethylation) M idazolam
Amitryptyline (N-demethylation) M ifepristone (R U 486) (N-demethylation)
A stem izole A-hydroxyarginine
Benzphetamine (N-demethylation) Nevaripine
Bupivacaine (N-dealkylation) Nicardipine (pyridine formation)
Carbamazepine ( 1 0 ,11-epoxidation) N ifedipine (pyridine formation)
Citalopram (N-demethylation) N iludipine (pyridine formation)
Claritromycin N im odipine (pyridine formation)
Clozapine N isoldipine (pyridine formation)
Codeine (N-demethylation) Nitrendipine (pyridine formation)
C olchicine (2,3) Omeprazole (S, 5)
Cortisol (6P) Oxodipine
Cyclophosphamide Paclitaxel (taxol) (3 '-phenyl para-OH)
Cyclosporine A Progesterone (6p,som e 16a)
Cyclosporine G Propafenone
Dapsone (N) Proquanil (cyclisation)
Dehydroepiandroterone 3 -sulfate (16a) Quinidine (3, N )
Delaviridine (6',N-dealkylation) Rapamycin (0-dealkylation)
Dextromethorphan (N-demethylation) Retinoic acid
Diazepam (3) Ritonavir
Digitoxin Sameterol (a )
Diltiazem Sequenavir
Disopyram ide (N-dealkylation) Sertindole (N-dealkylation)
Emetine (0-dem ethylem etine) Sulfam ethoxazole (N)
Ivp-Estradiol (2 ,4 ) Sulfentanil
Erythromycin (0-dem ethylation) Tacrolimus (FK 506) (several)
Ethylmorphine (N-demethylation) Tam oxifen (N-demethylation)
17 p -Ethynylestradiol (2) Tasosartan
Etoposide Teniposide
Felodipine (pyridine formation) Terfenadine (r-butyl, N-dealkylation)
Finasteride (t-butyl) Terguride
Flutamide Testosterone (6p, trace 15p, 2P)
Gestoden T etrahydrocannabinol
Granisterone (7, 9') Theophylline
Haloperidol (alcohol oxidation) Toremifine (4, N-demethylation)
Ifosphamide Triazolam
Imipramine (N-demethylation) Trimethadone (N-demethylation)
Indinavir Trofosfamide (4-hydroxylation,
Ivermectin (several) N-dechloroethylation)
Lansoprazole (5) Verapamil
Lidocaine (N-deethylation) Warfarin (R-10, S-dehydro)
Lisuride (N-deethylation) Zatosetron (N)
Loratidine Zonisamide
Parentheses indicate the positions of oxidation, if identified.
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other procarcinogens (Anttila et al, 1997). Several minor oxidation products of 
steroids (e.g. 15p-hydroxytestosterone) comprising up to ~20% of the total 
metabolites, are formed by CYP3A4 but not CYP3A5 (Aoyama et al, 1989). Clear 
differences were also detected in the catalytic activities toward the 
immunosuppressive drug cyclosporine, with two hydroxylated metabolites and one 
demethylated metabolite formed by CYP3A4 but only one hydroxylated metabolite 
formed by CYP3A5 (Aoyama et al, 1989). Also, CYP3A4 N-demethylates 
erythromycin roughly 10-fold faster than does CYP3A5 (Lown et al, 1994).
Of the large number of compounds identified as substrates of CYP3A sub-family 
members, CYP3A5 was found to rapidly metabolise nifedipine, testosterone, 
oestradiol, dehydroepiandrosterone 3-sulfate (DHEA), and cortisol, whereas it 
metabolised poorly or did not metabolise erythromycin, quinidine, 17a- 
ethinylestradiol, and aflatoxins (Wrighton et al, 1990). Shimada and Guengerich 
(1989) demonstrated that CYP3A4 activates a number of procarcinogens in a 
transformation bioassay with Salmonella typhimurium. Reconstituted CYP3A5 was 
found to have less than 15% of the activity of CYP3A4 in this assay with aflatoxin 
Bi, sterigmatocystin and (-)-benzo(a)pyrene-7,8-diol, and no activity with 
(+)-benzo(a)pyrene-7,8-diol and 6-aminochyrsene (Wrighton et al, 1990). However, 
using purified CYP3A5 and heterologously expressed CYP3A4 in reconstitution 
systems, Wrighton et al (1990) found that CYP3A5 contributes relatively little to the 
metabolism of the majority of the compounds are known to be metabolised by the 
CYP3A subfamily. The lower number of substrates and catalytic rates of CYP3A5, 
relative to CYP3A4, suggest that the substrate binding sites of the two enzymes 
differ, although the amino acid differences between the two proteins appear to be 
evenly distributed (Wrighton et al, 1990).
In vitro, CYP3A7 metabolises substrates such as testosterone, erythromycin, aldrin, 
triacetyloleandomycin, nifedipine, quinidine, benzo(a)pyrene, 7-ethoxycoumarin, 
ethylmorphine, N,N-dimethylaniline, aminopyrine, p-nitroanisole, cortisol, N- 
methylaniline, N,N-dimethylnitrosamine, indinavir and midazolam (Oesterheld, 
1998). Foetal hepatic CYPs have high mutagen-activating abilities. CYP3A7 can 
also activate promutagens such as aflatoxin Bi. Benzo(a)pyrene is metabolised by
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foetal CYP3A7 and CYPlAl enzymes. These foetal reactions could be associated 
with foetal carcinogenesis and dysmorphogenesis (Oesterheld, 1998).
1.4.5 CYP3A gene structure in humans
The whole CYP3A locus in man has been isolated and sequenced (Gellner et al, 
2001). The 231 kb locus on chromosome 7 contains the three CYP3A genes 
described previously (CYP3A4, CYP3A5 and CYP3A7), three pseudogenes and a 
novel CYP3A gene termed CYP3A43 (Figure 1.5).
The CYP3A4 gene is 27 kb long, with 13 exons and 12 introns. The promoter region 
of this gene contains a typical TATA box and the basal transcription element (BTE) 
which is reported to exist in the proximal region of several cytochrome P450 genes 
(Hashimoto et al, 1993; Gellner et al, 2001). In addition, the putative binding sites of 
transcriptional regulatory factors such as the oestrogen receptor (ER), the 
progesterone receptor/glucocorticoid receptor (PR/GR), hepatic nuclear factor-4 
(HNF-4), hepatic nuclear factor-5 (HNF-5) and the tumour suppressor p53 exist 
upstream of the major transcription initiation site (Hashimoto et al, 1993). No gene 
has been found for the cDNA sequence reported previously as CYP3A3 which differs 
from CYP3A4 in 14 coding positions. It is now considered as being an artefact 
resulting from sequencing errors (Guengerich, 1999).
The amino acid sequence deduced from CYP3A5 cDNA contained 502 residues, with 
a calculated protein molecular mass of 57,115 daltons and displayed 84% amino acid 
similarity with CYP3A4. The CYP3A5 promoter contains a CAT A box instead of the 
typical TATA box and a basal transcription element (BTE). The 5'-flahking region 
of CYP3A5, from nucleotide -1 to -1434, is 60% similar with the corresponding 
region of CYP3A4 and 59% with CYP3A7, respectively. However, the similarity 
increases to 74% when only nucleotides -1 to -700 were compared. The similarity 
between CYP3A4 and CYP3A7 in the same region is 92%. The 5'-flanking sequences 
of CYP3A4 and CYP3A7 appear therefore to be more closely related to each other 
than to CYP3A5. The similarity between the 5'-flanking sequences of CYP3A5 and 
that of the two other CYP3A genes drop abruptly to less than 42%, upstream from 
nucleotide -700, while the similarity between CYP3A4 and CYP3A7 remains greater
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than 89%, within the same region (Jounaidi et al, 1994). The similarity between 
CYP3A4 and CYP3A7 is 95% at the nucleotide level and 87% at the amino acid level. 
The similarity of the 5'-flanking region sequences (from -1 to 1000 bp) between 
CYP3A4 and CYP3A7 genes is 91% (Hashimoto et al, 1993). The CYP3A7 
apoprotein has been shown to have a slightly higher molecular weight than other 
members of the CYP3A subfamily (Oesterheld, 1998).
When comparing the proximal promoter region of CYP3A4, CYP3A5 and CYP3A7, 
several motifs or deletions appear to be characteristic of each gene (Figure 1.6). A ten 
nucleotide-long sequence (AGGGCAAGAG, termed ‘nifedipine specific element’ 
[NFSE], from nucleotides -286 to -295) is present in the proximal promoter of 
CYP3A4 and CYP3A5 (with three mismatches, gGGGCAgGtG, from -226 to -235). 
This region is absent in CYP3A7. A nine nucleotide-long sequence is present in the 
promoter of CYP3A7 (GATGGAGTG, termed ‘human foetal liver specific element’ 
[HFLa-SE], from nucleotides -727 to -736) but absent in CYP3A4 and CYP3A5. A 
12 nucleotide-long sequence GAGGGAATTTCG (from nucleotides -328 to -339) is 
present in CYP3A5 but absent in both CYP3A7 and CYP3A4. There is also a 57 bp 
deletion upstream of the BTE (basic transcriptional element) at -66 in CYP3A5. As 
shown in Figure 1.6, CYP3A5 has almost a different promoter sequence compared to 
CYP3A4 and CYP3A7. However, some similarities can be deduced (only up to -700 
bp of the promoter region) if deletions and insertions are being put aside. After that, 
it is not possible to find sequence match between CYP3A5 and other two CYP3As. 
Whether or not these specific sequences play a part in the differential regulation of the 
CYP3A genes in man remains to be established (Gellner et al, 2001).
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- 7 4 1
CAAGCAACCATTAGTCTATTGCTaI' c G G   - c
TAATGACCTAAGAAG’  ------   -jTCACCAGAAAGTCAGASGGGATGACATGCAGSGGCCCAGCAATC
TAATGACCTAAGAAGATGGAGTGGTCACCAGAAAGTCAGAbGAAGTGACAWcAGG'GGCCCAGCAATC
H F L a-S E
C C A  A A C G ^  CA T C A
TCAGCTAAGTCAACTCCACCAGCCTTTCTSGTpGCCCACTGTGTGTACAGCACCCTG§TAGGGACCAG
TCAGCpAAGTCAACTCCACCAGCCTTTCTjsbTrqCCCACTGTGTGTACAGCACCCTGATAGGGACCAG
G T A T A T C G  C A  A
AGCCATGAÎCAGGGASTAAGACTAGACTATGCCCTTGAGGAGCTCACCTCTCTTpAGGGAAACAGGCiT
AGCCATGAGAGTGAWTAAGAcWAGACTATGCCCTTGAGGAGCTCACCTCTGBlWAGGGAAACAGGCCT
A
TT
A C TG G A G G CA
GGAAACACAATGGTGGTAAAGAGGAAAGAGGACAATAGGApTGCATGAAGGGGATGGAAAGTGCCCAG
GGAAA^JcAATGGTGGTAAAGAGGAAAGAkGACAATAC^A^TGCATGAAGGGGATGGAAAGTGCCCAG
A T G A A T T  GC W G  G
cGGGAGGAAATGGTTACATCTGTGTGAGGSgTiTTGGTGAGGAAAGACTCTAAGAGAAOTCTCTGTCTGT
GGGAGGAAATGGTTACgTCTGTGTGAGGgGgTTGGTGAGGAAAGACTCTAAGAGAAGGCTCTGTCTGg
AC A A
GAGGGAATTTCG
ctgggtp t^c^ a a g g a t g t g t a g g a g t c t t c t a g g g g g c a c a g g c a c a c t c c a g g c Àt a g g t a a a g a t c
CTGGGTATGAAAGGATGTGTAGGAGTCTTCTAGGGGGCACAGGCACACTCCAGGCATAGGTAAAGATC
GA G T C A A G G  G
TGTAGGTGTGGCTTGTTGGGATGAATTTCAAGTATTpjTGGAATGAGGACAGCCATAGAGACAAGGGCA’
t g t a g g c a !t g g c t t g t t g g g a t g j^ t t t c a a g t a t t p t g g a a t g a g g a c a g c c a t a g a g a c a a ----------
- 2 8 6  [NFSE]
G t | ,  a  g g  c
kGAGAGAGGCGApTTAATAGATTTTATGCCAATGGCTCCACTTGAGTTT^TGATAAGAACCCAGAACC
 GAGG^GAbTTAATAGATTTTATGCCAATGGCTCCACTTGAGTTTfeTGATAAGAACCCAGAACC
GA C A C T C T ^  C A
CTTGGACTCCCCAGTAACATTGATTGAGTTGTpTATGATACÇl^CATAGAATATGAACTCAAAGGAGGT
CTTGGACTCCCCAGTAACATTGATTGAGTTGTGTATGATTCTACATAGAATATTAACTCAATGGAGGT
[ER6]
A CA A - GG C _  ---------- ----------------------------------------------------------------------------
CAGTGAGTGGTGTGTGTGTGATTCTTTGCCAACTTCCAAGGTGGAGAAGCCTCTTCCAACTGCAGGCA
c a g t g a g t g g t g t g t g t g t g a t t a t t t g c c a a c t g c c g a g g t g g a g a a g c c t c t t c c a Gc t g c a g g c a
------------ ^   T AT c c TCT T
GAGCACA'GGTGGCCCTGCTACTGGCTGCAGCTCCAGCCCTGCCTCCTTCTCTAGCATATAAACAATCC
GAGCACriGQSGGCCCTGCTACTGGCTGCAGCTCCAGCCCTGCCTCCTTCTCCAGCATATAAACAATCC 
^ ^ - 1  [BTE] [TATA box]
G T GG CYP3A5
AACAGCCTCACTGAATCACTGCT CYP3A4
AACAGCCTCACTGAATCACTGCT CYP3A7
Figure 1.6 Comparison of proximal promoter regions of the CYP3A4, CYP3A5 
and CYP3A7 genes (Gelner et al, 2001; GenBank GI No. 11177452). CYPS A4 
(bold) and CYP3A7 are presented as matched sequences (differences are highlighted). 
Sequence related to CYP3A5 is shown where there is a difference with CYP3A4. 
Hyphens show deletions and boxes indicate insertions. TATA box, BTE, NFSE and 
HFLa-SE are underlined respectively. Numbering (shown by arrows) is based on 
CYP3A4 sequence and defines the nucleotide close to the transcription start as -1.
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1.5 Control of gene expression by nuclear receptors
1.5.1 Role of the ‘hormone’ receptors
The concept that small lipophilic hormones could regulate cellular function by 
interacting with specific cellular proteins called receptors, was first proposed 40 years 
ago from direct ligand-protein binding studies (Jensen and Jacobson, 1962). Final 
proof of the ‘nuclear receptor’ hypothesis was provided by the molecular cloning and 
in vitro expression of functional steroid hormone receptors (reviewed in Sladek and 
Giguere, 2000). The subsequent isolation and characterisation of receptors that were 
activated by non-steroidal ligands such as vitamin A and thyroid hormone suggested 
that nuclear hormone receptors could potentially regulate gene expression in response 
to a wide variety of lipophilic ligands (Evans, 1988). More than 70 such reporters 
have been identified so far (reviewed in Honkakoski and Negishi, 2000). Nuclear 
receptors with no known ligands at the time of their discovery are referred to as 
‘orphan’ nuclear receptors and considerable effort has been devoted to identifying 
ligands and physiological functions for these gene products (Sladek and Giguere, 
2000). The nuclear receptor gene family is structurally and functionally conserved 
across species and is represented within metazoan phylae from cnidarians to 
vertebrates (Escriva et al, 1997).
The discovery that certain orphan nuclear receptors are activated by non-classical 
hormones such as vitamin A derivatives, prostanoids, sterols, and fatty acids, 
combined with the observation that nuclear receptor binding response elements (REs) 
are present in the 5' regulatory regions of genes encoding enzymes involved in 
cellular metabolism, suggest that many orphan nuclear receptors may be important 
regulators of as yet unidentified basic endogenous cellular functions in vivo (Sladek 
and Giguere, 2000). This hypothesis has been corroborated by genetic linkage 
studies in patients with certain metabolic disorders (e.g. Chang et al, 2000; Li et al, 
2000; Naville et al, 2000; Nishigori et al, 2001) as well as physiological studies of 
mutant mice harbouring defective nuclear receptor genes (e.g. Shinoda et al, 1995; 
Peet et al, 1998). Members of the nuclear receptor family may thus perform key 
roles in balancing the metabolic demands of the whole organism, regulated by 
classical endocrine hormones, with those of individual organs and cells, encoded by 
lipophilic paracrine and intracrine signals (Sladek and Giguere, 2000). Mutations in
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the structural genes of certain receptors may cause certain types of cancer and 
hormone-resistance syndromes (Honkakoski and Negishi, 2000).
The majority of nuclear receptors bind specifically and with high affinity to their 
cognate hormone response elements (HREs) in DNA. Contacts between key amino 
acid residues in the receptor DNA-binding domain (DBD) and nucleotide bases 
within the cognate HRE core motif are primarily responsible for recognition of the 
HRE. The HRE is usually composed of two half-sites related to the nucleotide 
hexamer AGGTCA. However, the organisation of the HRE mirrors the nature of 
receptor binding (Figure 1.7):
(1) Some steroid-hormone receptors bind as homodimers to palindromic elements 
spaced by three nucleotides in a symmetrical way.
(2) Many other hormone and orphan receptors (e.g. PXR) form heterodimers with 
the retinoid X receptor (RXR) and bind to repeats with variable spacing. 
Heterodimers can recognise diverse HREs in which half-core motifs can be 
arrange as palindromes (Pal), direct repeats (DRs), or inverted palindromes (IPs). 
The ability of binding to these different motifs implies that the DBDs can rotate 
with respect to the ligand binding domains (LBDs) that held together through the 
dimérisation interface.
(3) Some receptors bind as monomers (e.g. steroid receptor-related receptors) to a 
single AGGTCA-like site (Honkakoski and Negishi, 2000). Monomeric binding 
requires the half-core motif preceded by a 5'-flanking A/T-rich sequence.
Also, gene regulation by some nuclear receptors can occur independently of direct 
DNA binding and is mediated by protein-protein interactions involving other 
transcription factors or adapter proteins. This has been demonstrated most clearly for 
the glucocorticoid receptor (Sladek and Giguere, 2000).
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Figure 1.7 Binding of receptors to the hormone response elements (HREs). 
Receptors can bind as monomers, homodimers, or RXR heterodimers to DNA 
(Aranda and Pascual, 2001). Dimérisation is mediated by a strong interface 
(composed of hydrophobic repeats) present in the LBD, and cooperative binding of 
receptor dimmers is facilitated by a DNA-dependant interface that forms between the 
DBDs.
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1.5.2 Structure of the nuclear receptors
Members of the nuclear receptor family have a well-conserved protein domain 
structure that parallels the functions of the receptor protein. The ligand-binding 
domain (LED), which is less well conserved among family members, occupies the 
C-terminal region of the receptor and mediates ligand binding, dimérisation, 
interaction with heat shock proteins, nuclear localisation and transactivation 
functions. Although quite variable in primary sequence, nuclear receptor LEDs can 
be defined by a signature motif overlapping with helix 4. In addition, ligand- 
dependant transactivation is dependant on the presence of a highly conserved motif, 
referred to as activation function-2 (AF-2), localised at the carboxy-terminal end of 
the LED (Giguere, 1999 and reference therein).
The DED displays the highest protein sequence conservation among family members 
and consists of two zinc finger motifs encoded by 66-70 amino acid residues, each 
containing four cysteine molecules bound to a zinc atom, and a carboxy-terminal 
extension (GTE) that spans approximately 25 residues. This results in the formation 
of a tertiary structure containing helices that interact specifically with DNA 
sequences that are organized appropriately in response elements (Freedman et al, 
1988a; Freedman et al, 1988b; Luisi et al, 1991). In other words, the DED may be 
considered as two interdependent sub-domains each consisting of a zinc ion, 
tetrahedrally coordinated to the sulphurs of four cysteine residues, and an 
amphipathic helix. They differ both structurally and functionally. The helix of the 
first sub-domain is mainly involved in site-specific recognition based on its 
interaction with DNA response element hexamer (Luisi et al, 1991; Lee et al, 1993a). 
A loop formed in the second sub-domain provides the DED homodimerisation 
interface and less specific DNA interactions (Figure 1.8).
The hinge domain of nuclear receptors has a connecting function between the DED 
and LED. High variability in both length and primary sequence of the hinge region 
allows the DED to rotate by up to 180° in some receptors enabling them to bind as 
dimers on direct and inverted hormone response elements. However, some studies 
have reported that the hinge region also contains a functional feature called the 
CoR-box may serve as a binding site for co-repressors (Giguere, 1999).
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Figure 1.8 Functional domains in nuclear receptors and typical NR gene 
structure (adapted from Giguere, 1999). A) General structure of nuclear 
receptors indicating the conserved zinc finger-based DNA binding domain (DBD) 
and the C-terminal ligand binding domain (LBD) which mediates ligand 
binding and dimérisation. In addition, constitutive (AF-1) and ligand dependent 
(AF-2) activation functions have been identified. Amino acid sequence conservation 
is the basis for defining the A to F domains of the same receptor in different species. 
B) Representative organisation of a nuclear receptor gene indicating alternative 
promoter usage (arrows) and splicing (linked exons). The zinc finger modules are 
encoded by distinct exons while the hinge and LBD are encoded by between 6 and 10 
exons. Nuclear receptors with modified LBDs may also be generated via further 
alternative splicing events.
40
The modulator domain, also referred to as the A/B domain, displays the most 
variability both in terms of length and primary sequence. This region usually 
contains a transcriptional activation function, referred to as AF-1. Studies of the 
oestrogen and progesterone receptors have clearly demonstrated that the modulator 
domains possess promoter- and cell context-dependant activities, suggesting that the 
amino-terminal region of nuclear receptors may interact with cell-specific cofactors. 
The modulator domain can also interact directly with steroid receptor co-activators 
(SRCs) to enhance the activity of the receptor complex (Giguere, 1999 and reference 
therein).
The three dimentional structure of the recombinant LBDs of the retinoic acid receptor 
y  (RAR-y), thyroid receptor (TR) and oestrogen receptor (ER) have been 
characterised by x-ray diffraction, as has that of the unliganded retinoid X receptor a  
(RXR-a) (Bourguet et al, 1995; Renaud et al, 1995; Wagner et al, 1995; Brzozoeski 
et al, 1997). Ail are composed of a series of 11-12 a-helices (HI-H 12) closely folded 
in a similar manner (Figure 1.9). The C-terminal part of the LBDs of these receptors 
has been shown to have a ligand-inducible trans-aetivation function, termed AF-2 
(Green and Chambon, 1988; Nagpal et al, 1993). Both deletion and mutation studies 
have shown that the AF-2 activation helix is essential for ligand-induced 
transcriptional activation (Kumar and Thompson, 1999). It appears that the 
activation of AF-2 upon ligand binding corresponds to major eonformational 
changes, which create the surface required for efficient interaction with transcription 
factors, the putative mediators of AF-2 function (Danielian et al, 1992; Mcinemey 
et al, 1996). The LBD not only serves to provide a class-specific ligand-binding site, 
but also as a homodimerisation domain. It also interacts with other proteins in 
transactivating genes and still others in regulating receptor activation (Kumar and 
Thompson, 1999). Thus, a ligand interacts with its cognate receptor to induce 
conformational changes in the tertiary protein structure, enabling productive 
interactions between the hormone-bound reeeptor and its target response element on 
DNA sequences (Heery et al, 1997; Masuyama et al, 1997).
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Figure 1.9 Schematic representations of the RXR-a LBD (left) and RAR-y 
LBD (right) (Kumar & Thompson, 1999). H2 is found in RXR but not in RAR. 
The LBDs of TR and ER have a similar overall topology.
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1.5.3 Categories of nuclear receptors
The nuclear hormone receptor super family is divided into three well-known major 
categories based on functional studies, ligand specificity, and DNA- and ligand- 
binding regions:
(1) Steroid hormone receptors
(2) Thyroid/retinoid/vitamin D and peroxisome proliferator activated receptors
(3) The largest category, receptors for which no ligand is known, or orphan receptors 
(Kumar and Thompson, 1999).
Although these proteins are called the nuclear receptor family, some members such as 
glucocorticoid and mineralocorticoid receptors are transported to the nucleus only 
after ligand binding (Savory et al, 1999; Lombes et al, 1994). The first decade of 
orphan nuclear receptor research has yielded a large number of new family members 
and many tantalising clues to their biological functions (Kliewer et al, 1999). 
However, ligands have been identified for only a handful of these receptors. Given 
the large number of remaining orphan nuclear receptors and the recent advances in 
combinatorial chemistry, high-throughput screening, and funetional genomics, the 
next decade promises an explosion in our understanding of nuclear hormone 
signalling pathways.
1.5.4 Regulation of cytochrome P450 expression by nuclear receptors
After activation by ligand binding, the nuclear receptors ean modify expression of 
cytochrome P450 and other genes through a complex control network (Figure 1.10). 
Also, nuclear receptor ligands can be metabolised by cytochrome P450s creating a 
feedback loop. The cytochrome P450s involved in metabolism of vitamin D 
(CYP24) and retinoids (CYP26, CYP2C7) are examples (Honkakoski and Negishi, 
2000). Other examples of similar relationships are shown in Table 1.5.
In early attempts to investigate the mechanisms by which the drug metabolising 
cytochrome P450 genes are controlled, a phénobarbital response element (PBRE) was 
identified upstream (-2318 to -2155 bp) of the rat CYP2B2 gene (Trottier et al, 
1995) and two nuclear reeeptor binding sites of type AGGTCA known as direct 
repeat 4 (DR-4) were identified as important in the induction of CYP2B genes by
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CYP-dependent metabolism 
of xenobiotics and endobiotics
CYP genes XO, EO
NRs
Other genes
Figure 1.10 Relationship between nuclear receptors, their ligands and 
cytochrome P450 enzymes (after Honkakoski and Negishi, 2000). Nuclear 
receptors are ligand-activated transcription factors regulating the activity of 
cytochrome P450s and other genes to generate specific cellular responses to 
activating ligands. These ligands are formed and degraded via specific cytochrome 
P450 enzymes. The ligands may be xenobiotics (X), endobiotics (E) or their 
oxidation products (XO, EO).
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Table 1.5 Examples of interactions between genes and nuclear receptors 
(modified from Honkakoski and Negishi, 2000)
CYP gene CYP substrates/products NRs affected by the CYP NRs known to regulate
that can serve as NR ligands substrate/product CYP genes*
CYPIA Oestrogens, retinoids ERs, RARs, RXRs ER, GR, RAR
CYPIB Oestrogens ERs E R ,G R
CYP2A Androgens AR HNF-4
CYP2B Xenobiotics^ M any CAR (PXR)
Androgens^ oestrogens, AR, ER, PPAR, PXRs GR
retinoids
CYP2C X enobiotics^
N SA ID s
Androgens, retinoids, 
fatty acids derivatives
M any
AR, ER, RARs, RXRs 
PPARs
HNF-4, orphan 
RAR
CYP2D Xenobiotics^ M any ER
Androgens, oestrogens. A R ,E R V D R
vitamine D 3 HNF-4
CYP3A Xenobiotics^
M ethoxychlor
M any PXR (CAR) 
HNF-4, orphan
Androgens, corticoids. AR, ER, GR GR
oestrogens, pregnanes^
CYP4A Fatty acid derivatives PPARs PPAR, (orphan)
CYP26 Retinoic acid RARs, RXRs RAR
CYP27B1 Vitamin D V D R
CYP24 Vitamin D V D R V D R  
(RXR, orphan)
Steroidogenic
CYPs Androgens, oestrogens, 
corticoids, pregnanes^
AR, ER, GR, M R SF-1, orphan
CYP74 Precursors o f steroids CPF, LXR, 
FXR
Bile acid- Oxysterols LXR, FXR LXR?, FXR?
forming CYPs
CYP51 Sterols LXR
* Nuclear receptors in parentheses have a tentative role.
 ^M any compounds in this class are activators o f PXR, C AR or PPAR.
Abbreviations: N SA ID S, nonsteroidal anti-inflammatory drugs; M R, mineralocorticoid 
receptor; VDR, vitamin D  receptor.
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phénobarbital (Park et al, 1996). A similar sequence in the mouse CyplblO gene was 
shown to be activated by several compounds in reporter gene assays in mouse 
primary hepatocytes (Honkakoski et al, 1998). It has now been revealed that the 
orphan nuclear receptor CAR (constitutive androstane receptor) binds to DR-4 
elements a heterodimer with the retinoid X receptor a  (RXRa) and transactivates the 
CYP2B genes (Sueyoshi et al, 1999). Sequence analysis of the CYP3A  gene 
regulatory regions established an array of response elements that interact with another 
orphan nuclear receptor PXR (pregnane X receptor) as a direct (DR-3) repeat in 
rodent CYP3A genes (Kliewer et al, 1998) and everted (ER-6 ) repeats in the rabbit, 
and human CYP3A promoters (Lehmann et al, 1998). It has also become evident that 
HNF-4 (hepatocyte nuclerar factor 4) or related orphan nuclear receptors control 
basal expression of certain cytochrome P450 enzymes, e.g. CYP2D (Yoshioka et al,
1990), CYP2C (Ibeanu and Goldstein, 1995), CYP2A (Yokomori et al, 1997) and 
CYP3A (Ogino et al, 1999). Since the cytochrome P45ÜS are responsible for the 
metabolism of a wide range of endogenous compounds as well as xenobiotics, the 
complexity of the control loops is evident.
1.5.5 Nomenclature of nuclear receptors
The unified nomenclature system for nuclear receptors (Laudet et al, 1999) is based 
on amino acid sequence similarity and follows the rules applied for the cytochrome 
P450 super-family. Briefly, it recommends the capital letters NR (for nuclear 
receptors) followed by an Arabic number indicating gene family, a capital letter for 
subfamily members, an Arabic number for defining the individual gene and a lower 
case letter for receptor isoforms generated from the same gene by alternative 
promoter usage or differential splicing.
1.6 Co-activators and co-repressors of gene expression
1.6.1 Role of co-activators and co-repressors
The regulation of transcription by members of the nuclear receptor family occurs by a 
mixture of mechanisms, involving direct interaction of each receptor with specific 
DNA sequences and a variety of other proteins. These include other sequence- 
specific DNA-binding transcription factors, the basal transcription factors, various
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co-activators, co-repressors, and ‘integrators’ of transcription (Kumar and Thompson, 
1999).
The interplay between distinct nuclear receptor responsive transcription pathways has 
been recognised for some time (Bocquel et al, 1989; Meyer et al, 1989). The 
capacity for the activation of transcription by one nuclear receptor to compromise a 
transcriptional response, which depends on a second receptor, implies that shared 
components of transcriptional machinery were involved. An explanation for this 
transcriptional interference became apparent with the discovery of shared co-activator 
proteins that facilitated communication between nuclear receptors, the basal 
transcriptional machinery and the chromatin environment (reviewed by Torchia et al,
1998).
1.6.2 Activation of co-activators and co-repressors
Control of gene expression by nuclear receptors requires the recruitment of 
functionally distinct co-regulatory complexes which appear to operate through 
different mechanisms (Figure 1.11). A structural feature of the common co-activators 
and co-integrators such as p300/CBP, SRC-1 and TIF-2 is an a-helical LXXLL 
(leucine zipper) motif, or NR box present from a single to several copies and 
implicated in ligand-dependent recruitment by the LBD-embedded activation 
function 2 (AF-2) of nuclear receptors (Darimont et al, 1998). As a result, several 
functional properties are common across different groups of co-activators. 
Acetyltransferase activity, for instance, with which co-activators are thought to target 
histones and other proteins can cause disruption of chromatin packing and activation 
of transcription (Grant and Burger, 1999). This process usually starts with the initial 
binding of a nuclear receptor ligand and dissociation of co-repressor proteins such as 
nuclear hormone receptor co-repressor (NcoR) and silencing mediator of retinoid and 
thyroid receptors (SMRT) (Chen and Evans, 1995; Horlein et al, 1995; Kurokawa 
et al, 1995; Zamir et al, 1997; Ordentlich et al, 1999; Xu et al, 1999). Subsequently, 
recruitment of e.g. switch/sucrose non-fermentable (SWl/SNF) family members of 
chromatin remodelling enzymes facilitates transcription indirectly by alleviating the 
repressive effects of histone-DNA contacts. These two classes of co-activators may 
act in concert to regulate transcription initiation (Collingwood et al, 1999).
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Figure 1.11 Model for gene activation and gene repression by nuclear receptors 
(after Honkakoski and Negishi, 2000). L igand  b in d in g  or other activa tin g  
p ro cesses  in d u ce the b in d in g  o f  the nuclear receptor (N R ) to the D N A  e lem en t. T he  
ligan d -b ou n d  nuclear receptor then recruits a co m p lex  o f  co m m o n  and/or N R -sp e c if ic  
co-activators and co-in tegrators, and turns on  acéty la tion  o f  h iston es to activate  
transcription. In the a b sen ce  o f  lig a n d s or upon  antagon ist b ind ing , so m e but n ot all, 
nuclear receptors b in d  co-repressors to trigger d eacety la tio n  o f  h isto n es and  
m aintenance o f  chrom atin  structure.
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Acétylation of the core histones also destabilises chromatin folding and a major 
consequence of this is facilitated transcription factor access to DNA and (Lee et al, 
1993b; Ura et al, 1997; Tse et al, 1998). One effect of acetylating the basic 
N-terminal domains of the core histones is to reduce the stability of electrostatic 
interactions between the tail domains, the acidic phosphodiesterase backbone of 
DNA, the acidic domains of other proteins associated with nucleosomes and on other 
chromatin fibres (Hong et al, 1993; Tse et al, 1998). There may also be 
consequences for histone secondary structure and shape-related interactions with non­
histone proteins following acétylation (Hansen et al, 1998). Also, histone acétylation 
coupled with the action of SWl/SNF chromatin remodelling complexes can facilitate 
the processivity of RNA polymerase through chromatin (Brown et al, 1996; Ura et al,
1997).
Repression of transcription in many ways is similar to transcriptional activation. 
Analogus to co-activators, the nuclear receptor co-repressors NcoR and SMRT are 
recruited in the absence of ligand or in the presence of antagonists to deacetylate 
histones, stabilise chromatin structure and repress transcription (Johnson and Turner, 
1999). The transcription intermediary factor 1 (TlF-1) is another repressor protein 
with co-repressor activity via deacetylation of histones (Le Dourain et al, 1995; vom 
Baur et al, 1996). Also, it has been shown that nuclear receptor activity can be 
repressed directly by binding of other transcription factors such as STATSb (Zhou 
and Waxman, 19990.
1.7 Nuclear receptor activation and CYP3A regulation
CYP3A genes are characterised by expression in liver and intestine (main tissues), 
catalysis of steroid hormone and bile acid 6 p-hydroxylation reactions, selective 
inhibition by the mechanism based inactivator troleandomycin, and induction by a 
broad range of steroids and antibiotics (Waxman, 1999). There are, however, 
important species-specific differences in the induction response. Most notably, while 
the rat, rabbit and human CYP3A genes are all inducible by dexamethasone, the anti­
glucocorticoid pregnenolone 16a-carbonitrile (PCN) is an efficacious CYP3A inducer 
in rat but not in human or rabbit. By contrast, the antibiotic rifampicin is an excellent 
CYP3A inducer in human and rabbit, but not in the rat (Kocarek et al, 1995).
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Transfection studies carried out in rat and rabbit hepatocytes utilising CYP3A 
constructs containing dexamethasone-respsonsive regulatory elements derived from 
rat CYP3A23, rabbit CYP3A6, and human CYP3A4 genes demonstrated that the 
species-specific induction responses are not due to speeies differences in the 
individual CYP3A genes, but rather are a function of factor(s), most likely a receptor, 
provided by the host species liver cell (Waxman, 1999 and references therein). The 
first indication that the complex regulation of CYP3A might reflect a conunon 
mechanism involving a nuclear hormone receptor (NHR) came from cw-acting 
control elements in the proximal promoter region of CYP3A genes (Savas et al,
1999). Using deletion analysis and DNA foot-printing, these responses were mapped 
to each of two sites that conform closely to NHR binding sequences and that are 
distinct from glucocorticoid receptor (GR) binding sequences (Table 1.6). One of 
these sites corresponds to a direct repeat of the hexameric, consensus binding site for 
NHRs, (A/G)(A/G)(G/T)TCA, separated by three nucleotides (DR3), that is also 
found in the promoter of the rat CYP3A2 gene. The other NHR binding site 
constitutes an imperfect everted repeat separated by six nucleotides (ER6 ) with an 
overlaying DR-4 motif. This element is found in rat CYP3A23 and CYP3A2 
promoters as well as in the promoters of the human CYP3A7 and CYP3A4, and rabbit 
CYP3A6 genes (Savas et al, 1999). The NHR, which binds to these elements, has 
been cloned and termed the pregnane-X-receptor (PXR) (Kliewer et al, 1998).
1.7.1 PXR and its role in species-specific induction of CYP3A
Identification of the dexamethasone/pregnenolone 16a-carbonitrile (PCN) response 
element of the CYP3A genes provided the initial firm evidence for involvement of a 
nuclear receptor in CYP3A induction. Cloning of PXR (NR 112), a PCN-activated 
nuclear receptor in mouse liver, by Kliewer’s group at Glaxo Welcome (Kliewer 
et al, 1998) confirmed this conclusion. Kliewer’s group demonstrated that PXR, 
named the pregnane-X-receptor because of its strong activation by pregnane 
compounds, seemed to mediate CYP3A induction not only in mice, but through its 
homologous counterparts in rat, rabbit, and humans, as well (Bertilsson et al, 1998; 
Blumberg et al, 1998; Lehmann et al, 1998; Zhang et al, 1999; Savas et al, 2000). 
The human PXR receptor is also referred to as steroid and xenobiotic-sensing 
receptor (SXR) (Blumberg et al, 1998). It soon become apparent that PXR was an
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Table 1.6 Nuclear receptor response elements in the 5'regulatory regions of CYP 
genes (adapted from Savas et al, 1999).
Receptor Motif Sequence Gene
PPAR/RXR DR-1 aactAGGGTA a AGTTC Agtg 
aactAGGGTA a AGTTGAggg 
aagtAGGACA a AGGCCAggg
CYP4A1
CYP4A6
CYP4A6
PXR/RXR DR-3
ER- 6
AGTTCAtgaAGTTCA
agaataXGA ACT caaagg AGGTC Agtgagt 
agcacaTGA ACT cagaggAGGTC Accacgg 
agaatgTTAACT caaagg AGGTC Aaaaata
CYP3A23
CYP3A4
CYP3A6
CAR/PXR DR-4
DR-4
DR-4
gtgccaAGGTC Aggaa AGT AC Agattct 
gGTGTCAggcaAGTTGAggtgg 
caAGGTCAggaaAGTACAgt
Cyp2bl0
Cyp2bl0
CYP2B6
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unusual receptor in that it was activated by a remarkably diverse collection of 
compounds, including both xenobiotics and natural steroids (Bertilsson et al, 1998; 
Blumberg et al, 1998; Lehmann et al, 1998; Zhang et al, 1999; Jones et al, 2000; 
Savas et al, 2000). Among the chemicals that activated PXR were the macrocyclic 
antibiotic rifampicin, the glucocorticoid dexamethasone, the anti glucocorticoids PCN 
and mifepristone, which provided the first hint that PXR regulated CYP3A. Over the 
past 4 years, a large body of evidence has accumulated linking PXR to the regulation 
of CYP3A gene expression. The evidence includes the following:
(1) High expression of PXR has been shown in the liver and intestine of humans, 
rabbit, rats and mice (Bertilsson et al, 1998; Blumberg et al, 1998; Lehmann 
et al, 1998; Zhang et al, 1999; Jones et al, 2000; Savas et al, 2000). CYP3A 
genes are expressed and induced in response to xenobiotics in these tissues. 
Similar to other nuclear receptors, PXR contains an N-terminal transactivating 
domain (TAD), followed by a DNA binding domain (DBD), and a C-terminal 
ligand-binding domain (LBD) (Figure 1.12A).
(2) Mutation analysis of the previously identified CYP3A response elements 
established the PXR binding site of the rodent CYP3A promoter/enhancer as a 
direct repeat, DR-3 (TGAACT3nTGAACT) (Kliewer et al, 1998), and the 
rabbit and human CYP3A response elements as everted repeats ER - 6  
(TGAACT6 nAGGTCA) (Lehmann et al, 1998) or inverted repeats, IR- 6  
(Blumberg et al, 1998). The PXR forms a heterodimer with RXR (NR2B1), a 
requirement for binding and activation. PXR/RXR heterodimer can interact with 
either the DR-3 or ER-6 /IR- 6  elements in CYP3A promoters and through these 
response elements activates transcription efficiently (Figure 1.12B). This 
heterodimer can also bind to and activate the regulatory response through DR-4 
and ER- 8  elements located in the regulatory region of CYP2B genes (Xie et al, 
2000a; Goodwin et al, 2001) and the multi-drug resistance-associated protein 2 
(MRP2) gene (kast et al, 2002). Thus, the PXR/RXR heterodimer is capable of 
activating transcription through a variety of response elements with distinct 
architectures. The human CYP3A4 gene appears to have not only the ER6  
response element, located in the proximal promoter (Barwick et al, 1996) 
but also a second, distal xenobiotic responsive element module (XREM), located
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Figure 1.12 Comparison of PXR sequence homology among species (A) and 
interaction of PXR-RXR heterodimer to different xenobiotic response elements 
(B) (adapted from LeCluyse, 2001; Kliewer and Wilson, 2002).
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-7.8 kb upstream of the transcriptional starts site (Goodwin et al, 1999). XREM 
contains PXR binding sites DR-3 and ER-6 . In transient transfection studies in 
HepG2 cells, XREM was required for induction of CYP3A4 constructs by 
numerous dmgs (Goodwin et at, 1999).
(3) It has become evident that almost all the chemicals that activate PXR in reporter 
gene assays are in vivo CYP3A inducers. They belong to a wide range of 
pharmacologically and structurally diverse endogenous, and xenobiotic 
chemicals such as steroid hormones and therapeutic agents (Blumberg et at, 
1998; Moore et at, 2000a) as well as dietary compounds such as coumestrol and 
carotenoids (Blumberg et al, 1998). The most potent PXR ligand is hyperforin, a 
constituent of St. John’s wort, a herbal remedy for depression with an EC5 0  of 
23 nM (Moore et al, 2000b). The best-known pharmaceutical agents that activate 
PXR include rifampicin, phénobarbital, nifedipine, clotrimazole, R U 486  
(mifepristone), and metyrapone (Goodwin et al, 1999; Moore et al, 2000a).
PXR activation profiles have shown to vary considerably between species. For 
example, while PCN effectively activates mouse and rat PXR, its activity towards 
human and rabbit PXR is low (Lehmann et al, 1998; Savas et al, 2000). Rifampicin, 
in contrast, produces an opposite effect and strongly activates human and rabbit PXR 
with almost no effect on rat or mouse PXR. The PXR activation profiles produced by 
rifampicin and PCN closely correlate with their induction profile of CYP3A enzymes 
in hepatocytes derived from these species (Kocarek et al, 1995; Jones et al, 2000). 
These results provided strong pharmacological evidence that PXR regulates CYP3A 
expression in vivo. Cloning and characterization of PXR from human, rabbit, rat and 
mouse have shown that there is >95% sequence identity in DBD regions. However, 
the LBDs of the PXRs are much less similar and share only 75-80% amino acid 
identity (Figure 1.12A) and display markedly different activation profiles in response 
to xenobiotics (Zhang et al, 1999; Jones et al, 2000). As the DBD is highly 
conserved among the PXRs in several species the difference in CYP3A regulation by 
xenobiotics is likely due to the differences in the LBDs of the receptors.
Zhang et al (1999) reported that specific amino acid substitutions found in the LBD 
regions of PXR may be responsible for the species differences in CYP3A induction
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by xenobiotics. Their data reveal that rat PXR has nine amino acid substitutions 
compared with the mouse PXR in the LBD, and are likely to be responsible for the 
lower responsiveness of rats to rifampicin. Compared with the human PXR, five of 
the nine amino acids in mouse PXR are conserved in human PXR, and the remaining 
four residues, Phei8 4 , Arg2 0 3 , Lyss3 4 , and Ser4 i4 , are substituted by Serig?, Leuzos, 
GIU3 3 4 , and He4 i4  respectively. The five amino acids conserved between mouse and 
human PXRs likely support the interaction between PXR and rifampicin. In contrast, 
the remaining four substitutions could cause drastic changes in the hydrophobicity 
or the net charge of the ligand-binding domain. Thus, these substitutions likely 
contribute to the lower responsiveness of mice to rifampicin compared with that of 
humans.
Given their high degree of sequence identity, it is not surprising that the rat and 
mouse PXR have very similar activation profiles, although there are subtle 
differences in their response profiles. Overall, these data support the important role 
of PXR in the regulation of CYP3A expression in multiple species, and, although the 
human, rabbit, rat and mouse PXR are activated by several of the same compounds, 
each is pharmacologically distinct (LeCluyse, 2001).
(4) Transgenic mice have been developed to establish the role of the PXR in vivo 
(Xie et al, 2000b; Staudinger et al, 2001). Targeted disruption of the mouse PXR 
gene eliminated the induction of Cyp3Al 1 by PCN. PXR-null transgenic mice 
harbouring the human PXR gene, when challenged with drugs known to induce 
human CYP3A such as rifampicin and clotrimazole, displayed induced CYP3A 
mRNA in the liver. Transgenic mice expressing a constitutively active human 
PXR were shown to develop sustained CYP3A expression, resulting in enhanced 
protection against challenges of xenobiotic toxicants (Xie et al, 2000b).
PXR is now known to play a key role in the regulation of both drug metabolism and 
efflux by inducing a net work of genes, including those that encode cytochrome 
P450s (particularly CYP3A4) (Kliewer et al, 1998) and the multidrug resistance gene 
ABCBl (previously known as MDRl) which encodes P-glycoprotein (Synold et al, 
2001) (Figure 1.13). It is also shown that PXR is activated by LCA (lithocholic 
acid, a toxic hydrophobic secondary bile acid that is primarily formed in the intestine
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Figure 1.13 PXR activation by xenobiotics results in a defensive mechanism 
involving more than one gene (adapted from Ekins and Schuetz, 2002). P X R  has
a very large (> 1 1 0 0  A), spherica l ligan d -b in d in g  cav ity , w h ich  accou n ts for its  
p rom iscu ou s ligan d -b in d in g  properties (W atkins et al, 2 0 0 1 ). D rugs can  b ind  and  
activate the nuclear horm one receptor, pregnane X  receptor (P X R ) lea d in g  to  
induction  o f  cy toch rom e P 4 5 0  iso form  3 A 4  (C Y P 3 A 4 )-m ed ia ted  drug m eta b o lism  
and A B C B l-P -g ly co p ro te in -m ed ia ted  drug e ff lu x  (E k ins and S ch u etz, 2 0 0 2 ).
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by the bacterial 7a-dehydroxylation of chenodeoxycholic acid) and its 3-keto 
metabolite, and coordinately regulates genes involved in the biosynthesis, transport, 
and metabolism of LCA. PXR thus joins FXR as nuclear receptors that are activated 
by bile acids and plays a fundamental role in protecting the liver against 
pathophysiological levels of LCA (Staudinger et al, 2001).
Moreover, it is recently revealed that under a variety of dietary conditions, the control 
of lipid homeostasis is dependent upon cross-talk between PXR, LXR (Liver X 
activated receptor) and FXR (famesoid X activated receptor). For example excess 
uptake of cholesterol from the diet results in the hepatic production of oxysterols, 
activation of LXR, increased expression of CYP7A1, and enhanced production of 
primary bile acids. In turn, bile acid-activated FXR enhances the expression of genes 
involved in bile acid excretion and reabsorption, while inhibiting the expression of 
additional CYP7A1. At the same time, hepatic PXR, activated by LCA generated in 
the intestine, represses CYP7A1 and activates genes involved in bile acid metabolism 
(CYP3A) (Edwards et al, 2002).
1.7.2 Roles of CAR and GR in induction of CYP3A
The constitutively active receptor (CAR, also called constitutive androstane receptor) 
is a novel orphan nuclear receptor, which was originally characterised as a 
constitutive activator of retinoid acid response elements (RARE). It is called 
“constitutive” because of its apparent ability to transactivate RAREs and other 
response elements without being bound to ligand (Baes et al, 1994, Tzameli et al,
2000). CAR is predominantly expressed in liver (Baes et al, 1994). It mediates the 
induction of CYP2B6 and, to a lesser extent, CYP3A4 (Sueyoshi et al, 1999, Tzameli 
et al, 2000). Recent results indicate that CYP2C8 and CYP2C9 are also regulated 
by CAR (Pascussi et al, 2000). CAR is down regulated by the inflammatory cytokine 
interleukin-6, which could explain the repression of CYPs by inflammatory mediators 
(Abdel-Razzak et al, 1995). Biochemical and genetic studies had previously 
established the CAR/RXR heterodimer as the main CYP2B regulator. Xie et al 
(2000b) found that PXR could also regulate CYP2B both in cultured cells and CAR- 
null transgenic mice via ‘adaptive recognition’ of the phénobarbital response element 
(PBRE). In similar experiments on CAR activation, it was found that CAR can bind
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to PXR response elements and activate CYP3A expression in PXR null mice (Xie 
et al, 2000a). These findings again demonstrate the existence of different nuclear 
receptor activation mechanisms and ‘cross-talk’ between several known and 
unknown regulatory proteins which control multiple cytochrome P450 genes.
Moore et al (2000a) demonstrated that PXR and CAR have the potential to cross- 
regulate CYP3A gene expression by sharing certain ligands and binding of PXR and 
CAR to each other’s DNA response elements (Sueyoshi et al, 1999). Studies in 
primary cultures of rat hepatocytes, using natural CYP3A and CYP2B promoters, 
demonstrated that CAR could regulate CYP3A reporter gene activity, but only in 
response to its own ligands (e.g. the human PXR activator rifampicin had little effect 
on CAR activity). Likewise, co-transfection with human PXR resulted in induction 
of CYP2B reporter gene activity in response to rifampicin and mifeprisrone (Xie 
et al, 2000a). The most convincing evidence was obtained when it was demonstrated 
that even in PXR-null mice, the PXR ligands clotrimazole and phénobarbital were 
efficacious inducers of CYP3A (Xie et al, 2000b). However, these studies led to the 
conclusion that in humans PXR is the dominant regulator of CYP3A4 gene 
expression.
Close inspection of other reports regarding the role of hPXR and CAR in CYP3A 
gene induction suggests that these receptors may not totally account for drug and 
steroid induction of CYP3A. Some lines of evidence suggest that induction of 
CYP3A by glucocorticoids can also occur through a pathway distinct from PXR. 
Dexamethasone which is an efficacious inducer of rat (Wrighton et al, 1985), mouse 
(Yanagimoto et al, 1997) and human (Watkins et al, 1989) CYP3A expression, was 
only a weak ligand for mouse and human PXRs (Kliewer et al, 1998; Bertilson et al,
1998). Indeed, Bertilsson et al (1998) found no activation of human PXR by 
dexamethasone, concluding that there must be additional mechanisms for induction 
of CYP3A4 by glucocorticoids. None of the four reports on PXR activation has used 
the authentic CYP3A4 5'-flanking sequence which also contains putative GR binding 
elements (Ogg et al, 1999). Instead, only reporter constructs with multiple copies of 
the PXR binding motif were used. Moreover, rifampicin which is a good inducer of 
mouse CYP3A (Wrighton et al, 1985; Yanagimoto et al, 1997) is reported to be a
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weak activator of mouse PXR, suggesting there may also be an alternative 
mechanism for rifampicin induction of CYP3 A in the mouse.
Recent studies in human primary hepatocytes (Pascussi et al, 2000; Pascussi et al,
2001) suggest that in maintaining the GR in a fully activated state, physiological 
levels of circulating glucocorticoids control the transcriptional expression of nuclear 
receptors including PXR and CAR. Also, in the absence of added xenobiotics both 
PXR and CAR appear to be able to transactivate the CYP3A4 gene (albeit at a low 
rate). This process of transactivation is strongly increased in the presence of 
appropriate activators resulting in the induction of CYP3A4 above basal levels. Thus 
in contrast to other xenobiotics, glucocorticoids appears to play a dual role in 
CYP3A4 expression, first by controlling the expression of PXR and CAR mRNA 
(under low dose physiological conditions), and second in perhaps being able to bind 
to the CAR/PXR receptors under high dose bolus or stress conditions.
1.8 Polymorphic cytochrome P450 genes
Pharmacogenetics has evolved from its beginning in the 1950’s when genetic 
polymorphisms were defined at the phenotypic level, to the modem era of molecular 
studies to elucidate the genetic basis of these inherited traits. While new 
polymorphisms in constitutive expression and regulatory mechanisms continue to be 
discovered for drug metabolising enzymes, there is also increasing focus on genetic 
polymorphisms of dmg targets (e.g. receptors). Theoretically, polymorphisms in 
drug metabolism and disposition (e.g. transporters) will be important in selecting the 
optimal dosage and schedule of medications for individual patient, while 
polymorphisms in dmg targets will influence the choice of medications for a specific 
genetic subtype of the disease or receptor (Krynetski and Evans, 1999).
Today it is known that each human being is different from most other human beings 
at about one nucleotide in a thousand, or about 3 million sites in the genome. Only 
3-5% of the genome is protein coding sequence and the frequency of polymorphism 
is about 1 in 1159 bases in the coding region of genes (Wang et al, 1998), so about 
78,000 polymorphisms will occur in protein coding regions. Many will be silent, but 
theoretically 68% of all possible mutations will result in an amino acid substitution.
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Therefore, we all harbour about 50,000 inherited amino acid differences in our 
proteome compared with our neighbour’s. With 30,000 to 40,000 genes in humans, 
about two-thirds of our proteins will have an amino acid difference between unrelated 
individuals. Since there are about 50 different cytochrome P450 genes in humans, we 
can expect about 30 of these will bear polymorphic sites that affect the protein 
sequence. Some of these are already known and have been associated with an altered 
ability to metabolise drugs (Yamano et al, 1990; de Morals et al, 1994; Haining et al, 
1996). Other polymorphic sites that lie outside the coding region may also influence 
gene expression (Rebbeck et al, 1998; Kuehl et al, 2001; Hamzeiy et al, 2002). The 
need to name these inherited differences (polymorphisms) in a consistent manner has 
prompted the formation of a human cytochrome P450 allele nomenclature committee, 
http:// www.imm.ki.se/CYPalleles (Nelson, 1999).
In the discussion of natural variations in a population, it is important to distinguish 
between rare disease-causing mutations and polymorphisms that are present in greater 
than 1 % of a population. Many mutations are known in the cytochrome P450s that 
are associated with specific diseases, e.g. CYPIB 1 related congenital glaucoma 
(Martin et al, 2000), CYP17 related 17a-hydroxylase deficiency (Fardella et al, 
1993), CYP19 related pseudo-hermaphrodism (Conte et al, 1994), CYP21 related 
congenital adrenal hyperplasia (Delague et al, 2000) and CYP27B1 related 
pseudo vitamin D deficiency rickets (Kitanaka et al, 1999) but these clear-cut effects 
are different from polymorphisms that may affect drug metabolism or influence 
susceptibility to disease without causing disease directly. However, it must be 
remembered that cytochrome P450 mutations are recessive in their effects. Thus, any 
adverse effects may only be expressed in homozygotes and any change in drug 
metabolism in heterozygotes will perhaps have little or no effect on therapeutic 
responses. Also, for many CYP substrates, metabolism by multiple CYPs is possible. 
Again, this relates to the fail-safe aspects of xenobiotic metabolism and the evolution 
of compensatory capacity to detoxify most foreign compounds even if an individual 
CYP isoenzyme is lacking.
Polymorphisms may be heterogeneous, having several alleles, as in nucleotide 
repeats, or they may be single nucleotide polymorphisms (SNPs) with only two
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different alleles and heterozygosity near 50% (Nelson, 1999). Automated searches of 
the human expressed sequence tag (EST) database for conunon sequence variations 
have already been performed and more than 3000 candidate coding region SNPs have 
been discovered (Buetow et al, 1999). Some rare polymorphisms near the 1% 
frequency level may however be difficult to find unless hundreds of chromosomes are 
examined. However, these small differences are important. Mutagenesis experiments 
on CYP2C2 (lauric acid hydroxylase) have shown that a single amino acid 
substitution, S473V, allows CYP2C2 to accept progesterone as a substrate (Ramarao 
and Kemper, 1995). The change in substrate specificity from fatty acid to steroid is 
significant. This characterisation is being extended to all the P450 genes in humans. 
Such knowledge could characterise a person’s risk of adverse drug reactions and 
possible predisposition to disease (Nelson, 1999).
Owing to the rapid development of efficient and inexpensive methods for genotyping, 
plus the need to genotype a patient only once in a lifetime, it would be possible to 
include the genotype in the patient’s medical record. This would provide medical 
practitioners with valuable information in order to individualise the drug treatment 
(Ingelman-Sundberg 6[/, 1999).
To assist genetic analysis, the activity of a cytochrome P450 can be measured in vivo 
using a prototypic probe substrate (e.g. debrisoquine or dextrometorphan for 
CYP2D6). The amounts of unchanged drug and metabolite are measured in urine or 
plasma and expressed as a ratio. Those who have two null alleles and show no 
activity are termed poor metabolisers. The remainder of the population, who perform 
this reaction to varying degrees, are called extensive metabolisers (Sellers and 
Tyndale, 2000). The relative activity of the enzyme expressed in this way is constant 
over time since it is genetically differed (Eichelbaum et al, 1986; Vincent-Viry et al, 
1991). All polymorphic enzymes demonstrate large inter-racial differences in the 
frequency of allele variants (Kalow, 1991). In addition to the null or deletion alleles 
described above, other variants resulting in lowered activity and gene duplications 
with increased activity have also been identified (reviewed in Ingelman-Sundberg et 
a/, 1999).
Approximately 40% of human P450-dependent drug metabolism is carried out by 
polymorphic enzymes, which can cause abolished, quantitatively/qualitatively
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altered, or enhanced drug metabolism. The main causes for the variation in drug 
metabolism are:
(1) Genetic polymorphisms
(2) Induction or inhibition due to concomitant drug therapies or environmental 
factors
(3) Physiological status
(4) Disease states (Ingelman-Sundberg et al, 1999).
Of these, the first two appear to be of most importance for the occurrence of adverse 
effects or lack of therapeutic efficacy in many cases.
1.8.1 Polymorphic variations in the cytochrome P450 genes 
In general, alleles that cause defective, qualitatively altered, diminished or enhanced 
rates of drug metabolism have been identified for many of the P450 enzymes and 
the underlying molecular mechanisms elucidated (Figure 1.14). Polymorphisms 
resulting in amino acid substitutions can give rise to an unstable enzyme or an 
enzyme with an altered active site, causing a change in substrate specificity. 
Furthermore, duplication/multiplication of active genes can result in higher levels of 
mRNA and enzyme, and therefore increased metabolic activity. The genes encoding 
CYP2A6, CYP2C9, CYP2C19 CYP2D6 and CYP3A4 are functionally polymorphic, 
thus at least 40% of P450-dependent drug metabolism is performed by polymorphic 
enzymes. The relative distribution of variant alleles for these P450s differs markedly 
between ethnic groups, making the extent and characteristics of genetically- 
determined differences in drug response quite specific for the global region in 
question (Ingelman-Sundberg etal, 1999).
1.8.1.1 Human cytochrome P450 allele nomenclature
The most accepted nomenclature system has been described in the Human 
Cytochrome P450 (CYP) Allele Nomenclature Committee web site 
(http ://www.imm.ki.se/CYPallele). Briefly, a cytochrome P450 gene is usually
considered as the sequence from the transcription start site to 500 bp down stream of
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the last exon. However, if a regulatory region has been described at a more distant 
part of the gene it would be considered in the gene. The wild type gene is designated 
by the name of the gene followed by an asterisk, the Arabic number 1 and the capital 
letter A (e.g. CYP3A4^1A). Any new alleles should contain nucleotide changes that 
have been shown to affect transcription, splicing, translation, post translation, post 
transcriptional and post translational modifications or result in at least one amino acid 
change and will be assigned by an Arabic number of higher order (CYP3A4^2, 
CYP3A4^3). Any mutation in regulatory region or introns with unclear function will 
be assigned by a capital letter closest to the previously assigned gene (e.g. 
CYP3A4HB, CYP3A4nC, CYP3A4H5B).
1.8.1.2 Cytochrome P450 alleles producing inactive enzymes
Completely inactive alleles have been found for CYP2D6, CYP2C19 and CYP2A6. 
Defective alleles can be the result of gene deletions, gene conversion with related 
pseudogenes and single base mutations causing frame shift, missense, nonsense or 
splice-site mutations. The homozygous presence of such alleles leads to a total 
absence of active enzyme and an impaired ability to metabolise probe drugs specific 
for the enzyme, hence the poor metaboliser (PM) phenotype (Ingelman-Sundberg 
et al, 1999). The number of known defective alleles is growing and at least 30 
different defective CYP2D6 alleles resulting in about 55 CYP2D6 variant genotypes 
have been identified (Marez et al, 1997). It appears, however, that genotyping for 
only the six most common defective alleles will predict CYP2D6 phenotype with 
about 95-99% certainty (Sachse et al, 1997; Griese et al, 1998). Individuals that lack 
functional CYP2D6 genes have been shown to metabolise selective CYP2D6 
substrates, particularly antidepressants (Carrillo et al, 1996; Hamelin et al, 1996; 
Spina et al, 1997) and neuroleptics (Jerling et al, 1996), at a substantially lower rate 
than normal. A lack of CYP2D6 enzyme would also be expected to result in reduced 
therapeutic effectiveness where prodrugs requiring CYP2D6 activation are used. For 
example, following administration of the prodrug codeine, no trace of morphine in 
plasma or any analgesic effect could be observed in CYP2D6 PMs (Poulssen et al, 
1996).
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Figure 1.14 Overview of the major molecular mechanisms that can result in 
altered human drug metabolism (Ingelman-Sundberg et al, 1999).
E xam p les o f  co m m o n  hum an cy toch rom e P 4 5 0  variant a lle les  that h ave b een  found  
to ca u se  the corresp on d in g  ch an ges in  drug m eta b o lism  are sh o w n  at the b o tto m  o f  
the diagram . T he transcription-translation pathw ay resu ltin g  in  norm al en zy m e  and  
m eta b o lism  is sh ow n  b y  the th ick  arrows and the thin arrows represent g en etica lly  
altered pathw ays. A A A  in d icates the p o ly  (A ) tail.
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The polymorphism of CYP2C19, which causes impaired drug metabolism, affects as 
many as 20% of Asians but only 3% of Caucasians (Ingelman-Sundberg et al, 1999), 
causing impaired metabolism of S-mephenytoin and certain other drugs (Goldstein 
et al, 1994; de Moris et al, 1994). Today, at least six different defective CYP2C19 
alleles have been identified (Ibeanu et al, 1998). Of these, CYP2C19*2 and 
CYP2C19*3 contain mutations that create an aberrant splice site and a premature stop 
codon, respectively and are the most common defective alleles. Three different 
defective CYP2A6 alleles have been described so far, of which CYP2A6^2 encodes an 
inactive enzyme resulting from a Leul60His substitution (Yamano et al, 1990). 
CYP2A6*3 is proposed to have been generated through a gene conversion between 
CYP2A6 and CYP2A7 (Femandez-Salguero et al, 1995). There are also alleles in 
which the CYP2A6 gene is deleted (Nunoya et al, 1999; Oscarson et al, 1999).
1.8.1.3 Cytochrome P450 alleles producing diminished or altered metabolism
There are also variant alleles that cause diminished or altered drug metabolism. The 
most common CYP2D6 allele in the Chinese population is CYP2D6'^10, which has a 
Pro34Ser substitution in the proline-rich region near the NHi-terminal. This results 
in an enzyme that exhibits impaired folding and the expression of functional 
enzyme is therefore severely diminished (Johansson et al, 1994). CYP2D6'^17 
(Masimirembwa et al, 1996), CYP2C9^2 (Crespi and Miller, 1997) and CYP2C9'^3 
(Haining et al, 1996) are other alleles that result in cytochrome P450 enzymes with 
diminished capacity for drug metabolism. Regarding the CYP2C9 polymorphism for 
example, reports have clarified the importance of the CYP2C9*2 and CYP2C9'^3 
alleles to CYP2C9-catalysed 6- and 7-hydroxylation of the anticoagulant S-warfarin. 
The enzyme variants, in particular CYP2C9'^3, are much less effective at warfarin 
hydroxylation in vitro (Crespi and Miller, 1997; Haining et al, 1996) and the 
clearance of S-warfarin among subjects homozygous for the CYP2C9^3 allele has 
been shown to be reduced by 90% compared with subjects homozygous for the wild- 
type allele (Carrillo et al, 1996).
1.8.1.4 Cytochrome P450 alleles producing ultra-rapid metabolism
Ultra-rapid metabolism as seen in some individuals for metabolism via CYP2D6 is 
caused by the presence of duplicated, multi-duplicated, or tandem gene copies in the
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genome (Johansson et al, 1993). At present, CYP2D6 alleles with two, three, four, 
five and 13 gene copies in tandem have been reported and the number of individuals 
carrying multiple CYP2D6 gene copies is highest in Ethiopia and Saudi Arabia, 
where up to the third of the population displays this genotype (Ingelman-Sundberg,
1999). Interestingly, the number of defective CYP2D6 gene is very low in this 
region. Alleles with two-to-five gene copies in tandem have likely been formed by 
unequal recombination between two homologous but non-allelic sequences flanking 
the gene. The outcome is one locus that contains two genes in tandem and a deleted 
gene on the other locus. By contrast, the allele containing 13 copies of the gene has 
probably occurred by unequal segregation and extra-chromosomal replication of 
acentric DNA (Lundquist et al, 1999). Subjects with 13 CYP2D6 gene copies on one 
allele formed a substantially higher amount of metabolite(s) from substrates specific 
to this enzyme. For example, extensive formation of morphine occurs if these 
subjects take the prodrug codeine (Hedenmalm et al, 1997) and severe abdominal 
pain, a typical adverse effect of morphine, was observed in an ultra-rapid metaboliser 
treated with codeine. Duplication of the genes encoding drug-metabolising enzymes 
is not restricted to CYP2D6 since duplicated glutathione-S-transferase, e.g. GSTMl 
genes have been identified in the GSTji locus, although this allele appears to be quite 
rare (McLellan et al, 1997). Another type of ultra high metaboliser genotype is not 
related to gene amplification, but to mutation in the promoter region of the gene.
1.8.2 Polymorphism in the CYP3A locus
The CYP3A enzymes are the most abundant CYPs in human liver and small 
intestine. Substantial inter-individual differences in CYP3A expression, exceeding 
30-fold in some populations (Watkins, 1995), contribute greatly to variation in oral 
bioavailability and systemic clearance of CYP3A substrates, including HIV protease 
inhibitors, several calcium channel blockers and some cholesterol-lowering drugs. 
Variation in CYP3A expression is particularly important for substrates with narrow 
therapeutic indices, such as cancer chemotherapeuties and the immunosuppressive 
eyelosporine A and tacrolimus. Such variation in CYP3A can result in clinically 
significant differences in drug toxicities (e.g. nephrotoxicity) and response (e.g. graft 
survival) (Kivisto et al, 1995). Moreover, because CYP3A metabolises oestrogens to 
2-hydroxyestrone, 4-hydroxyestrone and 16a-hydroxylated oestrogens, all of which
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have been implicated in oestrogen-mediated carcinogenicity (Huang et al, 1998), 
variation in CYP3A may influence the circulating levels of these oestrogens and the 
risk of breast eancer.
Human CYP3A activities reflect the heterogenous expression of its four members: 
CYP3A4, CYP3A5, CYP3A7 and CYP3A43 (Gellner et al, 2001). CYP3A5, a 
polymorphic form, is present to a variable extent in adult livers. CYP3A5 is believed 
to be present in the livers of approximately 20% of Caucasians, but a recent study 
suggests that CYP3A5 is expressed and may predominate in more than 50% of 
African-Americans (Kuehl et al, 2001). There is evidence of polymorphism in the 
coding (Jounaidi et al, 1996) and promoter regions (Kuehl et al, 2001) which may 
contribute to variation in the overall hepatic metabolism of CYP3A substrates. 
However, two mutations which were believed to be related to CYP3A5 promoter and 
an association with polymorphic CYP3A5 expression (Paulussen et al, 2000) were 
revealed to be actually in the promoter of the pseudogene CYP3AP1 (Finta and 
Zaphiropoulos, 2000). CYP3A7 is found in intestine, reproductive system and infant 
liver but also present in some adult livers (Schuetz et al, 1994). CYP3A43 has 
recently been suggested to be a non-fimctional isoform (Westlind et al, 2001).
CYP3A4, the adult-specific isoform, is considered the most important and is the 
most extensively studied member of the CYP3A subfamily. Although there had been 
no indication of genetic polymorphism in the CYP3A4 gene until 1997 (Linder et al, 
1997; Lewis and Pratt, 1998; Lewis et al, 1998), investigations since then have 
reported inherited variation in both the promoter (Rebbeck et al, 1998; Kuehl et al, 
2001; Hamzeiy et al, 2002) and coding region of the gene (Sata et al, 2000; Hsieh 
et al, 2001; Fiselt, et al, 2001; Dai et al, 2001; Lamba et al, in press). However, the 
impact of these mutations on mRNA expression or enzyme activity has not been 
extensively investigated. Also the proposed relationship between the CYP3A4"^1B 
allele (-392 A ^G ) and an increased incidence of prostate cancer was not confirmed 
in later studies (Westlind et al, 1999; Ball et al, 1999). Sata et al (2000) showed that 
the CYP3A4^2 allele (Ser222Pro) produces a lower in vivo intrinsic clearance of 
nifedipine, but no significant difference from the wild type enzyme activity for 
testosterone 6p-hydroxylation. In addition, Hsieh et al (2001) have recently reported
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three further mutations in the coding region of the CYP3A4 gene and related them to 
a decreased urinary 6p-hydroxycortisol/cortisol ratio in heterozygotes. In a further 
study of 213 subjects, Eiselt et al (2001) have identified 18 new CYP3A4 variants of 
which several showed altered enzyme activity. All the recognised CYP3A alleles are 
now listed on in the Human Cytochrome P450 {CYP) Allele Nomenclature 
Conunittee Home Page (http:// www.imm.ki.se/CYPalleles).
In a more recent genetic analysis on white individuals for some of CYP3A4 variant 
alleles, including CYP3A4^1B, CYP3A4^2, CYP3A4H, CYP3A4^5, CYP3A4^6, 
CYP3A4^8, CYP3A4^11, CYP3A4^12 and C7P3A4*73, none of these alleles (except 
CYP3A4'^1B) were present in 30 genes from persons with extremely low enzyme 
activity. CYP3A4'^1B was present with an allele frequency of 5.5% but no 
relationship to the low enzyme activity established (Garcia-Martin et al, 2002).
1.8.3 Cytochrome P450 polymorphism and neoplastic disease
Many carcinogenic compounds require metabolic activation before being capable of 
reacting with cellular macromolecules. Thus, individual features of carcinogen 
metabolism must play an essential role in the development of cancer (Raunio et al, 
1995). A complicating factor is the multistage aetiology of carcinogenesis implying 
the involvement of many distinct events. However, it has become evident that the 
enzyme activating and inactivating exogenous carcinogens are involved in the 
aetiology of eancer (Hietanen, 1999).
Many compounds are converted to reactive electrophilic metabolites by the oxidative 
(mainly cytochrome P450-related) enzymes (e.g. Bartsch et al, 2000; Dehal and 
Kupfer, 1996). Secondary metabolism mainly involving epoxide hydrolase (Miyata,
1999), sulfotransferases (Seth et al, 2000) and aeetyltransferases (e.g. Hett et al,
1991) can also lead to the formation of the highly reactive metabolites that bind to 
genomic DNA. Thus, the concerted action of these enzymes may be crucial in 
determining the final biological effect of a carcinogen. The activity of these enzymes 
is modulated by many host and environmental factors. Host factors include both life­
style factors, diseases, and genetic factors while environmental factors include 
exposures to various chemicals as well as dietary habits (Hietanen, 1999).
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CYP 1 Al has been implicated in the conversion of numerous polycyclic aromatic 
hydrocarbons into electrophilic species capable of binding covalently to DNA and 
has therefore been postulated to be involved in the initiation of carcinogenesis 
(Geneste et al, 1991; Petruzzelli et al, 1998). In addition, a restriction fragment 
length polymorphism located in the 3'-noncoding region of this gene {MspI) 
identified in the Japanese population has been associated with an increase in CYPlAl 
activity and an elevated risk of lung cancer (Hayashi et al, 1991; Kawajiri et al, 
1993). Another polymorphism of the CYPlAl gene, linked to the Mspl 
polymorphism, has been identified in exon 7 and results in a substitution of valine to 
isoleucine in the haem-binding region (Hayashi et al, 1991) and higher enzyme 
activity (1.5-fold) (Kawajiri et al, 1993). It is associated with an elevated risk of 
developing lung and endometrial cancers (Esteller et al, 1997; Spivack et al, 1997), 
although opposing results have been shown as well (reviewed by Drahushuk et al,
1998).
Numerous studies have demonstrated an association of certain CYP2D6 genotypes 
with lung cancer risk and poor metabolisers (defined by either genotyping or 
phenotyping) have a lower risk than other genotypes (Bouchardy et al, 1996; Stacker 
et al, 1995). The risk was dose-dependent with smoking and in persons with low or 
medium CYP2D6 activity no such an increase was found even at very high smoking 
levels. CYP2D6 gene mutations may also be involved in an increased risk of liver 
cancer since extensive metabolisers appear to have 6.4-fold greater risk of primary 
liver eancer in comparison with poor metabolisers (Agundez et al, 1995).
CYP3A4 and CYP3A7 also mediate the metabolism of hepatocareinogens, including 
mycotoxins, aflatoxin Bi and 2,4-dichlorophenol. Over expression of these 
cytochrome P450s in cultured human hepatoma cells is associated with an inerease in 
afiatoxin-induced mutations, particularly in the P53 tumour suppressor gene (Kondoh 
et al, 1999). Similarly, the presence of CYP3A5 in normal proximal tubular 
epithelium has been suggested as a eausative factor in renal tumour development 
(Murray et al, 1999).
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1.9 Concluding remarks
Presently, some of the significant polymorphisms causing genetic differences in 
phase I drug metabolism are known and therapeutic failures or adverse drug reactions 
caused by these polymorphism genes can, to a great extent, be foreseen. This 
information is currently being used by the pharmaceutical industry during drug 
development. The majority of eompanies regularly genotype the patients involved in 
their clinical trials in order to obtain more information regarding pharmacokinetics 
properties and observed side effects. Furthermore, eandidate drugs that are 
selectively metabolised by polymorphic enzymes are often eliminated early in drug 
screening. Therefore, fewer problems with polymorphic variation during drug 
therapy will oecur in the future. However, owing to the rapid development of 
efficient and inexpensive methods for genotyping, plus the need to genotype a patient 
only onee a lifetime, it might be advisable to include drug metabolism genotype in 
the patient’s medical record. In the future, this could also include the genotypes of 
transport proteins and drug reeeptors whieh taken together would provide the 
physician with highly predictive genetic information concerning the likelihood of 
successful drug therapy (Ingelman-Sandberg et al, 1999).
1.10 Aims and objectives of this project
It is clear that inter-individual variation in the level or activity of the cytochrome 
P450 enzymes may play an important role in the development of both adverse drug 
reactions and diseases such as cancer. Sinee CYP3A4 represents a significant 
proportion of the hepatie cytochrome P450 content, identification of the genetic 
polymorphisms and analysis of their effeets on enzyme expression will be of great 
value in elucidating the genetic basis of inter-individual variation. Although 
polymorphic variations have been reported in both 5' regulatory and eoding regions 
of the CYP3A4 gene, those investigated so far do not appear to make a major 
contribution to CYP3A4 variation as a whole.
In this projeet, in order to identify novel genetie variations in the proximal and distal 
5'regulatory regions of the CYP3A4, a new population screening will be performed. 
Functional analysis of the novel CYP3A4 alleles, using a reporter gene assay, will 
also be performed.
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(1) 100 blood samples will be collected from suitable volunteers for the purpose of 
genomic DNA extraction.
(2) Proximal (1141 bp) and distal (300 bp) 5'regulatory regions of the CYP3A4 gene 
will be isolated from genomie DNAs using PCR amplifieation.
(3) Screening for mutations in the resulting PCR produets will be carried out using a 
non-radioaetive single strand conformation polymorphism (so called ‘cold 
SSCP’) and confirmatory sequencing.
(4) A reporter gene expression system will be developed by cloning the wild type 
and mutant 5' regulatory regions of the CYP3A4 gene into a vector containing the 
human secreted alkaline phosphatase (SEAP) eDNA.
(5) The individual reporter eonstructs will be transfeeted into human liver (HepG2, 
HuH7) and intestinal (Caeo-2) cell lines. Xenobiotic modulation of CYP3A4 
promoter activity will be measured by ehemiluminescent SEAP assay.
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CHAPTER TWO 
MATERIALS AND METHODS
2.1 Materials
2.1.1 Chemicals and reagents
All chemicals and reagents used in the experimental work were purchased from 
Sigma-Aldrich Ltd (Dorset, England) unless speeified below.
Acrylamide 40% and Bis-acrylamide 2% stock solutions were purchased from 
Promega Corporation (Madison, WI, USA).
Bactriologie agar. Phosphate Buffered Saline tablets, Tryptone and Yeast extraet 
were supplied by OXOID LTD, (Hampshire, England).
FuGENE 6 transfection reagent was purchased from Roche Molecular Biochemicals 
(Indianapolis, USA).
Multipurpose agarose was provided from FMCproducts (Rockland, Maine, USA).
SYBR® Gold nueleic acid stain (lOOOOx concentration in DMSG) and SYBR® gel 
stain photographic filter were supplied by Molecular Probes (Oregon, USA).
2.1.2 Enzymes and DNA Markers
All restriction enzymes, T4 DNA ligase, 1 kb DNA ladder. Lambda DNAJHindiW 
DNA marker were supplied by Promega Corporation (Madison, WI, USA).
2.1.3 Kits
Advantage®-HF 2 (high fidelity) PCR kit was purehased from Clontech Laboratories 
Inc (Palo Alto, CA, USA).
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TripleMaster PCR system was supplied by Eppendorf AG  (Hamburg, Germany).
Aurora’^"' AP Chemiluminescent Reporter Gene assay system for measuring alkaline 
phosphatase was purchased from ICNBiomedicals Inc (Costa Mesa, CA, USA).
Wizard® genomic DNA purification and Wizard® Plus SV Minipreps DNA 
purification kits were purehased from Promega Corporation (Madison, WI, USA).
Endofree Plasmid Maxiprep, QIAquick PCR purification and QIAquick gel 
extraetion kits were supplied by QIAGEN (Hilden, Germany).
Ultra Clean™ 15 DNA purification kit was purchased from MO BIO Laboratories Inc 
(Carlsbad, CA, USA).
2.1.4 PCR primers
The primers were purehased from MWG Biotech AG (Ebersberg, Germany). On 
arrival the primer tubes were centrifuged for a few seeonds to collect the dry DNA at 
the bottom of the tube. An appropriate volume of TE buffer or nuclease-free water 
was added to the tubes and, after rehydration for 2 minutes, the solution was vortexed 
for 15 seconds and stored at -20 ”C.
2.1.5 Human cell culture reagents
HepG2 (a human hepatocyte carcinoma cell line originally established from a 15 
years old Caucasian male) and Caco-2 (a human colon adenocarcinoma cell line 
isolated from a primary colon tumour in a 72-year old Caucasian male) were supplied 
by European Collection of Animal Cell Cultures (ECACC) (Salisbury, Wiltshire UK) 
as frozen cultures. On receipt of the frozen cultures the cells were grown up in bulk 
and aliquots were frozen to be used as a bank for subsequent work. HuH7 (a human 
hepatoeellular careinoma cell line originally established from a 57 years old Japanese 
male) was a gift in a 75 cm^ flask from a colleague in our laboratory.
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Minimum essential medium (MEM with Earle's salts), L-glutamine 200 mM (lOOx), 
foetal bovine serum, gentamicin (10 mg/ml) and trypsin-EDTA solutions were 
purchased from Gibco BRL Life Technologies Inc (Paisley, Seotland).
2.1.6 Instrumentation
PCR amplifications were performed using either the DNA ENGINE PTC-200 (MJ 
Research Inc, Watertown, MC, USA) or GeneAmp® PCR system 9700 {PE Applied 
Biosystems, Foster City, CA, USA).
A RunOne™ Electrophoresis cell, Embi Tec (San Diego, CA, USA) was used for 
agarose gel electrophoresis of DNA preprations.
Chemiluminescent assays were carried out on a Lumicount Microplate Lumometer 
Packard Instrument Company (Meriden, CT, USA).
Polyacrylamide gel electrophoresis was performed using a Bio-Rad mini Protean II™ 
set, Bio-Rad Laboratories (Hercules, USA).
2.1.7 Bacteria and Plasmids
Competent TOPI OF' E. coli cells were purchased from Invitrogen (Carlsbad, CA, 
USA).
The pSEAP2-Basic vector was supplied by Clontech Laboratories Inc (Palo Alto, 
CA, USA). This plasmid was used to develop pX-SEAP2 (eontaining xenobiotic 
responsive enhaneer module, XREM, of the cytochrome P450 3A4 gene) and 
pXP-SEAP2 (eontaining XREM and 1141 bp of proximal promoter of the same gene) 
plasmids.
The human pregnane X reeeptor plasmid (pSG5-hPXRAATG) was a gift from 
Dr. Steven Kliewer {GlaxoSmithkline Ltd). This expression vector was generated by 
PCR amplifieation and subcloning of 1.3 kb of the hPXR cDNA, modified at the first 
amino aeid (CTG —> ATG), into the pSG5 expression vector (Lehman et al, 1998).
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Positive control, alkaline phosphatase reporter vector (pCMV-cSPAP) was supplied 
by Glaxo Smithkline Ltd (Dr. S. Hood).
Restriction maps of the plasmids are given in Figures 2.1 to 2.5.
2.1.8 Subject recruitment
Study subjects were ehosen from among healthy male and female volunteers working 
at the University of Surrey. After obtaining phlebotomy authorisation aecording to 
the University of Surrey regulations, an advertisement was prepared. In the first 
stage only 40 subjects participated in the study. For recruitment of additional 
volunteers via payment of an honorarium, approval from the University of Surrey 
Advisory Committee on Ethics was obtained.
Following this, recruitment of subjects (finally 41 females and 59 males) was 
completed. They were mainly from 2 populations; 32 Iranians (including myself) and 
58 Caucasians (mostly British). The other 11 subjeets were from Arab or South East 
Asian countries. Each subject read and signed the University of Surrey consent form 
for donation of blood and urine for research purposes.
2.1.9 Blood sample preparation
20 ml of blood was taken, via phlebotomy, from each volunteer. Blood samples were 
collected into 2 separate 10 ml EDTA eontaining tubes. One of them was stored at 
-70 °C and the other was kept at -20 °C for a short period and used for genomic 
DNA extraction.
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Xhol 33
EcoRIMlul 16
H indlll 54CSTBNotI4511
f l  ori
780
SEAP
pSEAP2-Basic
4677 bp
Am p’^
3117 1559,
X bal 1602
SV40 Poly A2338
Sail 1870 BamHI 1864
pUC ori
Figure 2.1 Functional map of pSEAP2-Basic {Clontech Laboratories Inc, CA, 
USA), a plasmid that has been used for constructing pX-SEAP2 and pXP- 
SEAP2 plasmids.
Amp^: ampicillin resistance gene
f l  ori: origin of replication of the filamentous phage fl
MCS: multiple cloning site showing the restriction enzymes that were used for 
cloning of the XREM and proximal promoter region of cytochrome P450 3A4 
gene
pUC ori: origin of replication
SEAP: cDNA for human secreted alkaline phosphatase
SV40 Poly A: simian virus 40 late mRNA polyadenylation signal
TB: transcription blocker (composed of a synthetic polyadenylation site and a
transcription pause site from the human a2 globin gene)
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4974465
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S E A P
Figure 2.2 Functional map of pX-SEAP2, a plasmid containing the XREM 
region of the cytochrome P450 3A4 gene.
Amp :^ am picillin resistance gene
fl ori: origin o f  replication o f  the filam entous phage f l
M C S: multiple cloning site
pUC ori: origin o f  replication
SEAP: cD N A  for human secreted alkaline phosphatase
SV40 Poly A: sim ian virus 40 late m R N A  polyadenylation signal
TB: transcription blocker (com posed o f  a synthetic polyadenylation site and a
transcription pause site from the human a 2  globin gene)
XREM: CYP3A4 distal xenobiotic responsive enhancer module
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6099 bp
18284264
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SV4G ployA
Figure 2.3 Functional map of pXP-SEAP2, a plasmid containing the XREM and 
1141 bp of proximal promoter regions of the cytochrome P450 3A4 gene.
Amp*^: am picillin resistance gene
fl ori: origin o f replication o f the filam entous phage f l
M C S: multiple cloning site
pUC ori: origin o f replication
SEAP: cD N A  for human secreted alkaline phosphatase
SV40 Poly A: sim ian virus 40  late m R N A  polyadenylation signal
TB: transcription blocker (com posed o f  a synthetic polyadenylation site and a
transcription pause site from the human a l  globin gene)
3A4 Prom: 1141 bp proximal promoter region o f  cytochrom e P450 3A 4  
XREM: CYP3A4 distal xenobiotic responsive enhancer module
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Figure 2.4 Map of pSG5-hPXR (a gift from Dr. Steven Kliewer, Glaxo Smithkline 
Ltd) a plasmid encoding the human pregnane-X- receptor.
Amp :^ am picillin resistance gene
fl ori: origin o f  replication o f  the filam entous phage f l
hPXR cDNA: hPXRAATG, the human pregnane X  receptor cD N A  w ith a
m odified codon 1 (CTG —> ATG)
ori: origin o f  replication
SV40: sim ian virus 40  promoter
T7: T7 R N A  polym erase promoter
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Figure 2.5 Functional map of pCMV-cSPAP control alkaline phosphatase 
expressing plasmid (was supplied by Glaxo Smithkline Ltd, Dr. S. Hood).
Amp^: ampicillin resistance gene
CMV: eukaryotic cytomegalovirus strong promoter
ori: origin of replication
SPAP cDNA: cDNA for human secreted placental alkaline phosphatase 
SV40: simian virus 40
2.2 Molecular biology
2.2.1 DNA extractions
Genomic and plasmid DNA can be isolated from cells by disrupting the tissue and 
then exploiting the difference in properties between DNA, protein and other 
constituents. The techniques require the use of partition and precipitation to purify 
the DNA sample. All reagents should be the best available and made up in high- 
quality water (Towner, 1991).
The isolation and purification of DNA is a key step for most protocols in molecular 
biology. Methods to purify DNA generally fall into two broad categories. The first 
category covers the isolation of recombinant DNA constructs such as plasmids or 
bacteriophage after propagation by the host organism. These techniques form the 
basis of molecular cloning experiments and constitute the most frequently used 
protocols in molecular biology laboratories. The second type of DNA purification 
involves the isolation of chromosomal or genomic DNA from prokaryotic or 
eukaryotic organisms. These purification techniques have greatly facilitated studies 
of complex genomes, particularly by enabling the construction of genomic DNA 
libraries representative of many different species. In both types of DNA isolation, 
further purification and fractionation of DNA is often necessary; for example, 
following a restriction enzyme digestion or amplification of specific sequences. This 
may be conveniently accomplished by gel electrophoresis and purification of the 
fragment of interest (Towner, 1991).
2.2.1.1 Genomic DNA extraction
Genomic DNA can be obtained from any microorganism, plant or animal at any time 
during development and provides DNA which contains a copy of every gene from the 
organism. Genomic DNA is easy to isolate and characterise but will be of little use 
unless it is of high molecular weight, readily cleaved by a variety of restriction 
enzymes and clonable.
2x400 |xl of each blood sample were used to DNA extraction using Wizard® genomic 
DNA purification kit from Promega. For 400 pi sample volume, 1.2 ml Cell Lysis 
Solution was added to a sterile 2 ml microcentrifuge tube. The tube of blood was
81
gently rocked until thoroughly mixed before transferring to the tube containing Cell 
Lysis Solution. The tube was then invert 5 to 6 times to mix. The mixture was 
incubated for 10 minutes at room temperature (the tube was inverted 2 to 3 times 
once during the incubation) to lyse the red blood cells. The resulting lysate was 
centrifuged at 14000xg for 20 seconds at room temperature. The supernatant was 
removed as much as possible without disturbing the visible white pellet.
If blood samples had been frozen, the above steps were repeated until pellet was 
white. There may be some loss of DNA in frozen samples. The tube was then 
vortexed vigorously until the white blood cells were re-suspended (10-15 seconds). 
400 pi Nuclei Lysis Solution was added and the solution was pipetted 5 to 6 times to 
lyse the white blood cells. The solution then became very viscous. If clumps of cells 
were visible after mixing, the solution was incubated at 37 °C until the clumps were 
broken up. If the clumps were still visible after 1 hour, additional Nuclei Lysis 
Solution (about 130 pi) was add and the incubation was repeated.
RNase Solution (2 pi) was added to the nuclear lysate and the sample was mixed by 
inverting (25 times). The mixture was incubated at 37 °C for 15 minutes and then 
was cooled to room temperature.
Protein Precipitation Solution (130 pi) was added to the nuclear lysate and vortexed 
vigorously for 10-20 seconds. Small protein clumps may be visible after vortexing. 
Note: If it was necessary to use additional Nuclei Lysis Solution, a total of 170 pi of 
Protein Precipitation Solution was added. The tube was centrifuged at 14000xg for 
3 minutes at room temperature. A dark brown protein pellet should be visible. The 
supernatant was transferred to a clean 2 ml microcentrifuge tube containing 400 pi of 
room temperature isopropanol.
The solution was gently mixed by inversion until the white thread-like strands of 
DNA formed a visible mass. The tube was centrifuged at 14000xg for 1 minute at 
room temperature. The DNA was visible as a small white pellet. The supernatant 
was removed and 400 pi of room temperature 70% ethanol was added. The tube was 
gently inverted several times to wash the DNA pellet and the inside of the
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microcentrifuge tube. The tube was centrifuged again at 14000xg for 1 minute at 
room temperature. The ethanol was then carefully aspirated using a pipette tip. The 
DNA pellet was very loose at this point and care was required to avoid aspirating the 
pellet into the pipette. The tube was inverted on a clean absorbent paper and the 
pellet was air-dried for 10-15 minutes.
Finally, DNA Rehydration Solution (150 pi TE) was added to the tube and the DNA 
was re-hydrated by incubating at 65 °C for 1 hour. The solution was periodically 
mixed by gently tapping the tube. Alternatively, the DNA could be re-hydrated by 
incubating the solution overnight on the bench at room temperature or in the cold 
room. DNA quality was checked by agarose gel electrophoresis and the quantity was 
estimated by spectrophotometry.
2.2.1.2 Miniprep plasmid DNA extraction and purification
It is quite straightforward to isolate plasmid DNA from E. coli and this can be 
performed on either small or ‘mini-prep’ scale to obtain sufficient material for 
cursory analysis, or on a large, ‘maxi-prep’ scale to provide stock of plasmid for 
longer-term use. The isolation of plasmids is performed in essentially three stages. 
The bacterial cell wall is first weakened by the action of lysozyme, and the cells then 
lysed by EDTA and detergent at high pH. Finally, the insoluble cell debris consisting 
of genomic DNA and protein is precipitated at high salt concentration and centrifuged 
down, leaving the plasmid DNA in solution (Towner, 1991).
Wizard® Plus SV Minipreps DNA purification kit takes advantage of the benefits of 
alkaline lysis but eliminates the need for organic extraction and differential 
precipitation by employing a proprietary silica-based resin to bind the plasmid DNA 
in the cleared alkaline lysates. The principle of the method is based on selective 
adsorption of plasmid DNA to the resin in the presence of high concentrations of 
chaotropic salts and allows for elution of the DNA, after efficient removal of 
contaminants, with low ionic strength solutions such as TE buffer or water.
1 to 5 ml of bacterial culture was centrifuged for 5 minutes at lOOOOxg in a bench 
centrifuge. The supernatant was poured off and the tube blotted upside down on a
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paper towel to remove the residual liquid. The pellet was suspended in 250 pi of 
Wizard® Plus SV Cell Resuspension Solution by pipetting. The resuspended cells 
were transferred into a 1.5 ml micro-centrifuge tube(s). 250 pi of Wizard® Plus SV 
Cell Lysis Solution was added and after mixing (by inverting 4 times), the tube was 
incubated for 1 to 5 minutes at room temperature until the cell suspension became 
clear. 10 pi of Alkaline Protease Solution was added into the tube and incubated for 
5 minutes after mixing (by inverting 4 times). Then 350 pi of Wizard® Plus SV 
Neutralization Solution was added and immediately mixed by inverting the tube 
4 times. The resulting bacterial lysate was centrifuged at 14000xg for 10 minutes at 
room temperature.
Plasmid DNA purification units were prepared by inserting one Wizard® Plus SV 
Miniprep Spin Column into one 2 ml Collection Tube for each sample. The cleared 
lysate was transferred to the prepared Wizard® Plus SV Miniprep Spin Column, by 
decanting, and centrifuged at 14000xg for 1 minutes at room temperature. Wizard® 
Plus SV Miniprep Spin Column was removed from the tube and the flow through was 
discarded from the Collection tube. After reinserting the Spin Column into the 
Collection Tube, 750 pi of Wizard® Plus SV Miniprep Spin Column Wash Solution 
(previously diluted with 95% ethanol) was added to the Spin Column. Centrifugation 
at 14000xg for 1 minute at room temperature and removal of the flow through was 
performed again. 250 pi of Wizard® Plus SV Miniprep Spin Column Wash Solution 
was then added and centrifuged at 14000xg for 2 minutes at room temperature. 
Finally, the Wizard® Plus SV Miniprep Spin Column was transferred to a new, sterile
1.5 ml micro-centrifuge tube. The plasmid DNA was eluted by adding 100 pi of 
Nuclease-Free Water and centrifuged at 14000xg for 1 minute at room temperature.
2.2.1.3 Endotoxin-free Maxi Prep DNA purification
Endotoxins are lipopolysaccharide (EPS) components of the lipid portion of the outer 
layer of the cell membranes of gram-negative bacteria such as E. coli (Rietschel and 
Brade, 1992). Endotoxins are released during the lysis step of plasmid purification 
and significantly reduce transfection efficiency in sensitive cultured cells (Weber 
et al, 1995). Plasmid DNA purified with the Endo Free Plasmid Maxi Kit contains
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negligible amounts of LPS (less than 0.1 endotoxin units/pg plasmid DNA) due to 
the use of a special ‘endotoxin removal’ buffer that prevents LPS molecules from 
binding to the resin in the purification tips (QIAGEN kit protocol). DNA purified by 
this method can be used directly for transfection of mammalian cells in culture 
without the need for ethanol precipitation.
The Maxiprep plasmid purification technique is more time consuming and uses 
relatively large volumes of media, but results in large quantities of very pure plasmid 
DNA. The rationale of the method is similar to that described for the miniprep 
preparation, but the crucial purification step entails more complex resin binding 
methods (Towner, 1991).
The bacterial suspension from the maxi-culture was centrifuged at 6000xg for 
15 minutes at 4 ”C and the resultant pellet was suspended in 10 ml of buffer PI (see 
Appendix 1 for the kit components). 10 ml of buffer P2 was added and mixed with 
the suspension by gentle inversion 4 to 6 times and then incubated for 5 minutes. 
Then 10 ml chilled buffer P3 was added to the lysate, and mixed immediately by 
inversion (4 to 6 times). The lysate was poured into a QIAFilter Maxi Cartridge and 
incubated at room temperature for 10 minutes after which it was gently filtered using 
the piston supplied and the filtrate was collected in a 50 ml tube. After adding 2.5 ml 
of buffer ER and mixing by inversion (10 times), the solution was incubated on ice 
for 30 minutes, during which a QIAGEN-tip 500 was equilibrated by applying 10 ml 
of buffer QBT. The cleared lysate was then applied to the tip, allowed to enter the 
resin by gravity flow, and was washed twice with 30 ml of QC buffer. The DNA was 
eluted with 15 ml of buffer QN. 10.5 ml of room temperature isopropanol was added 
to the eluted DNA, mixed and centrifuged immediately at 15000xg for 30 minutes at 
4^C. After discarding the supernatant, the DNA pellet was washed with 2.5 to 5 ml 
of endotoxin-free, room temperature 70% ethanol and centrifuged at 15000xg for 
10 minutes. The supernatant was carefully discarded; the pellet was air-dried for 5 
minutes and suspended in suitable volume (200 to 500 pi) of endotoxin-free TE 
buffer.
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2.2.1.4 ültraCIean 15 DNA Purification kit from gels and solutions
Applications such as cloning, labeling and sequencing of DNA frequently require the 
purification of DNA fragments from agarose gels or amplification reactions. The gel 
extraction kit was provided by MO BIO Laboratories Inc (Carlsbad, CA, USA). It 
includes ULTRA SALT, ULTRA WASH solutions and ULTRA BIND silica-based 
suspension.
After weighing the gel slice into a 1.5 ml microcentrifuge tube, 3 volumes of ULTRA 
SALT was added (e.g. 0.3 ml for 0.1 g of gel) and mixed well. The mixture was 
incubated at 55 ”C while mixed occasionally by inverting until the gel melted 
(approximately 5 minutes). The ULTRA BIND suspension was vortexed until 
homogeneous (about 30 seconds). 7 pi was added to the melted gel mixture and 
incubated at room temperature for 5 minutes. At this stage binding of DNA to silica 
occurs. The mixture was mixed several times during this binding step by inversion. 
The mixture then was centrifuged for 5 seconds and the supernatant removed into a 
new microcentrifuge tube (if the DNA does not bind, it can be recovered from this 
supernatant). The pellet was resuspended in 1 ml of ULTRA WASH and centrifuged 
for 5 seconds. The supernatant was discarded and the pellet was washed and 
centrifuged again for 5 seconds. All traces of ULTRA WASH were removed by 
aspirating with a narrow pipette tip. The pellet was resuspended in water or TE and 
mixed by pipetting until homogeneous. The suspension was incubated for 5 minutes 
at room temperature to ensure that elution was complete. After centrifuging for 
1 minute, the clear DNA containing supernatant was collected and stored at 4 °C.
2.2.1.5 Purification of PCR products using QIAquick PCR Purification Kit
PCR products used for subsequent applications, such as sequencing and cloning, 
should be purified to remove primers, nucleotides and polymerases. Silica gel based 
membranes have selective binding properties and give efficient recovery of DNA. 
DNA adsorbs to the silica-membrane in the presence of high salt concentrations while 
contaminants pass through the column (Manufacturer’s manual).
Five volumes of Buffer PB were added to one volume of the PCR reaction and 
mixed. A QIAquick spin column was placed in a provided 2 ml collection tube.
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To bind DNA, the sample was applied to the QIAquick column and centrifuged for 
30 to 60 seconds. The flow-through was discarded and the QIAquick column was 
placed back into the same tube. To wash, 0.75 ml Buffer PE was added to the 
QIAquick column and centrifuged for 30-60 seconds. The flow-through was 
discarded and the QIAquick column was placed back. The column was centrifuged 
for an additional one minute at maximum speed. The QIAquick column was placed 
in a clean 1.5 ml microcentrifuge tube. To elute DNA, 50 |il of Buffer EB (10 mM 
Tris.Cl, pH 8.5) was added to the centre of the QIAquick membrane and the column 
was centrifuged for one minute.
2.2.2 Agarose gel electrophoresis of DNA
Due to its negative charge, DNA will migrate toward the positive pole (anode) of an 
electric field. This property is used to separate and size the fragments of DNA by 
electrophoresing them through an agarose gel in a running buffer. The smaller 
molecules travel more easily through the gel matrix, whilst the larger molecules are 
retarded, thus they separate according to size. Agarose gels are the most popular 
medium for the electrophoresis of medium and large-sized nucleic acids. In these 
gels typical agarose concentrations fall within the range 0.3-2.5%. The concentration 
used depending upon the sizes of nucleic acid molecules to be separated (Andrews, 
1991).
1% Electrophoresis gels were made by dissolution of Ig of agarose in 100 ml 
Ix TAE buffer (0.04 M Tris-acetate and 0.001 M EDTA) electrophoresis buffer using 
a microwave oven. After cooling the solution to about 60 °C, ethidium bromide was 
added (from a stock solution of 10 mg/ml) to a final concentration of 0.5 |Lig/ml and 
was mixed thoroughly. Enough of the solution was used, together with a slot-making 
comb, to make a gel of 3 to 5 mm thickness. Usually 30 to 45 minutes at room 
temperature was enough for an agarose gel to set. The comb was then carefully 
removed and the gel was mounted in the electrophoresis tank (mini gel, RunOne'^'^ 
electrophoresis cell from Embiotec, Sandiego, California). Enough electrophoresis 
buffer (Ix  TAE) was added to the tank to cover the gel to a depth of about 1 mm.
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5 |xl DNA samples (approximately 50 to 200 ng) were mixed with 1 pi of loading dye 
(bromophenol blue 0.35%, Xylene cyanol FF 0.25% and 50% glycerol in water) and 
loaded into the slots. The same amount of a 1 kb DNA ladder from Promega was 
also added into one of slots in order to estimate the size of the DNA in the samples. 
The gel was run at 2.5 to 5 V/cm until the bromophenol blue and xylene cyanole FF 
had migrated the appropriate distance through the gel (based on the expected DNA 
sample size). After electrophoresis was completed the gel was photographed under 
UV light.
2.2.3 Restriction enzyme digestion of DNA
The first step in processing DNA for a genetic engineering experiment is the 
generation of smaller and more manageable fragments. Almost without exception, 
this is now achieved by use of sequence-specific bacterial endonucleases called 
restriction enzymes. The palindromic substrate nucleotide sequence at which each of 
several hundred restriction enzymes digests double stranded DNA is known. The 
manner in which the enzymes digest the DNA (leaving a 5' protruding sequence, a 3' 
protruding sequence, or a blunt end) is also known. Appropriate complimentary 
termini can also be generated by two different enzymes (Gannon and Powell, 1991).
The restriction digest reaction mixture consisting of the following ingredients was 
incubated at 37 ”C for 1 to 4 hours:
Restriction enzyme lOx buffer 2 pi
Bovine serum albumin, acetylated (1 mg/ml) 0.5 pi
DNA sample (0.2 pg/pl) 1 pi
Restriction enzyme (10 unit/pl) 1 pi
Nuclease-free water up to 20
To stop further effects of the restriction enzyme or carry out digestion with another 
enzyme the reaction mixture was heated at 65 °C for ten minutes {Xhol, EcoRI and 
Hindlll) or was purified (Mlul) using QIAquick PCR Purification Kit (section 
2 .2 .6 .1).
2.2.4 Polymerase chain reaction (PCR)
Molecular biology relies on techniques that enable the detection or capture of minute 
quantities of nucleic acids. The use of radioisotopes and later non-radioisotope 
alternatives provides methods to detect and track nucleic acids. The cloning of 
nucleic acids into high copy number vectors allows amplification of DNA sequences 
in living cells, providing a nearly unlimited source of these DNA molecules for 
further manipulation. With the introduction of the polymerase chain reaction (PCR), 
more sensitive levels of detection and higher levels of amplification of specific 
sequences are achieved, and in less time compared to previously used methods 
(Kosher and Wilson, 1991).
PCR is a relatively simple technique by which a DNA or cDNA template is amplified 
many thousand or million-fold quickly and reliably. By amplifying just a small 
portion of a target nucleic acid, a researcher effectively isolates that portion from the 
rest of the nucleic acid in the sample, as with the traditional cloning methods. The 
PCR process generates sufficient material for subsequent experimental analysis. The 
entire amplification can now been performed in vitro as opposed to standard cloning 
procedures. While most biochemical analyses, including nucleic acid detection with 
radioisotopes, require the input of significant amounts of biological material, the PCR 
process requires very little. These features make the technique extremely useful, not 
only in basic research, but also in commercial uses including genetic identity testing, 
forensics, industrial quality control, and in vitro diagnosis. In order to analyse 
plasmid DNAs or gene promoter in genomic DNA, PCR reactions were performed 
using the appropriate primers (Kosher and Wilson, 1991).
2.2.4.1 Primer design
Selecting the correct primers is one of the most important steps in designing a PCR 
experiment. The primer set should efficiently hybridise to the target sequence with as 
little hybridisation as possible to other sequences that are also present in the sample. 
In general, oligonucleotides between 18 and 30 bases are extremely sequence- 
specific, provided that the annealing temperature is optimal and they have a G+C 
content of 45-60%. The 3'-ends of the primers should not be complementary 
to avoid the production of primer-dimers in the reaction and care should be taken to
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exclude structures that would produce internal secondary structure. The annealing 
temperature for the primer pair is generally calculated as 2 to 5 °C lower than the 
estimated melting temperature (Tm) and during optimisation the suitable annealing 
temperature will be achieved based on practical results. Differences of 4-6 °C 
between forward and reverse primers do not seem to affect the yield of PCR, 
however, ideally the annealing temperature of each primer should match and be 
within the 55 °C to 72 °C range. The inclusion of a G or C residue at the 3'-end of 
each primer helps to ensure correct binding at the 3'-end due to the stronger hydrogen 
binding of G and C residues (‘GC clamping’). 100% complimentarity between 
primer and template is not necessaiy for polymerase-catalysed extension to occur. 
However, to ensure stable annealing, the primers should be as complimentary to the 
desired DNA sequence as possible (Kidd and Ruano, 1995).
2.2.4.2 PCR optimisations
Polymerase chain reactions should be optimised to yield one amplified product 
band. In an optimisation experiment, important factors such as annealing 
temperature, or polymerisation temperature, reaction buffer components (especially 
Mg '^  ^ concentration), deoxynucleotide concentration, type of thermo-stable DNA 
polymerase, DNA template quality and primer/template concentrations are examined. 
However, conunercially available PCR kits have reduced the need for most of this 
time consuming effort. But even with the kits, template concentration, DNA 
polymerase concentration and polymerisation temperature are important factors that 
should still be optimised. In the case of multiple band appearances in the 
electrophoresis gel, decreasing template and polymerase concentration and increasing 
the annealing temperature will often prevent the non-specific amplifications (Kidd 
and Ruano, 1995).
2.2.4.3 PCR amplification of the 5' regulatory and coding regions of the
CYP3A4 gene
Specific primers were designed to amplify the proximal regulatory (Figure 2.6) and 
distal enhancer XREM (Figure 2.7) regions of the CYP3A4 gene and their relative 
positions are shown in Table 2.1. The proximal 1141 bp 5' regulatory region was 
amplified as 3 short overlapping segments to aid the SSCP analysis (Figure 2.6).
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Table 2.1 Primer pairs used for PCR amplification of the CYP3A4 5' regulatory 
and XREM regions.
Region Sequence Position* Size
(bp)
5'proximal
regulatory PI: 5 -GACCACTGCCCCATCATTGC-3' 
P2: 5'-GCTGGTGGAGTTGACTTAGC-3' -1201/-778 424
P3: 5 -GCACAGCCAAGAGCTCTGGC-3' 
P4: 5'-CTTGCCCTTGTCTCTATGGC-3' -884/-391 494
P5: 5-GGCACAGGCACACTCCAGGC-3' 
P6: 5'-TGCTGGGCTATGTGCATGGAGC-3' -493/-61 433
Distal
XREM P7: 5-ACTTCATGCAAAAATGCTGG-3' 
P8: 5 -GTTCTTGTCAGAAGTTCAGC-3'
-79727-7673 300
Numbering system defines the first coding AT G as position +1.
P3 PS
-1201 -4 9 3
Coding Region
-3 9 1 -6 1-7 7 8
P4 P6
Figure 2.6 The CYP3A4 proximal promoter region and position of the PCR 
primer sets.
P7
- 7 9 7 2 ----- > -7939
1---------- ------ XREM region (230 bp)------- ----- -1
-7710 <-------- 7673
PS
Figure 2.7 The CYP3A4 distal XRFM region and position of the PCR primer set.
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All PCR amplifications were carried out in a 50 |il reaction volume, using the 
Advantage-HF 2 (high fidelity) PCR kit (Clontech, Palo alto, California, USA). This 
kit is an AdvanTaq™-based system designed to amplify cDNA or genomic DNA 
templates with exceptionally high fidelity. The Advantage-HF 2 Polymerase Mix 
is a high-performance PCR system that combines AdvanTaq DNA polymerase 
(a 5'-exonuclease-deficient genetically modified variant of Taq polymerase) with a 
minor amount of proof-reading polymerase (such as Pfu DNA polymerase) and 
TaqStart™ Antibody. The dual-polymerase system provides both high sensitivity and 
flexibility in amplifying a wide range of DNA templates, and TaqStart provides 
automatic hot-start PCR (User manual).
Each reaction contained:
lOxHF 2 PCR buffer 5 pi
lOx HE 2 dNTP mixture 5 pi
Relevant primer mixture (15 pmol each) 6 pi
50x Advantage-HF 2 polymerase mixture 1 pi
Genomic DNA template 100-200 ng (1 pi)
Nuclease-free water up to 50 pi
The reaction conditions for the CYP3A4 proximal 5' regulatory region segments 
were:
94 °C for 90 seconds (initial dénaturation) 1 cycle
94 °C for 30 seconds (dénaturation)
65 °C for 30 seconds (annealing) > 30 cycles
72 ®C for 1 minute (extension)
72 °C for 7 minute (final extension) 1 cycle
The same conditions (except for the annealing temperatures) were used to amplify the 
distal XREM region and the coding exons. The annealing temperature used for 
amplification of the distal XREM region was 60 °C. PCR primers and annealing 
temperatures used for amplification of the individual CYP3A4 exons are shown in 
Table 2.2.
92
Table 2.2 Primers used for PCR amplification of the CYP3A4 exons.^
Primer pairs Sequence Size cD N A  PCR annealing 
position^ temp. °C
Exon 1-A* 
Exon 1-B*
5'-GTGGAGAAGCCTCTTCCAACTG-3'
5'-GGGAAAGAGAGGCCTGATTAGC-3'
357 -216/71 62
Exon 2-A 
Exon 2-B
5'-CATTGCCGTCAGAGTTACTG-3'
5-CTGAGGCAAACCTGAGGTTC-3'
439 72/165 60
Exon 3-A 
Exon 3-B*
5'-GCTTCCTCTAACTGCCAGCAAG-3'
5-GGCATGCAGATTCCCATTGC-3'
365 166/218 62
Exon 4-A* 
Exon 4-B
5'-GTGTCAGACTCTTGCTGTGTG-3'
5'-GAAGTGGACGTGGAACCTTC-3'
387 219/318 60
Exon 5-A 
Exon 5-B
5'-CATCACCCAGTAGACAGTCAC-3'
5-GGCAGCTCAAATTCAGTGGAC-3'
351 319/432 60
Exon 6-A* 
Exon 6-B*
5'-TGTCCTTCTGGGACTAGAGTC-3'
5-GGGAGAAGATCCTTTTCCTCC-3'
351 433/521 60
Exon 7-A 
Exon 7-B
5-CCTGTTGCATGCATAGAGG-3'
5-GATGATGGTCACACATATC-3'
366 522/670 58
Exon 8-A 
Exon 8-B*
5'-GCTTCCAGTTGAGAACCTTG-3'
5'-CTCTTGCTCTAAACATGAGCAG-3'
393 671/798 60
Exon 9-A* 
Exon 9-B
5-ACATCCTGCTTTCCAAGGA-3'
5'-CCTGCATGCCTCTAGAAAGTG-3'
419 799/865 60
Exon 10-A 
Exon 10-B
5-CCAGTGTACCTCTGAATTGC-3'
5'-CAGAGCCTTCCTACATAGAG-3'
430 866/1027 60
Exon 11-A* 
Exon 11-B*
5'-CCAGTATGAGTTAGTCTCTGGA-3'
5-TGTCCTGTAGATTAAGAGAGGC-3
416 1028/1253 60
Exon 12-A* 
Exon 12-B
5-AGGGGTGGCCCTAAGTAAG-3'
5'-GATCACAGATGGGCCTAATTG-3'
396 1254/1416 62
Exon 13-A* 
Exon 13-B*
5'-TGAAGGAGTGTCTCACTCAC-3'
5'-ACGCCAACAGTGATTACAATG-3'
735 1417/2065 60
1. * Indicates primers modified from (Sata et al, 2000).
2. Numbering system defines the first coding ATG as position +1.
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2.2.4.4 Long-range PCR
Long range PCR allows the amplification of PCR products, which are much larger 
than those achieved with conventional Taq polymerases (100 to 2000 bp). Up to 27 
kb amplimers are achievable from good quality genomic DNA and up to 40 kb 
from plasmid DNA, although 10 to 20 kb fragments are routinely achievable, given 
the appropriate conditions. The method relies on a mixture of thermostable DNA 
polymerases, usually Taq DNA polymerase for high processivity (i.e. 5'-3' 
polymerase activity) and another DNA polymerase with 3'-5' proofreading abilities 
(usually Pwo or Pfu). This combination of features allows longer primer extension 
than can be achieved with Taq polymerase alone. In addition, specific buffer 
formulation is needed to improve pH maintenance at high temperatures thus reducing 
pH-driven template degradation to minimum.
Long-range PCR became a necessity when three heterozygous mutations were found 
in genomic DNA amplifications of sample M-42 (two mutations in the promoter 
region and another in the exon 6 with a distance of 15.5 kb). PCR products of long- 
range amplification were needed to carry out linkage analysis on these mutations.
A few attempts to perform long-range PCR using different kits and polymerases such 
as Advantage 2 polymerase Mix (Clontech), Termoprime Plus DNA Polymerase 
(Abgene, Surrey UK) and TaqPlus Long PCR system (Stratagene, The Netherlands) 
were unsuccessful and the result of each amplification reaction was a smear without 
any specific band. Another trial using TripleMaster® PCR system (Eppendorf AG, 
Germany) was successful and sufficient PCR products of desired amplification were 
produced which were then extracted from the gel. However, background non­
specific amplification also occurred (see Figure 3.18).
The TripleMaster® PCR system combines a powerful polymerase blend with a 
Tuning Buffer® system for efficient amplification of genomic targets up to 20 kb and 
episomal targets up to 40 kb. The TripleMaster® Enzyme Mix is a blend of 
thermostable DNA polymerases with a ‘processivity-enhancing factor’ providing 
both an extremely high extension rate and maximal proof-reading assisted fidelity 
(Manufacturer’s manual).
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15.5 kb products from -858 bp of the 5' proximal regulatory region to the end 
of exon 6, were amplified from volunteer M-42 genomic DNA using a long- 
range PCR kit (TripleMaster PCR system, Eppendorf AG, Germany) and allele- 
specific forward primers 5^-AATGACCTAAGAAGTCACCAGAA-3^  (wild type) 
or 5 AAT GACCT A AG A AG AT GGAGT AG -3 ' (insertion-mutant) with a common 
exon 6 reverse primer 5'-TGGATATGTAAACCCTGGCCC-3'.
For each reaction two mixtures were prepared in separate sterile microcentrifuges 
tubes.
Tube 1 contained:
Template DNA 100-200 ng (1 pi)
Primer mixture (15 pmol each) 6 pi
Nuclease-free water up to 10 pi
It was mixed well, centrifuged and placed on ice.
Tube 2 contained:
lOx reaction buffer 5 pi
lOx dNTP mixture 5 pi
TripleMaster® Enzyme Mix 0.4 pi (2 units)
Nuclease-free water up to 40 pi
The tube was mixed well, centrifuged and placed on ice.
Just before cycling, the contents of the tubes were mixed gently by pipetting 3-4 
times in a 0.2 ml tube and placed immediately into a thermal cycler which was pre­
heated at 94 °C.
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The reaction conditions were:
94 °C for 2 minutes (initial dénaturation) 1 cycle
94 °C for 25 seconds (dénaturation)
62 °C for 30 seconds (annealing) >• 28 cycles
68 °C for 12 minutes (extension)
68 °C for 10 minute (final extension) 1 cycle
Following electrophoresis, the wild type or mutant 15.5 kb bands (-858/+14536) 
were extracted from the gel, purified using the Ultra Clean 15 DNA purification kit 
(MO BIO, Solana beach, California, USA) and then used as templates to amplify 
exon 6 from each corresponding allele. The exon 6 PCR products were then 
sequenced to identify on which allele the exon 6 mutation was present.
2.2.5 Single strand conformation polymorphism (SSCP)
SSCP is a widely used method for mutation detection because of its simplicity and 
versatility. In the original SSCP protocol (Orita et al, 1989), the region of interest in 
the genome or cDNA is amplified by PCR, using radio labelled PCR primers or 
nueleotides, to generate a 200-350 bp radioactive product which is then denatured 
and electrophoresed in a large-format (40x20 cm) 8-10% non-denaturing gel. The 
mobility of single-stranded nucleic acid molecules electrophoresed under 
non-denaturing conditions is determined by both their fragment length and their 
secondary structure which is sequence dependent. A DNA strand may adopt several 
conformations for any given set of electrophoresis conditions and these are visualised 
as separate bands in the gel (Figure 2.8). The test sample will take up a different 
conformation if there is a sequence change and will migrate differently during 
electrophoresis. Mutations are thus detected as differences of mobility of the DNA 
bands between control and test. Some or all of the bands may show a shift, a single 
base change being sufficient to alter secondary structure and hence mobility. 
Because of a lack of theoretical background to predict conformation, and therefore 
the mobility of single-stranded DNA in gel electrophoresis, optimal conditions for 
separation of conformers has to be determined by empirical observation (Hayashi 
etal, 1998).
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This method has several drawbacks. It requires the use of radioisotopes and 
electrophoresis on large denaturing gels to effect separation and detection of the 
single-strand conformers. Also, auto radiography (usually with multiple exposure) 
requires substantial time to produce a clear image of the resulting SSCP pattern.
There are now several reports describing non-radioactive (or ‘cold’) protocols for 
SSCP analysis. However, some require the purchase of expensive additional 
equipment or use of silver staining techniques. In ‘cold’ SSCP as used in this project, 
there is no need to use radioactivity and the gel is made of high percentage 
polyaerylamide (14-20%) in a mini format. The bands are visualised by staining the 
gel with conventional DNA stains (Hongyo et al, 1993).
In this project I have further developed this simple, ‘cold’ SSCP analysis method so 
that it can reliably detect single nucleotide changes in PCR products of up to 500 bp 
in length. I have utilised this system to identify novel mutations in the 5'-promoter 
region of the human CYP3A4 gene.
2.2.5.1 Polyacrylamide gel electrophoresis
Polyacrylamide gels are formed by the polymerisation of acrylamide monomers 
(CH2 =CH-C 0 -NH 2) into long random chains of polyacrylamide which 
are cross-linked by the inclusion into the mixture of small amounts of an 
appropriate bi-functional co-monomer, usually A,A'-methylene-bis-acrylamide 
(CH2=CH-C0-NH-CH2-NH-C0-CH=CH2) commonly known as ‘Bis’. The 
resulting cross-linked chains form a gel structure, the pore size of which is 
determined by the initial concentrations of acrylamide and cross-linker.
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Wild-type DNA Mutant DNA
Dénaturation to produce
F
single stranded D N A i r
Each single strand can produce one or more secondary structure and the result of 
a polyacrylamide gel electrophoresis is demonstrated in the following picture.
Figure 2.8 Simplified steps of the single strand conformation (SSCP) analysis.
PCR products of wild type and likely mutant samples denatured, using a 
denaturising buffer and heat, and the resulting single stranded DNAs were 
run in a high percentage non-denaturising polyacrylamide gel. Structural 
differences between the wild type and mutant strands cause mobility shift and 
therefore different SSCP pattern (adapted from Hayashi et al, 1998).
Lane 1: wild-type DNA sample
Lanes 2-4: mutant DNA samples showing different SSCP patterns
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A stock solution of 20% acrylamide mixture (39:1 acrylamide to bis-acrylamide) was 
prepared with following components and stored at cold room;
For 100 ml of 20% solution
40% Acrylamide solution (from Promega) 48.75 ml
2% Bis-acrylamide solution (from Promega) 25 ml
5xTBE Buffer 10 ml
50% Glycerol 10 ml
Water to 100 ml
After extensive optimisation trials (e.g. using gels of different strength, running the 
gels in the cold room or at room temperature and for different times) the best 
separation of SSCP bands for CYP3A4 PCR products up to 5()0 bp in length was 
obtained with 14.5 to 15.5% gels that had been run in the cold room at 15 V/cm for 
65 to 70 hours.
To prepare a 10 ml 15% acrylamide gel the following components were mixed;
20% Acrylamide mixture (see above) 7.5 ml
TEMED (tetramethylethylenediamine) 10 Pl
10% Ammonium persulphate (freshly prepared) 10 pi
Water to 10 ml
Each gel (8 cmx7.3 cmxl mm) was cast using the Bio-Rad mini Protean II™ set. 
The gels were ready after about 1.5 hour. Before sample loading the gels were 
pre-run in Ix  TBE (diluted from 5x TBE as described above) for about 1 hour.
After the pre-run, 5 pi of PCR product was mixed with 10 pi of denaturing-loading 
dye (95% formamide, 4 M urea, 0.1% bromophenol blue, 0.1% Xylene cyanol FF and 
0.5 pi 15% Ficoll) and the mixture was heated to 94 °C for 10 min (Ainsworth and 
Rodenhise, 1994). All of the 15 pi of the mixture was loaded into the well without
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quenching (Hayashi et al, 1998). A 1 kb DNA ladder (from Promega) was also 
added to one of the wells. The electrophoresis was carried out as indicated above.
After electrophoresis the gels were stained with SYBR® Gold nucleic acid stain 
(Molecular probes, Oregon, USA) for 30-40 minutes and photographed under UV 
light using a SYBR® gel stain photographic filter (Tuma et al, 1999).
2.2.S.2 Gel staining with SYBR® Gold
SYBR® Gold is one of a series of proprietary unsymmetrical cyanine dyes that have 
been recently developed. As a group, these dyes are characterised as having low 
intrinsic fluorescence, large fluorescence enhancement upon binding to nucleic acids, 
and high fluorescence quantum yields when complexed with nucleic acids. SYBR® 
Gold has a major excitation peak centred around 300 nm, penetrates thick and 
high-percentage gels efficiently, and is exceptionally photo-stable. It is > 10-fold 
more sensitive than ethidium bromide for detecting DNA and RNA in denaturing 
urea, glyoxal and formaldehyde gels, even with 300 nm transillumination. The 
presence of the dye in stained gels at standard staining concentrations does not 
interfere with restriction enzymes, T4 DNA ligase, Taq polymerase, or with Southern 
or Northern blotting. The dye is readily removed from nucleic acids by ethanol 
precipitation, leaving pure templates available for subsequent manipulation or 
analysis (manufacturer’s manual).
The stock SYBR® Gold stain was diluted 10000-fold to make a Ix  staining solution 
e.g. in TE (10 mM Tris-Cl, 1 mM EDTA, pH 7.5-8.0). The gel was incubated in 
Ix  staining solution for 10 to 40 minutes after adding enough staining solution to 
completely cover the gel. During staining the gel was proteeted from light by 
covering it with aluminium foil or by placing it in the dark. The gel was agitated 
gently at room temperature. No de-staining was required.
2.2.6 DNA sequencing
PCR products showing altered SSCP patterns were re-amplified from genomic DNA 
then purified with the Ultra Clean™ 15 DNA purification kit (MO BIO, Solana beach, 
California, USA). The purified samples were used directly for DNA sequencing of
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both strands without any further treatment. Where a variation in DNA sequence from 
the wild type was found, the original PCR product was also sequenced for 
confirmation. In the case of novel mutations, additional repeat amplification and 
sequencing was performed for final confirmation. In all samples where novel 5' 
regulatory region mutations were found, direct sequencing of PCR products from the 
13 CYP3A4 exons was also performed to identify any linked coding region mutations. 
Numbering of nucleotides was carried out by assigning the figure +1 to the base A in 
the translation initiation ATG codon and -1 to the base before the A (http:// 
www.imm.ki.se/CYPalleles).
Dye-termination sequencing, using a capillary sequencer (ABI PRISM® 3700 DNA 
analyser), was performed by MWG Biotech AG  (Ebersberg, Germany) throughout 
this project.
2.3 Recombinant DNA technology
2.3.1 Sterilisation by autoclaving
Plastic ware and solutions prepared for use in procedures involving the handling of 
nucleic acids, bacteria or mammalian cell culture were sterilised in an RSI series 32 
automatic autoclave. Items were sterilised for 20 minutes at 120 °C at a pressure of 
15 Ib/inl
2.3.2 Preparation of bacterial stock cultures
Bacterial cultures containing recombinant plasmids with DNA inserts of interest were 
stored in glycerol at -70 ”C. Overnight cultures of E. colt in LB medium containing 
100 jig/ml ampicillin (for plasmids coding for ampicillin resistance) were prepared. 
150 pi of sterile glycerol was added to 850 pi of bacterial culture in a sterile 1.5 ml 
centrifuge tube. The tube was vortexed briefly to ensure complete mixing of the 
contents before freezing the stocks at -80 °C.
2.3.3 Growth of bacterial cultures
Most plasmids carry a marker gene for a specific antibiotic resistance. By 
supplementing the growth medium with the appropriate antibiotic, only cells
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containing the plasmid of interest will grow. Addition of antibiotic to the optimal 
concentration will also help to maximise plasmid yields.
For growing plasmid-containing bacteria from a glycerol stock, a sterile inoculation 
loop was scraped across the surface of a frozen stock and then streaked on an LB agar 
plate containing 100 pg/ml ampicillin and incubated overnight at 37 °C. An isolated 
colony from a freshly streaked plate (less than 5 days old) was then picked using a 
sterile loop and inoculated into 5 ml LB medium containing 100 pg/ml ampicillin. 
This mini-culture was incubated in a rotary incubator at 225 rpm at 37 ”C for 8 hours. 
For subsequent maxi-culture, 500 pi of the miniculture was added to 250 ml of LB 
medium containing 100 pg/ml ampicillin and incubated overnight (12-16 hours) in a 
rotary incubator at 225 rpm at 37 (reconunendations of the manufacturer, 
QIAGEN Endo Free Plasmid Maxi Kit).
2.3.4 Ligation of DNA inserts into pSEAP2-Basic plasmid vector
pSEAP2-Basic enables expression of the reporter gene, human secreted alkaline 
phosphatase (SEAP). This vector lacks eukaryotic promoter and enhancer sequences 
and has a multiple cloning site (MGS) that allows putative promoter DNA fragments 
to be inserted upstream of the SEAP gene. The SEAP coding sequence is followed 
by the SV40 late polyadenylation signal to insure proper, efficient processing of 
the SEAP transcript in eukaryotic cells. A synthetic transcription blocker (TB), 
composed of adjacent polyadenylation and transcription pause sites, located upstream 
of the MGS reduces background transcription. The vector backbone also contains an 
fl origin for single-stranded DNA production, pUG origin of replication, and an 
ampicillin resistance gene for propagation and selection in E. coli (Figure 2.1). 
Following transfection of mammalian cells in culture the SEAP reporter gene product 
is secreted into the media. Samples of the medium can then be assayed for alkaline 
phosphatase activity by a simple chemiluminescence assay. Also because of lack of 
requirement for cell lysis multiple readings can be taken during the course of the 
experiment. SEAP activity can be distinguished from intracellular alkaline 
phosphatase by its resistance to heat dénaturation and insensitivity to certain alkaline 
phosphatase inhibitors.
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T4 DNA ligase catalyses the joining of two strands of DNA between the 5'-phosphate 
and the 3'-hydroxyl groups of adjacent nucleotides in either a cohesive-ended or 
blunt-ended configuration. The enzyme has also been shown to catalyse the joining 
of duplex RNA to either a DNA or RNA strands, but will not join single-stranded 
nucleic acids (Manufacturer’s manual, Promega).
Restriction digested, purified PCR products and plasmids were used to set up ligation 
reactions based on the manufacturer’s (Promega) recommended ratios. The following 
formula can be used to calculate the amounts of the vector and the insert DNA.
ng of vector x kb size of insert
-----------------------------------------------------X molar ratio of insert/vector = ng of insert
kb size of vector
Appropriate amounts of vector and PCR product were incubated together with 
ligation buffer and T4 DNA ligase at room temperature for three hours or overnight at 
4 ®C. Negative control (without insert DNA) reactions were also set up to assess the 
self-ligation and non-digestion of the vector.
2.3.5 Transformation of recombinant plasmid DNA into bacteria
Competent TOPI OF' E. coli cells were used in transformation reactions. For each 
transformation reaction one 50 |il vial of the cells were thawed on ice. 5 |il of the 
ligation reaction was added directly to the vial containing competent cells and mixed 
by tapping gently. The mixture was incubated in a 42 ”C water bath for exactly 30 
seconds. The vial was removed from the bath and was quickly placed on ice. 250 \il 
of pre-warmed SOC medium was added to the vial and incubated at 37 °C for exactly 
one hour at 225 rpm in a rotary shaker-incubator. 50 \i\ from transformation vial was 
spread onto an LB agar plate containing 100 pg/ml ampicillin and incubated at 37 ”C 
overnight. Positive (using pUC18 super coiled plasmid) and negative (bacteria itself) 
control transformations were also carried out.
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2.3.6 Cloning of the CYP3A4 proximal and distal promoter regions
pSEAP2-Basic plasmid (Clontech, Palo alto, California, USA) was used to create the 
constmcts containing these regions.
(1) PCR reactions were carried out as described in section 2.2.3 to amplify 300 bp of 
distal XREM region and 1141 bp of proximal promoter of the CYP3A4 gene.
Modified primers:
P7; 5'-cggacgcgtACTTCATGCAAAAATGCTGG-3' (Forward)
P 8:5'-ccgctcgagGTTCTTGTCAGAAGTTCAGC-3' (Reverse)
were used to create Mlul and Xhol restriction sites at the 5'- and 3'-ends of the 
amplified XREM region PCR products.
Modified primers:
PI : 5-cccaagcttGACCACTGCCCC ATCATTGC-3' (Forward)
P6: 5'-ccggaattcTGCTGGGCTATGTGCATGGAGC-3' (Reverse)
were also used to create Hindlll and EcoRl restriction sites at the 5'- and 
3'-ends of the amplified proximal promoter region PCR products.
(2) PCR products then were purified using QIAquick PCR purification kit.
(3) The purified PCR products of the XREM region and pSEAP2-Basic plasmid 
were digested with Mlul and Xhol as described earlier (section 2.2.3). The 
digested products re-purified and re-used in ligation reactions (section 2.2.4) to 
construct pX-SEAP2 plasmid (Figure 2.2). The authenticity of the plasmid was 
confirmed by re-digestion with relevant restriction enzymes, PCR of the insert 
region and sequencing of the PCR product using the constructed plasmid as 
template.
(4) The same procedure was carried out using Hindlll/EcoRl digested proximal 
promoter region PCR products (from four different mutant samples) and
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pX-SEAP plasmid to construct pXP-SEAP2 plasmids (Figure 2.3) containing 
wild-type and mutant promoters.
2.4 Human cell culture methods
Human hepatoma HepG2 (ECCAC No. 85011430) and HuH7 (Japanese collection 
No. JCRB0403) cells, and the human Caucasian colon carcinoma Caco-2 (ECCAC 
No. 86010202) cells were grown in 75 cm^ flasks in 5% CO2  in air at 37 °C. Cells 
were cultured in minimum essential medium (MEM) with Earle's salts supplemented 
with 10% (v/v) foetal bovine serum (FBS), 2 mM L-glutamine, 10% (w/v) 
gentamicin and 1% (v/v) non-essential amino acids. Cells were seeded at 2 to 3x10"^  
cells/cm^ and passaged using trypsin/EDTA.
2.4.1 Cell passage
Cells were split every 3 to 5 days when 90% confluent. The medium was aspirated 
and the cells were washed with phosphate buffered saline pH 7.4 (PBS) or trypsin- 
EDTA (Appendix I) to remove dead cells and any remaining medium. The washing 
solution was removed by aspiration. 2 ml trypsin-EDTA solution were added and left 
for 2 to 3 minutes to detach the cells from the flask. The flask was shaken to detach 
the cells completely. 8 ml of medium were added to inactivate the trypsin. The 
required amount of cell suspension (usually 1/3 of the suspension) was added to a 
new flask containing 20 ml of pre-warmed medium.
2.4.2 Storage of cells in liquid nitrogen
A flask of actively growing cells was trypsinised and resuspended in 20 ml medium. 
The cells were pelleted by centrifugation at 1200xg for 5 minutes and then 
resuspended at 10  ^cell/ml in medium containing 10% DMSO. This suspension was 
dispensed into cryovials (Nunc International) in 1 ml aliquots, packed in cotton wool 
and put into a polystyrene box. The cryovials were transferred to the -80 °C freezer 
overnight to freeze slowly (1 °C/min). They were then transferred to liquid nitrogen 
for storage.
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2.4.3 Recovery of cells from liquid nitrogen
A cryovial of cells was incubated in the water bath at 37 °C for 2 minutes to thaw 
completely, wiped with 70% ethanol, and the contents transferred into a sterile 50 ml 
centrifuge tube containing 20 ml pre-warmed medium. The cells were pelleted by 
centrifugation at 5000xg for 5 minutes after which the pellet was re-suspended in 20 
ml pre-warmed medium and transferred to a 75 cm^-cell culture flask.
2.4.4 Transfection with plasmid DNA
The ability to introduce nucleic acids into mammalian cells (DNA-mediated gene 
transfer, DMGT) has advanced our knowledge of gene regulation and protein 
function. The process of introducing nucleic acids into cells by non-viral methods is 
known as “transfection”. This process is distinct from “infection”, which is a virus- 
based method. Many transfection techniques have now been developed. Desirable 
features include high efficiency transfer of DNA into the nucleus, minimal intrusion 
or interference with normal cell physiology, low chemical toxicity, ease of use, 
reproducibility, successful generation of stable transfectants (if required).
2.4.4.1 Calcium Phosphate method
The calcium phosphate precipitation transfection technique is widely used because 
the components are easily available and cheap. The protocol is easy to use and many 
different types of cultured cells can be transfected. The method is routinely used for 
both transient and stable transfection of a variety of cell types. The protocol involves 
mixing DNA with calcium chloride, adding this in a controlled manner to a buffered 
saline/phosphate solution and allowing the mixture to incubate for a period. This step 
generates a fine DNA precipitate that is dispersed onto the cultured cells. The 
precipitate is taken up by the cells via endocytosis. The calcium phosphate also 
appears to provide protection against intracellular nuclease digestion of the DNA. 
However, the method gives relatively poor levels of transfection efficiency and the 
high Ca^ "^  concentration is toxic to some cell types. The transfection protocol was 
that used previously in our laboratory (Ogg et al, 1999).
Day 1: Seeding of HepG2 cells. Following trypsinisation, cells were diluted to a 
concentration of 6x10^ cells/ml with medium for seeding into 96-well plates (Nunc
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International). 80 jil of pre-warmed medium was dispensed per well, and then 40 |xl 
of cell suspension was added. The plates were placed in a humidified container in the 
cell culture incubator at 37 ”C for 24 hours.
Day 2: Transfection. One hour prior to transfection, the growth medium was 
removed, replaced with fresh medium and the plates returned to the incubator. The 
transfection mix was then prepared on ice for optimum precipitate formation. In a 
sterile tube 100 pi of 2 M CaCli was added to 25 pg plasmid DNA and the required 
volume of O.lx TE (1 mM Tris.Cl pH 8.0, 0.1 mM EDTA pH 8.0) was added to a 
final volume of 1 ml. Then 1 ml of 2x HBS (280 mM NaCl, 10 m M KCl, 1.5 mM 
Na2HP0 4 .2 H2 0 , 12 mM dextrose and 50 mM HEPES) was added and incubated on 
ice for 1 minute after which 4.6 ml medium was added to terminate the precipitation 
reaction. After removal of medium, 80 pi of transfection mix were added per well of 
the 96-well plate followed by 40 pi of medium to a final volume of 120 pl/well. The 
plates were replaced in the humidified container and transferred to the cell culture 
incubator.
Day 3: Dosing. A sample of growth medium was removed for alkaline phosphatase 
assay and then drug solutions or control solvent were added to the cell cultures in a 
small volume. The maximum final solvent concentration was 0.1%. All solutions 
were freshly prepared in the day of dosing. Incubation was then continued for a 
further 48 hours.
Day 5: Reporter assay. A further sample of the growth medium was removed for 
chemiluminescent assay of alkaline phosphatase activity.
2.4.4.2 Transfection with FuGENE 6 reagent (Roche Biochemicals)
FuGENE 6 transfection reagent is a proprietary, multi-component lipid-based 
transfection reagent that forms complexes with and transports DNA into cells during 
transfection. The FuGENE 6 transfection reagent provides very high transfection 
efficiency in many common cell types, demonstrates virtually no cytotoxicity even in 
many primary cell types and requires minimal optimisation. This reagent is unique as 
compared to other liposomal transfection reagents and requires special handling.
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Undiluted FuGENE 6 must not be allowed to come in contact with plastic surfaces 
other than the pipette tip and should always be stored in the original tubes. It has 
been shown that chemical residues in new plastic vials can significantly decrease the 
biological activity of the reagent. It is supplied in 80% ethanol, sterile-filtered, and 
packaged in polypropylene tubes.
Following trypsinisation, cells were diluted to a concentration of 2x10^ cell/ml with 
medium for seeding into 96-well plates (Nunc International) and 120 pi of cell 
suspension was added to each well. The plates were placed in a humidified container 
in the cell culture incubator at 37 °C for 48 hours.
On the day of transfection, serum-free medium was added to a micro-centrifuge tube 
(to a final volume of 100 pi) as diluent for the FuGENE 6 transfection reagent. 
Suitable amounts of FuGENE 6 reagent and DNA at a ratio of 3:1 (pi of FuGENE 6 
reagent:pg of DNA) was added to the medium. FuGENE 6 reagent was added first 
(directly into the medium without contact with the plastic surface) and, after mixing 
by gently tapping the tube, the DNA (3 to 4 pg) was added. The order of addition 
was critical (based on the manufacturer’s instructions). The tube was mixed as before 
and stood for at least 15 minutes at room temperature. The mixture was then diluted 
in suitable amount of serum-free medium and, after removing the old medium, 120 pi 
of the transfection solution was added to each well. Transfection was allowed to 
proceed for 5 hours in the serum-free medium. Subsequently the serum-free medium 
was removed and the cells were cultured for an additional 60 to 65 hours in fresh 
serum-containing medium in the presence or absence of the various CYP3A4 
inducers. 15 pi samples from each well were then removed for alkaline phosphatase 
assay.
2.4.6 Chemiluminescence assay of secreted alkaline phosphatase activity
Secreted Placental Alkaline Phosphatase (SPAP or SEAP) can be assayed using a 
chemiluminescent alkaline phosphatase substrate. Alkaline phosphatase-catalysed 
dephosphorylation of the chemiluminescent substrate produces a destabilised 
dioxetane anion. This decomposes rapidly with the concomitant production of light. 
Unique chemiluminescence-enhancing reagents consisting of a water-soluble
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macromolecule, e.g. poly (benzylmethylvinylbenzyl) amonium chloride, and a 
fluorescent dye are key to the rapid production of an intense stable signal from 
the excited state generated in these alkaline phosphatase-catalysed reactions. The 
polymer sequesters the dephosphorylated dioxetane anion into hydrophobic domains 
of the polymer chain, thereby eliminating the aqueous quenching reactions, which 
profoundly lower the intensity of the chemiluminescent signal. In the presence of this 
type of enhancer approximately 2.5 to 3 orders of magnitude signal enhancement is 
achieved (Manufacturer’s manual).
Dilution buffer, assay buffer (a mixture of intra-cellular alkaline phosphatase 
inhibitors) and reaction buffer (containing a luminescence enhancer) were allowed to 
equilibrate to room temperature (Appendix 1). 15 pi samples from each well were 
placed in the wells of fresh 96-well Optiplate polystyrene microplates {Packard UK). 
45 pi of Ix  dilution buffer was added to each well and the plates were incubated at 
65 for 1 hour to inactivate any background intracellular alkaline phosphatase 
activity presents. The plates were removed, incubated on ice for 2 minutes and then 
left to reach room temperature (about 15 minutes). 60 pi of assay buffer was then 
added and the samples were incubated for 5 minutes at room temperature. 60 pi of 
the reaction buffer was added and left for 20 minutes after which time the plates were 
analysed for chemiluminescence using the Lumicount™ (Packard) plate reader.
2.4.7 Definition of relative light units and gain settings in sample measurements
The luminometer uses a photomultipher tube (PMT) to measure the photons of light 
emitted by the samples. The PMT converts the photons striking it into a voltage 
which can be processed by the LumiCount into relative light units (RLUs). RLUs 
allow data to be analysed relative to a reference sample (e.g. in a 96 well plate the 
light emission from each well is set to be measured relative to the well with the 
strongest emission). The measurements are performed at different gain settings (or 
levels) to allow for different overall intensities of light from different experiments, 
the range (of gain level) being from 1.0 to 32.0. The lower the gain level, the 
stronger the light emission or response. The LumiCount has a range of 0.0-70,000 
RLUs per 0.5 second read length at each gain level. Thus, the amount of relative
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light units produced at any one gain level can not be directly related to the relative 
light units measured at a different gain level.
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CHAPTER THREE
MUTATION ANALYSIS OF THE HUMAN CYP3A4 
GENE 5 ' REGULATORY REGION
3.1 Introduction
CYP3A isoenzymes are the most abundantly expressed cytochrome P450s in human 
liver, accounting for up to 60% of the total hepatic cytochrome P450 activity in some 
individuals (Gonzalez, 1993). However the expression and activity of the CYP3A 
isoenzymes show wide inter-individual variation, influencing both drug responses 
and disease susceptibility (Guengerich, 1999). Four human CYP3A genes have been 
identified, CYP3A4, CYP3A5, CYP3A7 (Nelson et al, 1996) and most recently 
CYP3A43 (Domanski et al, 2001).
CYP3A4 is the major cytochrome P450 isoenzyme in adult human liver and is known 
to metabolise a large variety of xenobiotic and endogenous substrates (Li et al, 1995). 
Inter-individual variation in hepatic CYP3A4 levels of up to 40 fold (based on the 
metabolism of specific substrates such as triazolam, midazolam or cyclosporine) has 
been observed (Daly et al, 1993). The basis of this variation is not yet understood but 
may be due to genetic, environmental, pathological, hormonal or dietary factors 
(Guengerich, 1995).
The CYP3A4 gene and its 5'-fianking region has been isolated and sequenced 
(Hashimoto et al, 1993). The gene is approximately 27 kb long with a coding region 
composed of 13 exons located on chromosome 7q22.1 (Hashimoto et al, 1993; 
Goodwin et al, 1999). Although there had been no indication of genetic 
polymorphism in the CYP3A4 gene until 1997 (Linder et al, 1997; Lewis et al, 1998), 
investigations since then have reported inherited variation in both the promoter 
(Rebbeck et al, 1998; Kuehl et al, 2001) and coding region of the gene (Westlind 
et al, 1999; Sata et al, 2000; Hsieh et al, 2001). However, the impact of these 
mutations on mRNA expression or enzyme activity has not been extensively 
investigated. Also the proposed relationship between the CYP3A4'^1B allele (-392 
A ^G ) and an increased incidence of prostate cancer was not confirmed in later
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studies (Ball et al, 1999; Westlind et al, 1999). However, Sata et al (2000) showed 
that the CYP3A4^2 allele (Ser222Pro) produces a lower in vivo intrinsic clearance of 
nifedipine, but no significant difference from the wild type enzyme activity for 
testosterone 6p-hydroxylation. In addition Hsieh et al (2001) have recently reported 
three further mutations in the coding region of the CYP3A4 gene and related them to 
a decreased urinary 6p-hydroxycortisol/cortisol ratio in heterozygotes.
In the case of CYP3A5, there is also evidence of polymorphism in the coding 
(Jounaidi et al, 1996) and promoter regions (Kuehl et al, 2001) which may contribute 
to variation in the overall hepatic metabolism of CYP3A substrates. All the 
recognised CYP3A alleles are now listed on in the Human Cytochrome P450 (CYP) 
Allele Nomenclature Committee Home Page (http:// www.imm.ki.se/CYPalleles).
3.2 Human genomic DNA extraction
101 human genomic DNAs were isolated from whole blood using the Wizard® 
genomic DNA purification kit (Promega, UK) and used directly for PCR 
amplification of the proximal regulatory (1141 bp) and distal enhancer (300 bp) 
regions of the CYP3A4 gene. As mentioned in Materials and Methods (section 
2.2.1.1) all extracted genomic DNAs were quantified by spectrophotometry. Samples 
were in the range of 100-200 ng/pl with an A260/A280 nm ratio of more than 1.7 
indicating the absence of protein contamination. Subsequent use of the genomic 
DNA samples (e.g. in PCR) produced good results indicating reliability of the 
extraction method.
To determine the quality of extracted genomic DNA and the reliability of the 
purification kit, all DNA samples were analysed on 1% agarose gels. A photograph 
of the agarose gel electrophoresis of 16 samples is shown in figure 3.1 as an example. 
As this shows, all samples were of good quality with a high molecular weight 
compared to the DNA size marker.
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Figure 3.1 1% agarose gel electrophoresis of extracted genomic DNAs (2.5 pi of 
each sample) from blood samples.
M: 1 kb DNA marker
Lanes 1-16: different high molecular weight genomic DNAs from individual 
blood samples
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3.3 PCR amplifîcâtion of the CYP3A4 proximal and distal 5'
regulatory regions
Polymerase chain reactions were optimised to yield one product band under the 
conditions described in Materials and Methods (section 2.2.4.2). The proximal 1141 
bp 5' regulatory region was amplified as 3 short overlapping segments to aid the 
SSCP analysis (see diagram in section 2.2.4.3). The sizes of the PCR products were 
expected to be 433 (-493/-61), 493 (-884/-391), 423 (-1201/-778) and 1141 
(-1201/-61) bp respectively for proximal regulatory region and, 300 bp 
(-79727-7671) for distal xenobiotic responsive enhancer module (XREM) region 
(Table 2.1). Negative control reactions (without template DNA) were also included 
in the optimisations to ensure no contamination has occurred.
Figures 3.2 and 3.3 show 1% agarose gel electrophoresis (section 2.2.2) of the PCR 
products from optimised reactions. 5 p.1 of each PCR product was mixed with 1 |il of 
a loading dye and loaded into each well. As the photographs clearly indicate, all 
products have correct size and good yield indicating the efficiency of the reaction 
under optimised conditions.
The optimised conditions were then used for amplifications from 101 genomic DNA 
samples. PCR reactions for XREM region have been carried out in cooperation with 
Helen J. Edwards as an undergraduate project.
As exemplified in figures 3.4, 3.5, 3.6 and 3.7, all PCR reactions were successful and 
yielded high quality product. 5 |il of each PCR product was mixed with 1 p.1 of a 
loading dye and loaded into each well. There was no failure in the amplification of 
any sample and as the photograph shows all products had similar quality and yield. 
PCR products then were directly used for SSCP (section 2.2.4) analysis without any 
further treatment.
All PCR primers were checked initially for specificity by sequencing of the PCR 
products. No evidence was found to indicate non-specific cross-amplification of the 
CYP3A5 or CYP3A7 5' regulatory regions.
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Figure 3.2 1% agarose gel electrophoresis of optimised PCR amplifications of 
the CYP3A4 proximal regulatory region.
M: 1 kb DNA ladder 
Lane 1: negative control
Lane 2: PCR of the whole 1141 bp promoter region (-1201/-61)
Lane 3: PCR of the 433 bp first segment (-4937-61)
Lane 4: PCR of the 493 bp second segment (-8 847-391)
Lane 5: PCR of the 423 bp third segment (-12017-778)
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Figure 3.3 1 % agarose gel electrophoresis of optimised PCR amplification of the 
CYP3A4 distal XREM region.
M: 1 kb DNA ladder 
Lane 1: negative control
Lane 2: PCR of the distal 300 bp xenobiotic responsive enhancer module 
(XREM) region (-79727-7671)
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Figure 3.4 An example of 1% agarose gel electrophoresis of the PCR products 
for the -493/-61 segment Of the CYP3A4 promoter from different genomic DNA 
samples.
M: 1 kb DNA marker
Lanes 1-12: PCR products of different samples
10 11
750 —>
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250 -4»
<-493
Figure 3.5 An example of 1 % agarose gel electrophoresis of the PCR products 
for the -884/-391 segment of the CYP3A4 promoter from different genomic 
DNA samples.
M: 1 kb DNA marker
Lanes 1-12: PCR products of different samples.
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Figure 3.6 An example of 1% agarose gel electrophoresis of the PCR products 
for the -1201/—778 segment of the CYP3A4 promoter from different genomic 
DNA samples.
M: 1 kb DNA marker
Lanes 1-12: PCR products of different samples
bp M 1 8 9 10 11 12
750 - 4
500 - 4
250 - 4 <-300
Figure 3.7 An example of 1% agarose gel electrophoresis of the PCR products 
for the distal XREM (—7972/-7671) of the CYP3A4 promoter from different 
genomic DNA samples.
M: 1 kb DNA marker
Lanes 1-12: PCR products of different samples
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3.4 Non-radioactive single strand conformation polymorphism 
(Cold-SSCP) analysis of the CYP3A4 5' regulatory regions
As described in materials and methods (section 2.2.4), the SSCP technique is based 
on the appearance of new “refolding” conformations during electrophoresis due to 
mutation. In screening of unknown samples appearance of an extra band(s) or band 
shifts in the SSCP pattern of a sample in comparison to the normal samples 
indicates likely mutation in that DNA sample. SSCP analysis has a limited capacity 
for genetic mutation screening because it does not indicate the nature or position of 
the polymorphism. Mutations detected via SSCP must be confirmed by sequencing 
of the PCR product. In addition a fresh PCR amplification of that genomic DNA 
must be analysed to eliminate any possible changes that may be introduced by the 
polymerase itself into the first PCR product. The SSCP results obtained clearly 
showed that the Cold SSCP method for mutation detection was reliable and 
reproducible. Also, the staining dye SYBR Gold was found to be sufficiently 
sensitive to detect changes in mobility due to alteration in single strand conformation.
SSCP analysis for the -493/-61 segment of the CYP3A4 promoter showed altered 
SSCP patterns for ten out of the 101 PCR products indicating likely mutations. The 
photograph in figure 3.8 is an example showing the SSCP patterns produced. In this 
example, all samples have either two or three bands except one (lane 6 ) which has 4 
bands indicating the possible presence of mutations in the DNA. The occasional 
presence of the uppermost band does not appear in this case to be related to changes 
in DNA sequence in the PCR product but is due to either the concentration of the 
PCR product or the extent of single strand formation during dénaturation. The SSCP 
pattern of the sample with the new mutation was not distinguishable from that of the 
other 9 variant samples. In segment -884/-391, eighteen out of the 101 PCR 
products showed an altered SSCP band pattern indicating possible mutations (Figure 
3.9). In this example, all samples have three bands except one (lane 3) which has 4-5 
bands indicating the possible presence of mutation. SSCP analysis of the PCR 
products from -1201/-778 segment showed only one sample with an altered band 
pattern (Figure 3.10). All samples have three bands except one (lane 2) which has a 
split pattern in the uppermost band indicating possible mutation.
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SSCP analysis was also performed on the PCR products (Figure 3.7) of the distal 
XREM region (-7972/-7671) of the CYP3A4 promoter from 101 genomic DNA 
samples by Helen J. Edwards as an undergraduate project under my supervision. No 
differences in the SSCP patterns were identified. An example of the SSCP analysis 
band patterns from the XREM region is shown in Figure 3.11. Subsequent 
sequencing of 5 randomly selected PCR products revealed no mutation in this region 
indicating high sequence conservation in this essential regulatory element (see Figure 
4.5). Similar conservation of the XREM region of CYP3A7 has been reported 
recently (Bertilsson et al, 2001).
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Figure 3.8 An example of 15% polyacrylamide gel electrophoresis and SSCP 
analysis of PCR products from the -493/-61 segment of the CYP3A4 promoter.
M: DNA marker
Lanes 1-8: SSCP analysis of PCR products from different genomic DNA 
samples
Arrow indicates a PCR product producing an extra lower SSCP band.
Figure 3.9 An example of 15% polyacrylamide gel electrophoresis and SSCP 
analysis of PCR products from the -884/-391 segment of the CYP3A4 promoter.
M: DNA marker
Lanes 1-8: SSCP analysis of PCR products from different genomic DNA 
samples
Arrow indicates a PCR product producing an extra lower SSCP band.
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Figure 3.10 An example of 15% polyacrylamide gel electrophoresis and SSCP 
analysis of PCR products from the —1201/-778 segment of the CYP3A4
promoter.
M: DNA marker
Lanes 1-8: SSCP analysis of PCR products from different genomic DNA 
samples
Arrow indicates a PCR product producing an extra upper SSCP band.
Figure 3.11 An example of 15% polyacrylamide gel electrophoresis and SSCP 
pattern for PCR products of the CYP3A4 XREM region (-7972/-7671).
M: DNA marker
Lanes 1-8: SSCP analysis of PCR products from different genomic DNA 
samples
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3.5 DNA sequencing of the variant PCR products
PCR products producing altered SSCP patterns were re-amplified from the 
corresponding genomic DNA samples and purified with the Ultra Clean'^^ 15 DNA 
purification kit (MO BIO, Solana beach, California, USA). The purified samples 
were then used directly for DNA sequencing of both strands. Where a variation in 
DNA sequence compared to wild type (Figure 3.12) was found, the initial PCR 
product was also sequenced for confirmation. In the case of novel mutations, 
additional repeat amplification and sequencing was performed. In all samples where 
novel 5' regulatory region mutations were found, direct sequencing of PCR products 
from the 13 CYP3A4 exons was also performed to identify any linked coding region 
mutations. Numbering of nucleotides was carried out by assigning the figure + l t o  
the base A in the ATG translation initiation codon and -1 to the base before this A, 
(http:// www.imm.ki.se/CYPalleles).
In sequencing the -493/-61 section, the previously described CYP3A4"^1B allele 
-392 A ^ G  (Rebbeck et al, 1998) was found to be heterozygous in 9 of the 10 variant 
samples (Figure 3.13 A). A new allele (designated CYP3A4"^1E) containing a -369 
T->A transversion was found in sample F-14 (Figure 3.13 B). As it is shown, all 
detected mutations were heterozygous. It should be mentioned here that to confirm 
the new T->A mutation, 4 different PCR products were prepared from the relevant 
genomic DNA (F-14) and sequenced using 2 different DNA sequencing machines. 
The results were the same in all cases. The -884/-391 sequencing revealed 17 
samples with a novel allele (designated CYP3A4^1F) containing a -747 C ^ G  
transversion (Figure 3.14 A). The remaining sample (M-42) showed a 9-nucleotide 
heterozygous insertion (ATGGAGTGA) after -845 G (Figure 3.14 B). The double 
sequence read out due to the insertion and its normal interpretation are demonstrated. 
The insertion was also detected in the SSCP and sequencing analysis of the 
overlapping -1201/-778 segment of the M-42 promoter and was the only sample 
from this segment with an altered SSCP pattern (Figure 3.10). It should be noted that 
in addition to the insertion at -845 this sample also contained heterozygously a -392 
A-4G transition. All DNA samples containing novel mutations were subject to 
confirmatory PCR and sequencing to eliminate the possibility of PCR artefacts.
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Figure 3.12 Wild type sequence of 1141 bp of the proximal promoter region of 
the CYP3A4 gene.
The sequencing reactions have been performed on the PCR product 
of the whole promoter region using PI (Table 2.1) and 
5 -T  AG ACT AT GCCCTT G AGG AGC-3 ' (underlined) as primers. Arrows 
indicate the position of the various mutations found by SSCP and confirmatory 
sequencing. It should be noted that this picture was assembled from two 
successive sequencing reactions from the same sample. T 5 5 0  in the first part of 
the picture is T 5 7  in the second part. * Indicates the transcription start site.
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(A) -392
Sense strand Antisense strand
(B) -369
T
T A A T  A G  A T T A T  G C C A  A G C C ^ J T G G C A T  A N ^ ^ T C T A T T  A A ^ g
Sense strand Antisense strand
Figure 3.13 Panels (A) and (B) and demonstrate the sequence confirmation (both 
strands) of the previously reported heterozygous -392 A ^ G  transition (Rebbeck 
et al, 1998) and the novel heterozygous -369 T ^ A  transversion, identified by 
SSCP of the^93 /-61  section. Sense strands as per figure 3.12.
The -392 A ^ G  transition was found in 9 samples (F-05, 12, 27 and M-06, 10, 
14, 29, 32, 42).
The -369 T ^ A  trans version was found in sample F-14.
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(B)
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310 320
T T A A T G AC C T A A G A A  G A -
330 340 350 360 370
T CAC CAGAAAGT CAGAAGGGATGACATGCAGAGGC CCAGCAAT CT CAGC 
ATGGAGTAGTCACCAGAAAGTCAGAAGGGATGACATGCAGAGGCCCAGC
Sense strand
CT G Æ T T T C T  GOT GAC TAC T - -AT C T A T  T - A - A C A - T  - A  - T - C A G T C  GG - T GTOG- - G G AT GT GC T
Antisense strand CTTCTTAGGTCATTAATACAGCCAGAGCTCTTGGCTGTGCCTCAGCTGG
CTACTCCATCTTCTTAGGTCATTAATACAGCCAGAGCTCTTGGCTGTCC
Figure 3.14 Panels (A) and (B) and demonstrate sequence confirmation (both 
strands) of the novel heterozygous -747 C ^ G  transversion and a nine- 
nucleotide insertion between -845 and -844, identified by SSCP, respectively. 
Sense strands as per figure 3.12.
The -747 C ^ G  transversion was found in 17 samples (F-08, 11, 17, 18, 24, 26, 
31, 33, 34, 39 and M-02, 18, 31, 38, 44, 48, 53).
The -845 9 bp insertion was detected in sample M-42.
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As noted earlier sample M-42 showed a 9-nucleotide heterozygous insertion 
(ATGGAGTGA) after -845 G (Figure 3.14 B). This inserted sequence has close 
similarity to the ‘HFL-a’ motif in the CYP3A7 promoter region (in 8 out of 9 
nucleotides, Hashimoto et al, 1993) and may have arisen by recombination between 
CYP3A4 and CYP3A7 genes in this region. To investigate any reciprocal 
recombination between CYP3A4 and CYP3A7 promoters in subject M-42 PCR 
amplification was carried out to examine the CYP3A7 promoter sequence in this 
region. No reciprocal insertion of CYP3A4 DNA was found in the CYP3A7 promoter 
of M-42 as shown in Figure 3.15.
In all genomic DNA samples where novel CYP3A4 5' regulatory region mutations 
were found, direct sequencing of PCR products from the thirteen CYP3A4 exons 
(Figure 3.16) was also performed using primers and conditions as listed in table 2.2 to 
identify any linked coding region mutations. For amplification of the CYP3A4 exons 
the PCR primers and reaction conditions in Sata et al (2000) were used initially. In 
some instances, however the primers and annealing temperatures had to be modified 
to optimise the amplifications (Table 2.2). In the case of exons 1 and 2 the relevant 
primers did not distinguished between the CYP3A4 and CYP3A7 sequences, causing 
double sequence readings in places for the PCR products. However, the two 
sequences could be read easily from the sequencer printout and analysed for 
mutations by inspection.
The results from direct sequencing of the CYP3A4 exons, from samples with new 
mutations in the 5' regulatory region, showed no mutations in the coding region 
except in the case of sample M-42 where a heterozygous G ^ A  transition in exon 6 
(cDNA position 485, creating R162Q in the protein structure) was found (Figure 
3.17). This exon 6 mutation (designated CYP3A4"^15) has recently been described by 
J. Lamba (http:// www.imm.ki.se/CYPalleles/cyp3a4.htm).
It should be noted that in addition to the heterozygous 9 bp insertion at -845 and the 
heterozygous G ^ A  transition in exon 6, sample M-42 also contained heterozygously 
a -392 A ^ G  transition mutation. So it was crucial to identify the linkage between 
these mutations.
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Figure 3.15 Sequence of the CYP3A7 promoter from sample M-42 DNA. The 
HFLa-SE sequence is underlined.
To amplify this region 5 -CAGGACTTTTGAAGCTACAG-3' forward 
and 5'-GCCCCTGTGTGTCACTTCC-3' reverse primers were used. PCR 
amplifications were performed using M-42 and a wild type control genomic 
DNA.
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Figure 3.16 1% agarose gel electrophoresis of the PCR products for the CYP3A4 
exons.
M: 1 kb DNA marker 
Lanes 1: negative control
Lanes 2-14: PCR products of the CYP3A4 exons (1-13 respectively)
* Numbers under the lanes indicate the sizes of the PCR products.
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Figure 3.17 Identification by sequencing of a mutation in CYP3A4 exon 6.
Panel (A) indicates the wild type sequence of CYP3A4 exon 6. Panel (B) 
demonstrates the heterozygous G ^ A  transition in exon 6 (creating R162Q) in 
sample M-42.
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3.6 Linkage analysis of mutations in sample M-42
In order to determine whether the three heterozygous CYP3A4 mutations found in 
genomic DNA from subject M-42 were in the same allele, linkage analysis was 
performed. An initial amplification and cloning (section 2.2.6) of the 5'-proximal 
promoter region was used to separate the alleles and determine if the 9 bp insertion at 
-845 was linked to the -392 A—>G mutation. Using the recombinant plasmid DNAs 
as template, PCR amplification of 592 bp (to cover both mutations) of the CYP3A4 
promoter (-9297-337) was performed and sent directly for sequencing. The 
following primers were used for these PCR reactions.
5'-AGAATCACAGAGGACCAGCC-3'
5'-CTTATC AGAAACTCAAGTGG -3 '
The results of the sequencing reactions revealed that both mutations are in the same 
allele in M-42 (Figure 3.18).
Following this, long-range (-858/4-14536) allele-specific PCR products (Figure 3.19), 
as described in section 2.2.4.4, were used as templates after gel extraction and 
purification to amplify each corresponding exon 6. The exon 6 PCR products (Figure 
3.20) were then sequenced to identify on which allele the exon 6 mutation was 
present. The results (Figure 3.21) again showed that all three mutations of M-42 are 
present on the same allele.
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Figure 3.18 Sequence analysis of the cloned PCR fragment from the CYP3A4 
promoter of M-42.
The sense strand sequence from the M-42 pXP-SEAP2 plasmid (Figure 2.3) is 
shown.
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^ 1 5 .5  kb
Figure 3.19 Allele-specific long-range-PCR of the wild type and 9 bp insert- 
containing alleles of sample M-42 genomic DNA.
M: lambda DNAJHindlll DNA marker 
Lane 1: negative PCR control 
Lane 2: M-42 mutant allele PCR product 
Lane 3: M-42 wild type allele PCR product 
Arrow indicates the 15.5 kb PCR products.
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Figure 3.20 PCR amplification of the CYP3A4 exon 6 using gel extracted long- 
range PCR products from the M-42 wild type and 9 bp insertion-containing 
alleles.
M: 1 kb DNA marker 
Lane 1: negative control
Lane 2: PCR product of CYP3A4 exon 6 from the mutant allele 
Lane 3: PCR product of CYP3A4 exon 6 from the wild type allele
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Figure 3.21 Sequencing results of CYP3A4 exon 6 DNA amplified from the 9 bp 
insertion-containing allele of sample M-42.
The arrows indicate the CYF3A4'^15 mutation.
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3.7 Discussion
To provide suitable templates for PCR amplifications, genomic DNA extraction was 
performed on the collected blood samples. Although this was straightforward for 
fresh blood, some problems arose with frozen samples. It was found necessary to 
repeat the white cell pellet wash several times to remove haemoglobin contamination. 
However during these decontamination steps some loss of DNA always resulted. The 
most difficult issue, however, was genomic DNA rehydration. Complete removal of 
ethanol after washing the precipitated DNA pellet was critical for this step; otherwise 
DNA rehydration became difficult and was time consuming. Apart from these initial 
problems, the Promega DNA extraction and purification method proved to be fast and 
reliable in comparison to the other methods examined in this study (e.g. DNA Zol BD 
solution ‘Molecular Research Centre Inc., Ohio, USA’ and conventional laboratory 
non-kit methods). In general, the amount of extracted DNA in the samples was in the 
range of 100-200 ng/pl of final solution which was more than adequate for the 
purposes of this investigation.
Initially Pfu DNA polymerase was examined in PCR amplifications because of the 
high copying fidelity requirement of mutation analysis. But many attempts using 
different Mg^ "*" concentrations, touchdown PCR and varying concentrations of the 
reaction components failed to give the expected PCR products with good yield. 
Subsequently, a ‘high fidelity’ kit (Advantage-HF 2, see section 2.2.4.3) was 
examined. This had seemed to be very reliable and efficient when it was used 
previously in our laboratory. However, considerable effort and time was still needed 
to optimise the conditions for the PCR amplifications of the CYP3A4 promoter 
region. The most critical factors were annealing temperature and primer/template 
concentrations. After optimisation, the PCR results were very satisfactory indicating 
robustness and reliability of the method.
Optimisation of ‘Cold’ SSCP also took a relatively long time due to the larger than 
usual (> 300 bp) PCR products being examined. There is in fact only one publication 
suggesting the possibility of performing SSCP on PCR products of around 500 bp 
(Kukita et al, 1997). In my study different techniques from the literature (Hongyo 
et al, 1993; Ainsworth and Rodenhise, 1994; Hayashi et al, 1998; Tuma et al, 1999;
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Yip et al, 1999) were combined, particularly using different polyacrylamide gel 
concentrations and loading dye with high concentrations of dénaturants, to develop a 
reliable method. Moreover, it was found to be difficult to perform the high 
percentage (e.g. 15%) polyacrylamide gel electrophoresis of PCR products of more 
than 400 bp in a reasonable time scale. PCR products of this size, as single strands, 
move very slowly in high percentage gels. As a consequence the application of high 
voltages was necessary to perform efficient separation, however such voltages could 
cause melting of the gel and jeopardise the electrophoresis process. Due to the lack 
of suitable instrumentation (e.g. refrigerated buffer circulation) to perform ‘cold’ 
SSCP at high voltages and reduce the electrophoresis time to a matter of a few hours, 
SSCP electrophoresis had to be performed in the cold room at lower voltage and took 
almost three days to complete. However, the final results were very satisfactory and 
the optimised method was able to reliably reveal new mutations in amplified DNA 
from blood samples. In fact the ‘Cold’ SSCP method developed here seems to be 
robust enough to analyse PCR products up to 500 bp long.
DNA sequencing of samples that appear from SSCP analysis to contain a mutation is 
the only reliable method of confirmation. The in-house ABI Prism 373 DNA 
sequencer which was used initially for sequencing of the samples detected as 
mutants, had a reduced accuracy after 350 bp of sequence. To overcome this problem 
as well as possible ‘operator errors’ or the presence of PCR ‘artefacts’, several 
samples of each relevant DNA and PCR product were prepared for sequencing to 
obtain confirmation. Satisfactory DNA sequencing results were obtained for all 
samples analysed especially for the -493/-61 section of the CYP3A4 promoter. PCR 
products of the sample with the new mutation were also sequenced and confirmed 
using a different DNA sequencing machine (OpenGene system. Visible Genetic Inc., 
Canada). However, in order to reduce the time loss and cost of failed sequencing 
runs the commercial sequencing service of MWG Biotech AG  (Ebersberg, Germany) 
was used subsequently.
The frequency of the -392 A ^ G  transition polymorphism varies considerably among 
different racial populations; for example, the allele is present in only 4% to 9% of 
European Americans: but it is the predominant (55%) allele in African Americans
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(Wendel et al, 2000). The frequency of this mutation (all of them heterozygous) in 
our study was 9.6% among a white European population and is consistent with the 
previous studies. In the Iranian samples the frequency was lower at 6%. There has 
been a substantial debate regarding the association of the -392 A—>G transition with 
a higher clinical stage and grade of prostate cancer (Rebbeck et al, 1998) but this 
issue was not confirmed in later studies (Ball et al, 1999; Westlind et al, 1999).
The novel -369 T ^ A  transversion which was found here in one Caucasian subject 
may have some effect on enzyme expression because of its proximity to the CAAT 
box and other regulatory motifs.
The -747 C-^G transversion identified in this study is a mutation with a relatively 
high frequency of 20% in Caucasians and 18% in the Iranian populations. This 
mutation is not located in or near a known transcriptional element and might thus 
have little or no effect on gene expression.
Perhaps the most surprising result in mutation detection experiments was the 
genotype of subject M-42. This Caucasian male has inherited an allele containing a 
nine-nucleotide insertion after -845 G, a -392 A—>G transition, and a G-^A 
transition in exon 6 (resulting in (R162Q). Insertion of nine nucleotides at position 
-845 (which is identical in 8 out of 9 nucleotides to the ‘HFL-a’ response element in 
the CYP3A7 promoter) makes this region of the CYP3A4 gene in this allele similar to 
CYP3A7. Since CYP3A7 expression is repressed in adult liver and ‘HFL-a’ is one of 
the few substantial differences between the CYP3A4 and CYP3A7 promoter regions, 
this insertion may cause down-regulation of CYP3A4 expression from this allele. 
The linked mutation in exon 6 of the M-42 subject and conservative substitution of 
arginine for glutamine may not have a substantial effect on enzyme activity (Lewis 
et al, 1996; Szklarz and Halpert, 1997).
In summary, we have further developed a simple, non-radioactive SSCP analysis 
method so that it can reliably detect single nucleotide changes in PCR products up to 
500 bp in length. We have utilised this system and confirmatory sequencing to 
identify three novel mutations in the 5' regulatory region of the human CYP3A4 gene.
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The investigation in vitro of the possible impact of these novel mutations on hepatic 
CYP3A4 gene expression, using an alkaline phosphatase reporter gene system, is the 
subject of the next chapter.
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CHAPTER FOUR
EFFECTS ON GENE TRANSCRIPTION OF 
MUTATIONS IN THE HUMAN CYP3A4 GENE 
PROMOTER REGION
4.1 Introduction
It has been proposed that much of the substantial inter-individual variability in 
CYP3A4 activity can be attributed to genetic factors (Ozdemir et al, 2000), but 
extensive efforts to investigate a genetic role for inter-individual variation in enzyme 
activity have been inconclusive. Although a growing number of rare CYP3A4 
mutant alleles (mostly in the coding region) have been recently discovered 
(http://www.imm.ki.se/CYPalleles/cyp3a4.htm) their contribution to overall CYP3A4 
activity is limited. This finding and the fact that CYP3A4 activity is strongly 
correlated with CYP3A4 mRNA abundance, indicates that transcriptional control is 
the primary mechanism for regulating expression of CYP3A4 (Kuehl et al, 2001) and 
underlines the importance of investigating the role of regulatory region 
polymorphisms in modulating CYP3A4 levels.
Wild type and mutant proximal promoter region DNAs, as described in chapter three 
(section 3.3.), were inserted into alkaline phosphatase reporter vectors. The potent 
upstream XREM region (Goodwin et al, 1999) was also included in the constructs. 
The reporter plasmids were named according to the blood DNA samples from which 
the proximal promoter region had been amplified:
M-01: containing a wild type proximal promoter region.
F-14: containing the CYP3A4"^1E proximal promoter region (-369 T->A 
trans version).
F-27: containing the CYP3A4"^1B proximal promoter region (-392 A ^  G transition).
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M-18: containing the CYP3A4^1F) proximal promoter region (-747 C-^G 
transversion.
M-42: containing the CYP3A4^15B proximal promoter region (nine-nucleotide 
insertion after -845 G and -392 A ^ G  transition).
To evaluate the activity of these promoters a number of transfection studies were 
performed using three different cell lines and several classical CYP3A4 inducers.
4.2 Cloning of the CYP3A4 XREM region into the pSEAP2-hasic 
vector
In a detailed report, Goodwin et al (1999) characterised a distal XREM region that, in 
conjunction with elements in the proximal promoter region, directs hPXR-mediated 
transactivation of CYP3A4. This region, located ~ 7.9 kp upstream of the CYP3A4 
translation initiation site, is a complex array of transcriptional-binding sites that 
includes at least two elements (designated dNRl and dNR2) that are capable of 
binding the hPXR-RXRa heterodimer (see Figure 4.5). Disruption of the proximal 
hPXR binding site and dNRl destroys 80 to 90% of the CYP3A4 promoter xenobiotic 
responsiveness, demonstrating that these two elements are central to transactivation 
by ligand-activated hPXR.
The pSEAP2-basic expression vector (Figure 2.1) was digested with the restriction 
enzymes Mlui and Xhol to create sticky ends as described in Materials and Methods 
(section 2.2.3). The vector DNA was re-purified after each digestion reaction 
(section 2.2.6.1).
300 bp of the XREM region (-79727-7673) was amplified from genomic DNA 
(section 2.3.6) using modified P7 and P8 primers creating Mlu\ and Xhol restriction 
sites respectively. The purified and digested PCR products were then ligated into the 
digested and purified pSEAP2-Basic plasmid DNA (section 2.3.4). The recombinant 
plasmid DNA (designated pX-SEAP2, Figure 2.2) was transformed into E. coli 
TOPI OF' (Invitrogen, CA, USA) cells and transformed colonies were isolated.
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Miniprep plasmid DNA extraction and purification was performed (section 2.2.1.2).
The authenticity of the plasmid was confirmed by the following.
(1) The sizes of intact recombinant plasmid DNA were examined. As shown in 
Figure 4.1, pX-SEAP2 plasmid DNA was larger compared to pSEAP2-Basic 
plasmid DNA indicating insertion of the XREM region.
(2) The pSEAP2-Basic and pX-SEAP2 plasmids were digested with Mlu\ to check 
the sizes of the linear forms. Figure 4.2 clearly shows that linear pX-SEAP2 
plasmids DNA had the correct size as compared with the DNA marker and linear 
pSEAP2-Basic DNA.
(3) The Mlul digestion products were re-digested with Xhol to confirm the presence 
of the XREM region insert. Figure 4.3 indicates the results of the double 
digestions and confirms the identity of the selected pX-SEAP2 plasmid.
(4) Diagnostic PCR of the XREM region was performed using constructed pX- 
SEAP2 plasmid DNA as template. Figure 4.4 shows the XREM region can be 
amplified from the recombinant plasmids.
(5) DNA sequencing of the PCR product provided final confirmation of the presence 
of the unchanged XREM region in the pX-SEAP2 plasmid (Figure 4.5).
One of the authenticated XREM containing plasmid constructs was taken as the
reference pX-SEAP2 plasmid and used as the parent in all further manipulations.
143
bp
8000 ^  
6000 ^
4000
3000
Figure 4.1 Size control of the pX-SEAP2 plasmids in comparison to pSEAP2- 
Basic.
M: 1 kb DNA marker
Lane 1: pSEAP2-Basic DNA (4677 bp)
Lanes 2-4: different pX-SEAP2 plasmid DNAs (4966 bp) prepared from 
bacteria transformed by DNA from three different ligation reactions. Lane 2 is 
plasmid DNA prepared from transformation of a ligation reaction performed at 
room temperature for three hours. Lanes 3 and 4 are from reactions that were 
carried out overnight at 4 ”C.
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Figure 4.2 Agarose gel (1%) electrophoresis of recombinant plasmids digested 
with Mlul.
M: 1 kb DNA marker
Lane 1: pSEAP2-Basic DNA (4677 bp)
Lanes 2-3: different pX-SEAP2 DNAs prepared from two ligation reactions 
(4966 bp). Lane 2 is plasmid DNA prepared from transformation of a ligation 
reaction performed overnight at 4 °C. Lanes 3 is from a reaction that was 
carried out at room temperature for three hours.
Lane 4: uncut pX-SEAP2 DNA
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Figure 4.3 Restriction digests of recombinant pX-SEAP2 plasmids to check for 
the presence of the XREM region (300 bp).
M: 1 kb DNA marker
Lane 1: uncut pSEAP2-Basic DNA (4677 bp)
Lane 2: uncut pX-SEAP2 DNA (4966 bp)
Lane 3: pSEAP2-Basic DNA digested with Mlul (4677)
Lanes 4-5: pX-SEAP2 DNAs digested with Mlul and Xhol
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Figure 4.4 PCR amplification of the XREM region using the reference pX- 
SEAP2 plasmid as template.
M: 1 kb DNA marker
Lane 1: negative control (pSEAP2-Basic DNA)
Lane 2: PCR product of the XREM amplified from human genomic DNA 
Lane 3: PCR product of the XREM amplified from reference pX-SEAP2 DNA.
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Figure 4.5 Sequencing of the XREM region PCR product amplified from the 
reference pX-SEAP2 plasmid DNA. The putative hPXR responsive elements 
(dNRl and dNR2) are boxed (adapted from Goodwin et al, 1999).
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4.3 Cloning of the CYP3A4 proximal promoter region into the
pX-SEAP2 vector
Reference pX-SEAP2 plasmid DNA (Figure 2.2) was digested with EcoRl and 
Hindlll to create sticky ends (section 2.2.3). The vector was purified after each 
digestion reaction (section 2.2.6.1). As described in section 2.3.6, a 1141 bp of the 
proximal promoter region (-1201/-61) was re-amplified from the genomic DNA of 
wild type and mutant subjects, using modified P1/P6 primers (Table 2.1), creating 
EcoRl and Hindlll restriction sites. The purified and digested PCR products were 
then ligated into the cut pX-SEAP2 plasmid DNA. The recombinant plasmid 
DNAs (designated pXP-SEAP2, Figure 2.3) were transformed into E. coli TOPI OF' 
(Invitrogen, CA, USA) cells and transformed colonies were isolated. Five colonies of 
M-01 (wild type) and 10 colonies of each mutant were randomly selected and 
cultured in 5 ml LB. Miniprep plasmid DNA extraction and purifications were 
performed as in section 2.2.1.2. The authenticity of the plasmids was confirmed by 
performing the procedures described in section 4.2.
As Figure 4.6 shows all plasmid DNAs extracted from the minipreps were 
electrophoresed to check the size correctness in comparison to pSFAP2-Basic and 
pX-SFAP2 plasmid DNAs. Plasmid DNAs of the wrong size (e.g. lanes 14-16) or 
related to mixed colonies (lanes 9-11) were omitted from further experiments. 
Further size evaluation was performed by digesting with EcoRl of the plasmid DNAs. 
Figure 4.7 is an example of this procedure. The plasmid DNAs of the correct size 
were also re-digested with Hindlll. Figure 4.8 indicates the results of the double 
digestions and confirms the authenticity of the pXP-SFAP2 plasmids.
PCR amplifications of the CYP3A4 proximal promoter region using the constructed 
plasmids as template were also performed for further confirmation of the authenticity 
of the pXP-SFAP2 plasmid DNAs. Figure 4.9 is an example of PCR amplifications 
for each of the five pXP-SFAP2 plasmids related to the wild type and mutant 
CYP3A4 promoters.
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Figure 4.6 An example of size analysis of the constructed pXP-SEAP2 plasmids.
M: 1 kb DNA marker 
Lane 1: pSEAP2-Basic 
Lane 2: pX-SEAP2
Lanes 3-16: different newly constructed pXP-SEAP2 plasmids
Lanes 3 and 14-16 are plasmids that are similar in size to pX-SEAP2. These are 
probably derived from uncut original plasmid DNA. Lanes 9-11 are mixtures of 
pX-SEAP2 and pXP-SEAP2. Plasmids in lanes 4-8 and 11-12 are pure plasmid 
clones of the correct size.
150
M 1 2 3 4 5 6 7 9 10 11 12 13 14 15 16 17
5000^
3000^
2000 — >
<- 6099 bp 
<- 4966 bp
1000^
Figure 4.7 Restriction digest (EcoRl) of recombinant pXP-SEAP2 plasmids.
M: 1 kb DNA marker
Lane 1: pSEAP2-Basic plasmid DNA (4677 bp)
Lanes 2 and 17: pX-SEAP2 plasmid DNA (4966 bp)
Lanes 3-16: different newly constructed pXP-SEAP2 plasmids
Plasmids in lanes 3, 5-7, 9, 12 and 14-16 are new recombinant pXP-SEAP2 plasmid 
clones of the correct size.
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Figure 4.8 Restriction digest (EcoRl and Hindlll) of selected recombinant 
pXP-SEAP2 plasmids to cbeck for tbe presence of tbe CYP3A4 proximal 
promoter region.
M: 1 kb DNA marker
Lanes 1-5: pXP-SEAP2 plasmids M-01, F-14, F-27, M-18 and M-42 (section 
4.1)
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Figure 4.9 An example of PCR amplification of tbe CYP3A4 proximal promoter 
region using pXP-SEAP2 plasmids as template.
M: 1 kb DNA marker
Lane 1: negative control (pSEAP2-Basic DNA)
Lane 2: PCR product of the CYP3A4 proximal promoter amplified from 
genomic DNA
Lanes 3-7: PCR products of CYP3A4 proximal promoter insert from plasmids 
M-01, F-14, F-27, M-18 and M-42 respectively
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Due to the heterozygous nature of the mutations in the genomic DNA samples, 
sequencing of the PCR products amplified from several plasmid clones was the only 
way of selecting and confirming the final authenticity of the desired pXP-SEAP2 
plasmids containing the mutant alleles. Sequencing results (Figures 4.10, 4.11, 12) 
confirmed the identity and authenticity of five different pXP-SEAP2 vectors 
containing the wild type and mutant CYP3A4 promoters. The mutant alleles are seen 
as a homozygous readout with the mutation in each sequence marked by arrow. 
Sequencing information regarding the recombinant plasmid M-42 containing the 
CYP3A4"^15B allele has already been shown in Figure 3.17.
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Mutant forward and reverse sequences
Figure 4.10 Authentication by DNA sequencing of plasmid F-27 containing the 
CYP3A4'^1B promoter (A—>G transition at -392).
The wild type sequence was amplified from plasmid MO-1. The arrows indicate the 
site of the mutation.
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Mutant forward and reverse sequences
Figure 4.11 Authentication by DNA sequencing of plasmid F-14 containing the 
CYP3A4^1E promoter (T—>A transversion at -369).
The wild type sequence was amplified from plasmid MO-1. The arrows indicate the 
site of the mutation.
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Mutant forward and reverse sequences
Figure 4.12 Authentication by DNA sequencing of plasmid M-18 containing the 
CYP3A4^1F promoter (C ^G  tranversion at -747).
The wild type sequence was amplified from plasmid MO-1. The arrows indicate the 
site of the mutation.
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After designation of the mini-cultures of the desired recombinant plasmids containing 
mutant alleles, endotoxin-free maxiprep plasmid DNA preparations were performed. 
Diagnostic size and restriction digest control reactions were then performed for final 
confirmations.
As shown in Figure 4.13 all maxiprep plasmid DNAs were of correct size in 
comparison to pX-SEAP2 plasmid DNA. Further analysis was performed by 
digestion of the plasmid DNAs with EcoRl. Figure 4.14 is the result of this digestion 
and again indicates the correct size of the linear plasmids (6099 bp) compared to a 
DNA marker. The plasmid DNAs were then re-digested with HindMl. Figure 4.15 
indicates the result of the double digestions and confirms the authenticity of the 
maxiprep plasmid DNAs. The concentration of the authenticated maxiprep DNAs 
was then measured at 260 nm (section 2.2.1.3).
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Figure 4.13 Size control of the maxiprep DNA extracts of pXP-SEAP2 plasmids 
in comparison to pX-SEAP2.
M: 1 kb DNA marker 
Lane 1: pX-SEAP2 (4966 bp)
Lanes 2-6: pXP-SEAP2 plasmids (6099 bp) containing wild type (M-01) and 
mutant alleles (F-14, F-27, M-18 and M-42 respectively)
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Figure 4.14 Restriction digest {EcoRY) of the maxiprep DNA extracts of pXP- 
SEAP2 plasmids to check the size correctness.
M: 1 kb DNA marker
Lanes 1-5: pXP-SEAP2 plasmids (6099 bp) containing wild type (M-01) and 
mutant alleles (F-14, F-27, M-18 and M-42 respectively)
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Figure 4.15 Restriction digest {EcoRl and Hindlll) of the maxiprep DNA 
extracts of plasmids pXP-SEAP2 to check for the presence of the CYP3A4 
proximal promoter region insert (1141 bp).
M; 1 kb DNA marker
Lanes 1-5: pXP-SEAP2 plasmids containing wild type (M-01) and mutant 
alleles (F-14, F-27, M-18 and M-42 respectively)
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4.4. Functional analysis in vitro of the CYP3A4 promoter mutations
Studies of transcription control elements have been greatly facilitated by linking them 
to reporter genes, which are readily assayed and expression of the reporter gene is 
used as an indication of transcriptional activity. The key features of a useful reporter 
gene are that its activity be easily assayed and that its endogenous activity in the 
target cells be low (Yang et al, 1997).
Secreted alkaline phosphates (SEAP) based reporter gene system obviously fulfils the 
above criteria as described in chapter two (section 2.3.4). pSEAP2-Basic (Figure 2.1) 
vector that allows for expression of SEAP under control of putative promoters and/ or 
enhancers of interest, was used to construct the recombinant plasmids containing the 
CYP3A4 wild type and mutant promoter regions. Using three different cell lines 
described in section 2.4, transient transfection experiments were performed to 
evaluate the effects of the mutations found on the CYP3A4 regulation.
Considering the central rate of hPXR in CYP3A expression and its possible ‘cross­
talk’ and even interaction with other receptors such as CAR and GR, it was decided 
to use a representative panel of previously identified CYP3 A4 inducers which belong 
to different chemical and pharmacological groups (Lehmann et al, 1998; Goodwin 
et al, 1999). All drugs were dissolved in DMSO producing maximum 0.1% of the 
solvent in cell culture medium.
4.4.1 Initial transfection experiments: Calcium phosphate precipitation method
Preliminary transfection experiments were performed using calcium phosphate 
method (section 2.4.4.1) by Raman Dhir as an MSc project under my supervision. 
This method has been used previously in our laboratory for the study of CYP3A 
enzymes regulation in cell cultures such as HepG2 cells (Ogg et al, 1999 and 
El-Sankary et al, 2000).
The five pXP-SEAP2 reporter gene constructs described in section 4.1 were 
examined with known inducers of CYP3A4 dexamethasone (10 pM), phénobarbital 
(1 mM) and rifampicin (10 pM) in HepG2 cell line. All experiments included 
pSEAP2-Basic (Figure 2.1) and pCMV-cSPAP (Figure 2.5) vectors as negative and
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positive controls respectively. Although the cells transfected by the pCMV-cSPAP 
vector produced high levels of alkaline phosphatase (demonstrated by emitted relative 
light units “RLU”), no obvious differences \vere observed between pSEAP2-Basic 
(SEAP) and constructed reporter gene vectors (Figure 4.16). This could be due to 
transfection inefficiency (as seen by relatively high well to well variation shown by 
large standard error values for pCMV-SPAP), insufficient activation of the CYP3A4 
promoter region in this system or the toxicity induced by high concentration of 
calcium ions in this method.
Considering the report by Goodwin et al (1999) regarding the importance of 
co-transfection with hPXR expression plasmid in the study of CYP8A4 transcriptional 
activation, the same experiments were performed in the presence of the hPXR 
expression vector pSG5-hPXR. Again the results of the transfection experiments 
generally failed to demonstrate significant induction of the co-transfected plasmids by 
dexamethasone, phenobabital and rifampicin, the classical inducers of CYP3A4 in 
vivo (similar to the results illustrated in Figure 4.16).
As shown in Figure 4.16 there is only base line production of alkaline phosphatase 
for all vectors except pCMV-cSPAP which contains a potent cytomegalovirus 
promoter. None of the vectors was activated by known inducers of CYP3A4. 
Apparently the pCMV-cSPAP vector is capable of expression of alkaline phosphatase 
in high levels even at low transfection efficiency or in the presence of cytotoxicity 
due to high calcium concentration.
In view of the poor results using calcium phosphate as transfection reagent, it was 
decided to examine the FuGENE 6 transfection reagent (Roche Molecular 
Biochemicals) used by Goodwin et al (1999) in the HepG2 cell line and shown by 
them to produce high transfection efficiencies.
4.4.2 Characterisation of the FuGENE 6 transfection method
Experiments with FuGENE 6 were performed initially to examine the activation of 
the CYP3A4 promoter constructs without co-transfection with hPXR expression 
vector pSG5-hPXR. As Figure 4.17 shows no activation of constmcted reporter
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vectors was observed in comparison to the negative control plasmid pSEAPI-Basic 
(SEAP). The relative light units (RLU) produced are actually related to base line 
endogenous alkaline phosphatase activity which is not inactivated by heat treatment.
Subsequently the effects of co-transfection with pSG5-hPXR were examined. 
Dramatic activation of pXP-SEAP2 constructs (wild type and M-42) was observed in 
the presence of hPXR. As shown in Figure 4.18 both wild type and M-42 plasmids 
were able to express high levels of alkaline phosphatase. Small standard error values 
obtained clearly show that the cells in multiple wells were transfected almost equally. 
This obviated the need for further transfection efficiency evaluation or optimisation. 
Transfection of HepG2 cells in this experiment was performed 24 hours after seeding 
them into a 96 well plate. Although significant induction of both wild type and M-42 
promoters was took place by 10 |iiM rifampicin no obvious difference was observed 
between DMSO and 10 |iM dexamethasone (CYP3A4 inducers were applied 5 hours 
after transfection as described in section 2.4.4.2). This was thought to be due to the 
relatively short time from seeding until transfection of the cells (described below).
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Figure 4.16 Transfection of HepG2 cells using the calcium phosphate 
precipitation method.
□ DMSO 0.1% ;0 dexamethasone (10 pM) ; □  phénobarbital (ImM); □rifampicin 
(lOpM). Data are shown as mean ±SEM, n=6 and were taken from day 5 of alkaline 
phosphatase measurement (gain level 12) (section 2.4.4.1).
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Figure 4.17 Transfection of HepG2 cells with different pXP-SEAP2 plasmids 
using FuGENE 6 reagent.
Effects of different CYP3A4 inducers in the absence of co-transfected hPXR. 
□  DMSO 0.1%; ■  dexamethasone (10 pM); □  Phénobarbital (1 mM); □  rifampicin 
(10 pM). Data represent the mean+SEM, n=6 (gain level 32).
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Figure 4.18 Transfection of HepG2 cells performed using FuGENE 6 reagent.
Effects of CYP3A4 inducers in the presence of eo-transfected hPXR.D DMSO 0.1%; 
El dexamethasone (10 pM); □  rifampicin(10 pM). Data represent the mean+SEM, 
n=6 (gain level 1).
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In view of the high transfection efficiency using FuGENE 6 reagent, it was decided to 
perform further control experiments to ensure that any variation in alkaline 
phosphatase detection related only to differences between the mutant promoters, 
recipient cells, or xenobiotic inducers.
4.4.3 Lumicount™ {Packard) plate reader function
To be certain that the location of the columns in the Optiplate (when relative light 
units were being measured) did not affect the supposed biological responses, the 
Lumicount™ (P a c k a rd )  plate reader was checked using HepG2 cells co-transfected 
with wild type pXP-SEAP2 (M-01) and the pSG5-hPXR plasmid, to define any 
possible instrument-related chemiluminescence reading errors. The contents of a 
column of 6 wells, from a 96 well plate containing HepG2 cells transfected with wild 
type pXP-SEAP2 plasmid and treated with 10 pM rifampicin, were re-distributed 
(illustrated below) into 9 replicate columns in an Optiplate polystyrene microplates 
(P a c k a r d  U K). Alkaline phophatase activity was then measured using the 
chemiluminescence procedure (section 2.4.6).
1 2  3 4 5 6 7  8 9e Contents of one column ofe 6 transfected wells
re-distributed into 9 columns
A of the Optiplate in 10 piw••
aliqouts
Figure 4.19 shows the results of this experiment. Statistical analysis of data, with 
single factor ANOVA, confirmed there was no significant difference between 
measurements. It can be seen that a very small variance ratio (F) corresponding to a 
P  value of 0.999 in fact indicates negligible variation. Therefore the Lum icount'' 
(P a c k a rd )  plate reader was not subject to instrument or 96-well pi ate-derived 
variation of measurement.
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Figure 4.19 Lumicount™ (Packard) 96-well plate reader; examination for 
possible instrumental varation.
Data are shown as mean+SEM (gain level 1), where each column (1-9) is a replicate 
of 6 wells derived from one experiment. Single factor ANOVA analysis of the data is 
shown below (a= 0.05).
ANOVA
Source of Variation SS df MS F P-value F crit
Between Groups 4.24x10^ 8 5.30x10® 0.052 0.999 2.15
Within Groups 4.53x10® 45 1.00x10®
Total 4.57x10® 53
SS: sum of squares, df: degree of freedom, MS: mean sum of squares 
F :  variance ratio= MS (between groups)/ MS (within goups)
F  critical: indicates the variance ratio where the differences are significant
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4.4.4 Time from seeding the cells until transfection
It has been shown that primary human adult hepatoeytes at low cell density are 
relatively insensitive to typical CYP3A4 inducers such as rifampicin (Greuet et al,
1997). Based on this finding, the effects of the time after seeding of the HepG2 cells 
on the expression of transfected plasmids were examined. The rationale was that 
during the initial period of rapid cell division the cells would be less differentiated 
and thus less able to express transgenes containing liver-specific promoters (perhaps 
due to low levels of endogenous transcription factors). The inducer used in this 
experiment was dexamethasone since it was found in the previous experiments to be 
the weakest inducer of SEAP expression from the transgenes. Also the mechanism of 
action of dexamethasone is thought to be mediated by a complex interaction of 
endogenous transcription factors (Pascussi et al, 2001) and might thus be a better test 
for differentiation state.
As shown in Figure 4.20 it was found that the expression of transfected pXP-SEAP2 
plasmids was considerably increased when transfection was performed 48 hours after 
seeding of the HepG2 cells into 96 well plate instead of as previously at 24 hours. 
This finding indicates the importance of the rate of cell growth and extent of 
confluency in transfection experiments (Hoen et al, 2000). Figure 4.20 also shows 
that all the mutant promoters were more responsive to 10 |iM dexamethasone than the 
wild type promoter (P<0.05 for M-42 and F-14; P<0.01 for M-18 and F-27).
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Figure 4.20 The effect of the time after seeding of HepG2 cells on expression of 
transfected plasmids.
Cells were eo-transfected with pXP-SEAP2 and hPXR using FuGENE 6. Data 
represent as mean +SEM, n=6 (gain level 1). □  DMSO 0.1%; ■  dexamethasone (10 
pM).
A. Cells transfected 24 hours after seeding
B. Cells transfected 48 hours after seeding
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4.4.5 Concentration of CYP3A4 inducers
Although detailed dose-response measurements were beyond the main scope of this 
project some experiments were performed to cheek pXP-SEAP2 reporter construct 
activity and confirm the effective range of drug concentrations.
As shown in Figure 4.21 using the M-42 promoter as an example, significant 
induction of the mutant and wild type promoters commenced at 5 pM rifampiein and 
mifepristone, and a maximum effect was achieved at 40 pM. However, mifepristone 
produced a dose response curve in the HepG2 cells demonstrating almost equal 
aetivation of both promoters at 40 pM. For this strong hPXR ligand (Lehmann et al, 
1998) at high doses its ability to maximally activate hPXR may result in swamping of 
the CYP3A4 promoters and loss of distinction between mutant and wild type 
promoters. Statistical analysis (t-test) was performed to evaluate the signifieanee of 
the different pattern of activation between wild type and M-42 mutant promoters. It 
can be seen that M-42 reporter construet is significantly more active than wild type in 
both cell lines. It was also clearly demonstrated that at 10 pM rifampicin could 
distinguish wild type and mutant promoter activities. This is the same concentration 
as used by Goodwin et al (1999).
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Figure 4.21 Dose response curves for rifampicin and mifepristone as inducers of 
pXP-SEAP2 expression follovying co-transfection with hPXR into HepG2 or 
Caco-2 cells.
Statistical analysis was performed using a t-test. Data represent the mean±SEM, n=6  
(gain level 1). (* P<0.05; ** P<0.01; *** P<0.001)
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4.5 In vitro responses of mutant CYP3A4 promoters to xenobiotic 
inducers
Transfection experiments were performed in HepG2, HuH7 and Caco-2 cell lines 
using previously defined optimal conditions. As indicated in sections 4.4.4 and 4.4.5 
a concentration of 10 |iM for rifampicin, mifepristone and dexamethasone would give 
significant distinction between wild type and mutant promoters. For clotrimazole and 
phénobarbital the concentrations used by Goodwin et al (1999), 10 pM and 1 mM 
respectively, were used.
4.5.1 Activation of pXP-SEAP2 reporter gene constructs in HepG2 cells
HepG2 liver hepatoma cells have been extensively used in cytochrome P450 
expression and induction experiments due to their close similarity to normal liver 
cells (Goodwin et at, 1999; Pascussi et al, 1999; El-Sankary et al, 2001; Pascussi 
et al, 2001). The cells are easily passaged and retain their growth characteristics for 
about 20 passages from ECACC stock.
As shown in Figure 4.22 the activation profile of pXP-SEAP2 reporter constructs 
containing the CYP3A4 wild type and mutant promoters in HepG2 cells were 
compared. Statistical analysis of the data is shown in Table 4.1. It can be seen that 
except for F-14 (only more active than the wild type in response to dexamethasone, 
p<0.05) the mutant promoters are all more active with CYP3A4 inducers than the 
wild type promoter with F-27 the strongest. However M-18 was the only reporter 
construct that showed significantly increased activation with all the drugs tested 
(Table 4.1). Although the M-42 reporter construct also contained the A ^ G  transition 
(the same as in F-27) it demonstrates less induction than F-27 and indeed with 
phénobarbital, a response that was not significantly different from the wild type 
(p>0.05).
173
50000
(/)
r 40000
Z)
o ) 30000
(D
"fri 20000
~ô
OC
10000
WT M-42 M-18 F-27 F-14
Figure 4.22 Induction profile of reporter construct containing the CYP3A4 wild 
type and mutant promoters in the HepG2 cell line.
Cells were co-transfected with pSG5-hPXR plasmid. Data represent the mean+SEM 
(gain level 1). DMSO and rifampicin, n=24 (four experiments); dexamethasone, 
phénobarbital, clotrimazole and mifepristone n=12 (two experiments); rifampicin 
without hPXR, n=6 (one experiment). □  DMSO; B1 dexamethasone (10 pM);
□  phénobarbital (1 mM); □  clotrimazole (10 pM); ■  mifepristone (10 pM);
□  rifampicin (10 pM); B rifampicin (10 pM) without hPXR.
Table 4.1 Statistical analysis (t-test) of the data in Figure 4.22 represented as 
relative inductions compared to the CYP3A4 wild type promoter.
Drug 
Promo te r ^ ^
DEX PB CLTZ MIF RIF
M-42 136** 1.04 E23* 132* 132*
M-18
CYP3A4^1F
1.62 *** E23* 127** 189*** 137***
E-27 E47*** E20* 1.16 2.15 *** 139***
F-14 E22* 0.95 1.00 1.12 1.10
* P<0.05, ** P<0.01, *** P<0.001. p values relate to the wild type promoter.
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4.5.2 Activation of pXP-SEAP2 reporter gene constructs in HuH7 cells
The HuH7 cell line (Pascussi et al, 1999) was chosen as a second hepatoma cell line 
having similar characteristics to HepG2 cells (in handking requirements and growth 
rate) to examine the activation profile of the reporter constructs. Observation could 
be made regarding the effects of cell environment and availability of different 
transcription factors.
There is no extensive information published regarding the HuH7 cell line and 
expression of cytochrome P450 enzymes except a report by Pascussi et al (1999) 
indicating the expression of CYP3A7 by typical PXR activators rifampicin, 
clotrimazole and mifepristone. Also the cell line is not available commercially. 
However, study of CYP3A4 wild type and mutant promoters- dependant reporter gene 
construct expression in another hepatoma cell line was felt to be important.
The activation pattern of pXP-SEAP2 reporter constructs containing the CYP3A4 
wild type and mutant promoters was different in the HuH7 cell line compared to 
HepG2 cells. As shown in Figure 4.23 and also the statistical analysis in Table 4.2, it 
can be seen that although M-18 and F-27 were the most active promoters (as in 
HepG2 cells), all the mutant promoters showed significantly increased activity in 
comparison to the wild type (P<0.001 in most of the cases). Another difference was 
that with all the reporter constructs phénobarbital produced a greater effect than 
mifepristone or clotrimazole (p<0.05 and p<0.01 respectively). This could be 
explained by higher expression of the nuclear receptor CAR in HuH7 cells. 
However, as with HepG2 cells rifampicin was the most powerful inducer (p<0.01 in 
all cases). The different drug induction patterns in the different hepatoma cell lines 
again indicates that drug metabolism and interaction studies using liver cancer cells 
may not be a good reflection of the events in normal hepatoeytes in vivo (Hamilton 
et al, 2001).
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Figure 4.23 Induction profile of reporter construct containing the CYP3A4 wild 
type and mutant promoters in the HuH7 cell line.
Cells were co-transfected with pSG5-hPXR plasmid. Data represent the mean±SEM 
(gain level 1). DMSO and rifampicin, n=24 (four experiments); phénobarbital, 
clotrimazole and mifepristone n=l 2 (two experiments). □  DMSO; □  phénobarbital 
(1 mM); □  clotrimazole (10 pM); ■  mifepristone (10 pM); □  rifampicin (10 pM).
Table 4.2 Statistical analysis (t-test) of the data related in 4.23 represented as 
relative induction compared to the CYP3A4 wild type promoter.
Drug
P rom oter\^
PB CLTZ MIF RIF
M-42 1.18 0 3 6 * 1.60 *** 172***
M-18
CyP3A4*7F
170*** 0.66 ** 2.22 *** 1.97***
F-27
CyP3A4*7R
E75*** 2 21 *** 2.47 *** 1.96 ***
F-14
CyP3A4*7F
E26* 0.75 ** 158*** 1.70 ***
* P<0.05, ** P<0.01, *** P<0.001. p values relate to the wild type promoter.
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4.5.3 Activation of pXP-SEAP2 reporter gene constructs in Caco-2 cell line
Since CYP3A enzymes are extensively expressed in gastrointestinal tract tissue 
(Schmiedlin-Ren et al, 1997 and references therein) it was decide to perform similar 
experiments to those in hepatic cell lines using a colon-derived cell line. The colon 
adenocarcinoma cell line Caco-2 has been used extensively to examine both intestinal 
drug uptake and xenobiotic metabolism. Under certain conditions it has been shown 
to express some members of CYP3A enzymes (Schmiedlin-Ren et al, 1997; Hara 
et al, 2002; Tran et al, 2002). Its use in here was designed to examine the possibility 
of tissue specific variation in transcription factor availability and induction profile.
Figure 4.24 shows the results obtained from the experiments using Caco-2 cell. As it 
can be seen the M-42 construct is the only promoter that shows substantially 
increased activation for all of the inducers compared to the wild type (p>0.01) (Table 
4.3). Also of note was that in Caco-2 cells phénobarbital produced higher activation 
of some promoters (M-42 p>0.01 and M-18 >0.05) than rifampicin. This again 
indicates the important role of endogenous factors in manifesting drug effects in this 
in vitro system.
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Figure 4.24 Induction profile of reporter constructs containing the CYP3A4 wild 
type and mutant promoters in Caco-2 cell line.
Cells were co-transfected with pSG5-hPXR plasmid. Data represent the mean+SEM 
(gain level 1). DMSO and rifampicin, n=24 (four experiments); phénobarbital, 
clotrimazole and mifepristone n=12 (two experiments). □  DMSO; □  phénobarbital; 
□  clotrimazole(10 pM); ■  mifepristone(10 pM); □  rifampicin(10 pM).
Table 4.3 Statistical analysis (t-test) of the data in Figure 4.24 represented as 
relative induction compared to the CYP3A4 wild type promoter.
Drug
Prom oter^^
PB CLTZ MIF RIF
M-42 1.87 ** 2.78 *** 1.78 ** 1.64 **
M-18 1.14 1.08 1.06 1.00
F-27
CyP3A4+7B
1.04 1.45* 1.19 1.06
F-14
CyPjA4+7F
1.18 1.13 1.28 * 1.34*
* P<0.05, ** P<0.01, *** P<0.001. p values relate to the wild type promoter.
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4.6 Discussion
A carefully designed and constructed reporter gene system can be a very valuable 
tool in functional analysis of mutant regulatory regions in vitro. Cloning of the 
CYP3A4 XREM region into the pSEAP2-Basie vector was performed first. Due to 
the commercial availability of high quality cloning reagents and kits this step of the 
work was performed without difficulty. Amplification of the PCR product from this 
region with different restriction digest sites at each end provided the possibility of 
insertion of the XREM in the correct orientation in the pX-SEAP2 vector. 
This vector was authenticated by several electrophoresis and restriction digest 
examinations as well as final sequencing of the insert using the pXP-SEAP2 plasmid 
DNA as template (Figures 4.1 to 4.5).
A similar approach was applied to construct the five different pXP-SEAP2 reporter 
genes containing the CYP3A4 wild type and four mutant proximal promoter regions. 
The only problem encountered was the heterozygous nature of the mutations. In 
cloning experiments a 1:1 mixture of pXP-SEAP2 plasmids containing wild type and 
mutant promoters was produced as expected. Sequencing of the PCR products of the 
promoter region, using the cloned plasmid DNAs as template, was the only way of 
identifying these plasmids containing mutant promoters. However, using several 
authentication procedures (Figures 4.6 to 4.12), all five pXP-SFAP2 vectors were 
demonstrated to contain the required CYP3A4 proximal promoter.
The maxiprep pXP-SEAP2 plasmids DNAs were used directly in transfection 
experiments. The initial transfection experiments using the calcium phosphate 
precipitation method failed to demonstrate any activation of the reporter constructs in 
HepG2 cell line. Later co-transfection attempts with pSG5-hPXR also failed. Based 
on these findings and other unsuccessful transfection results reported in our lab 
(Vahdati-Mashhadian PhD thesis, 2001) it was decided to use an alternative 
transfection reagent. It seemed that relatively high levels of calcium ions produced 
during DNA-calcium precipitation caused cellular toxicity and hence interfered with 
proper reporter gene expression. Apparently this kind of toxicity is more obvious in 
the case of the reporter genes that contained an endogenous promoter rather than 
virus derived strong promoters such as pCMV-cSPAP. This plasmid expressed
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moderate levels alkaline phosphatase in transfections using calcium phosphate 
method (section 4.4.1).
Experiments using FuGENE 6 reagent produced satisfactory and reproducible results 
when the pXP-SEAP2 reporter constructs were co-transfeeted with pSG5-hPXR 
plasmid (section 4.4.2). These results were in agreement with Goodwin et al (1999) 
and once again indicated the crucial role of hPXR in CYP3A4 regulation. Functional 
analysis of the novel mutations in the CYP3A4 regulatory region as well as 
CYP3A4^1B allele (Rebbeck et al, 1998) in human liver (HepG2, HuH7) and a colon 
adenocarcinoma (Caco-2) cell lines became possible by use of this reagent.
Significant variation in promoter strength was found among the mutant CYP3A4 
alleles depending on the inducer used and the recipient cell line (section 4.5). Also 
different induction patterns were observed in different cell lines with different 
CYP3A4 inducers (most notably by phénobarbital and mifepristone). This indicates 
the role of endogenous transcription factors (such as CAR and PXR) and their 
concentration relative to each other.
Transfection of wild type and mutant containing reporter constructs in HepG2, HuH7 
and Caeo-2 cells, in general, produced similar pattern of induction by the same drugs. 
The only exception was phénobarbital which produced more induction with all 
CYP3A4 alleles in HuH7 and Caco-2 cells compared to HepG2 cells. However, the 
induction pattern of the CYP3A4 alleles was substantially different in Caeo-2 cells. 
Only the M-42 reporter construct showed a significantly different (increased) activity 
for all of the inducers examined in comparison to the wild type promoter in this cell 
line. This may suggest the possibility of binding of a specific transcription factor to 
the nine-nucleotide insertion site in the M-42 promoter in these cells. Further studies 
are required to evaluate this assumption.
The most notable finding in the transfection experiments was the high promoter 
activity in hepatic cell lines of the F-27 reporter construet (containing the 
CYP3A4'^1B allele). This allele which is common in the African-American 
population, has been the subject of several investigations and a connection with some 
abnormalities such as prostate cancer has been proposed (Rebbeck et al, 1998; Ball
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et al, 1999; Westlind et al, 1999). Most of these studies reported no difference in 
promoter activity of CYP3A4*1B in comparison to the wild type allele as judged by 
measurement of hepatic microsomal CYP3A4 levels in biopsy samples and gel shift 
analysis (Westlind et al, 1999) or the erythromycin breath test (Ball et al, 1999). 
However, none of these reports used an in vitro reporter gene analysis approach. It 
seems that direct in vivo analysis of steroid and drug metabolism in populations that 
express this allele homozygously could clarify the situation.
In summary, I have shown that polymorphisms in the human CYP3A4 gene 
regulatory region can significantly affect transcriptional responses to xenobiotic 
inducers in vitro. However, due to their heterozygous nature, these mutations may 
have only a limited overall effect on hepatic CYP3A4 expression in vivo.
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CHAPTER FIVE 
FINAL DISCUSSION AND CONCLUSIONS
5.1 Introduction
Understanding the genetie basis of inter-individual variability in drug disposition and 
response is a fundamental foeus for pharmaeogenetic research, and for rational 
and individualised drug treatment. Pharmacogenetics is the study of the linkage 
between an individual’s genotype and that individual’s ability to metabolise a 
foreign compound. Pharmaeogenetic studies are often related to the genotyping of 
polymorphic alleles that encoding drug-metaboHsing enzymes in order to identify an 
individual’s drug metabolism phenotype. Genetic polymorphism has been linked to 
three classes of phenotypes based on the extent of drug metabolism. Extensive 
metabolism (EM) of a drug is characteristic of the normal population; poor 
metabolism (PM) is associated with accumulation of specific drug and is typically an 
autosomal recessive trait due to mutation and (or) deletion of both alleles for 
phenotypic expression; and ultra extensive metabolism (UEM) results in increased 
drug metabolism and is an autosomal dominant trait often arising from gene 
amplification (Linder et al, 1997).
CYP3A4 is usually the most abundant GYP isoform in the adult human liver, displays 
large inter-individual variability in its expression and hence, has considerable 
relevance for personalised medicine, carcinogenesis risk associated with exposure to 
procarcinogens and other xenobiotics. It also plays the main role in metabolic fate of 
endogenous steroids (Ozdemir et al, 2000). CYP3A4 is considered the most 
important and is the most extensively studied member of the CYP3A subfamily. 
CYP3A4 activities in liver biopsies vary up to 40-fold in the population (Daly et al, 
1993; Shimada et al, 1994; Westlind et al, 1999). However, the variability measured 
in vivo is usually much smaller (five fold) (Thummel and Wilkinson, 1998). This 
variation is generally assumed to contribute to harmful drug interactions frequently 
encountered in development and application of drugs that are CYP3A4 substrates. In 
addition to modulation of bioavailability of drugs, the inter-individual variation in 
CYP3A4 activity may contribute to the individual predisposition to several common
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cancers caused by environmental carcinogens. For example, CYP3A4 metabolises 
aflatoxin Bi (Wang et al, 1998), a mycotoxin strongly implicated in the aetiology of 
liver cancer, which is a major cause of premature death in many areas of Africa and 
Asia (Henry et al, 1999). It has also been proposed that high levels of CYP3A in 
humans could predispose an individual to cancer risk from bio-aetivated tobacco- 
smoke proearcinogens (Paolini et al, 1999). Taken together, the elucidation of factors 
controlling a patient’s CYP3A4 expression level could permit individual dose 
adjustments in therapies with its substrates and also lead to the identification of sub­
populations at increase risk for several common cancers.
It has been proposed that much of the variability in CYP3A4 activity can be attributed 
to genetic factors (Ozdemir et al, 2000) but, until recently (Rebbeck et al, 1998; Sata 
et al, 2000; Hsieh et al, 2001; Eiselt et al, 2001; Dai et al, 2001; Lamba et al, in press) 
no reports of screens for CYP3A4 variants were available. However, the protein 
variants described so far may contribute to, but obviously do not fully explain, the 
variability of CYP3A4 expression. Therefore, it could be postulated that functionally 
relevant genetic variance may be located in the regulatory rather than in coding region 
of the CYP3A4 gene. In this project a new population screening for CYP3A4 
regulatory region polymorphism has been performed and novel alleles with relatively 
increased enzyme activity are introduced.
5.2 Mutation detection: a non-radioactive (Cold) SSCP approach
In order to analyse a relatively large number of PCR samples (more than 400) with a 
cost effective and efficient mutation detection method several approaches were 
considered. For example, direct sequencing of the PCR products was considered as 
the easiest and the most accurate mutation detection method. However, the high cost 
of the of primary sequencing of the samples and further confirmation sequencing 
reactions as well as unavailability of a robust in house DNA sequencing 
instrumentation made it almost non practical. Single-strand conformation 
polymorphism (SSCP) facilitates rapid identification of genetie polymorphisms within 
segments of DNA up to 300 bp. This method has many advantages compared to other 
mutation detection methods such as simplicity and inexpensiveness (Hayashi et al,
1998). Use of a non-radioaetive SSCP method for analysis of known mutations of
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p53 coding region PCR products from human gastric carcinoma had already been 
reported and compared to conventional SSCP (in which radio-labelled PCR primers 
or nucleotides are used to generate radioactive PCR products) (Hongyo et al, 1993). 
In this report a mutation detection efficiency of 100% using ‘cold’ SSCP, compared to 
57-94% (in different exons) for radioactive SSCP, was achieved. It was also 
mentioned that the use of methylmereury hydroxide as a strong dénaturant (to produce 
and maintain high amounts of single strand DNA) was necessary to the success of this 
method. Considering all options it was decided to use a similar approach for mutation 
detection in this project.
During initial cold SSCP trials I could not acquire methylmereury hydroxide from any 
known commercial company. However, as described in section 2.2.4.1 using a 
mixture of different dénaturants it was possible to produce sufficient amounts of 
single-strand DNA required to be easily visualised using SYBR® Gold stain. Cold 
SSCP analysis of PCR products from the CYP3A4 proximal 5' regulatory region 
(amplified as three overlapping segments) revealed several samples with altered 
electrophoretic patterns (described in detail in section 3.4). The presence of proximal 
5' regulatory region mutations was confirmed by sequencing of both DNA strands in 
the original and freshly amplified PCR products. In all samples where novel CYP3A4 
regulatory region mutations were found, direct sequencing of PCR products from all 
13 exons was performed to identify any linked coding region mutations. Some PCR 
samples with wild type SSCP pattern were also selected randomly and sequenced to 
be assured that no mutation remains undetected. No mutation was detected in these 
sequencings.
Briefly, in addition to detection of the previously reported CYP3A4'^1B allele in nine 
subjects, three novel alleles were found: CYP3A4*1E (having a T ^ A  transversion at 
-369 in one subject), CYP3A4^1F (having a C ^ G  transversion at -747 in 17 
subjects) and CYP3A4'^15B having a nine-nueleotide insertion between -845 and 
-844 linked to an A—>G transition at -392 and a G—>A transition in exon 6 (position 
485 in the cDNA) in one subject (M-42). Linkage of the three mutations in subject 
M42 was confirmed using cloning and long-range allele-speeifie PCR to separate the 
alleles. No variant electrophoretic SSCP patterns were found in PCR products from
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the distal enhancer (XREM) region indicating extensive conservation of sequence in 
this essential regulatory region. Out of three novel CYP3A4 alleles identified in this 
project, each of the two alleles {CYP3A4^1E and CYP3A4^15B) was only found in 
one Caucasian subject and can be categorised as rare alleles. However, CYP3A4^1F 
was found in both Iranian and European populations with a high frequencies, i.e. 18 
and 20% respectively.
The strategy designed to screen for novel mutations in the CYP3A4 5' regulatory 
region worked very well and is easily applicable to further large-scale population 
screening studies. Indeed the relatively high number (28 in total) of the mutations 
found clearly demonstrated the robustness and reliability of the cold SSCP protocol 
that was developed and used in this project. The only modification which seems to be 
necessary for large-scale applications is to provide suitable conditions to reduce the 
electrophoresis time by applying higher voltages. This could be achieved by using a 
thermostatically controlled refrigerated circulator to maintain a constant preset 
temperature of the buffer during electrophoresis in order to prevent melting of the gel 
due to high voltages.
5.3 Effects of the CYP3A4 gene variation on enzyme activity
Since 1998 considerable effort has been made to elucidate the genetic basis of the 
inter-individual variability of hepatic CYP3A4 activity but the results obtained so far 
suggest a limited genetic contribution. Most of CYP3A4 alleles are either rare or 
specific to a given population. Indeed, Chinese and Europeans share only one out of 
eight protein variants (CFP3A4*3) found in these ethnic groups (Sata et al, 2000; 
Eiselt et al, 2001). Likewise, the CYP3A4'^2 allele has only been identified in the 
Finnish population which is in agreement with their distinct genetie heritage. The 
population-specific character of CYP3A4 protein variation is likely to affect further 
efforts to identify alleles underlying the variable activity of the gene. However, the 
utilisation of ethnically matched sample sets will improve the odds of finding a 
correlation with a clinical or biochemical phenotype (Eiselt et al, 2001).
As described in sections 4.4 and 4.5, functional analysis of the regulatory region 
mutants was performed in vitro using reporter gene constructs in which the whole
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1141 bp proximal promoter region from each mutant allele was inserted between a 
single copy of the 300 bp core distal enhancer sequence and the cDNA for human 
secreted alkaline phosphatase (SEAP). The individual reporter constructs were eo- 
transfected with an hPXR expression vector into human liver (HepG2, HuH7) and 
intestinal (Caeo-2) cancer cell lines. Xenobiotic modulation of CYP3A4 promoter 
activity was measured by chemiluminescent SEAP assay.
Novel mutations in CYP3A4 proximal promoter discovered in this project were not 
located in/or near any of the known transcriptional regulatory elements. Only the 
mutation in the CYP3A4"^1E allele (-369 T-^A transversion) is located near a 
regulatory element, the CAAT box (Figure 5.1). Therefore it might have been 
predicted that the novel alleles might not show altered promoter activity compared to 
the wild type allele. However, significant increased promoter activity of the reporter 
constructs containing the novel alleles CYP3A4"^1F and CYP3A4^15B as well as the 
previously described CYP3A4^1B allele (Rebbeck et al, 1998) was observed in human 
hepatoma cell lines (HepG2 and HuH7) when different CYP3A4 inducers were 
applied. In Caco-2 (colon carcinoma) cells only the CYP3A4^15B allele showed 
significantly increased activity. The promoter activity of the CFP3A4 *7 £  allele was 
not significantly different from the wild type allele in HepG2 and Caeo-2eell lines. In 
HuH7 cell line, however, it showed increased activity. Another notable feature was 
the different induction effects produced by drugs when the three cell lines were 
compared. While there was some similarity between the xenobiotic induction patterns 
for wild type and mutant promoters in HepG2 and HuH7 cells the pattern in Caeo-2 
cells was substantially different (section 4.6).
To further identify possible transcriptional binding sites related to the various 
mutations, the proximal wild type and mutant promoter sequences were analysed 
for putative transcriptional factor binding using the most up-to-date versions 
of the AliBaba 2.1 and Matlnspector online promoter analysing programmes 
(http:// www.imm.ki.se/CYPalleles/eyp3a4.htm and http://genomatix.gsf.de/mat_fam 
respectively). Similar overall pictures emerged from both programs. The AliBaba 
analysis for the CYP3A4 wild type proximal promoter, neighbouring the mutation 
sites, and the corresponding mutant sequences are presented in Figures 5.1 and 5.2.
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When the mutant promoters are compared to the wild type sequence, changes in 
putative transcription factor binding are only seen in the cases of the T—>A 
{CYP3A4^1E) and C— {CYP3A4^1F) mutations. As shown in Figure 5.2 (A) the 
T ^ A  transversion would result in NF-1 (nuclear factor 1) and Oct-1 (oetamer 1) 
binding preferentiality and position being changed. In the case of the C ^ G  
transversion a potential Sp-1 (specificity protein 1) binding site would be deleted. 
Whether these alterations actually lead to increased or decreased binding activities 
remains the subject of future detailed studies. Further analysis of these findings by 
carefully directed gel mobility shift assays and site-directed mutagenesis might clarify 
the situation.
It is also worth remembering that the findings in this project and indeed most of the 
published information regarding CYP3A genotype to phenotype come from in vitro 
and/or ex vivo experiments, and may not provide an accurate picture of the in vivo 
events. Large groups of subjects and/or patients will need to be examined using 
kinetic data to determine whether the mutant alleles discovered here, or possibly other 
genetie variations, affect phenotypic enzyme activity. Initial reports from trials of this 
type have not established a link between the CYP3A4^1B mutation and CYP3A 
activity in vivo (Ball et al, 1999). For this reason studies that pre-select individuals 
with unusually high or low CYP3A-mediated drug metabolising activity may be 
particularly important in determining whether genetie variation underlies the in vivo 
phenotypes exhibiting clinically significant variation in hepatic drug metabolism.
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(A) - 3 9 2  - 3 6 9
GGACAGCCATAGAGACAAGGGCAAGAGAGAGGCGATTTAATAGATTTTATGCCAATGGCT 
NFSE CAAT box
= = = = S p l  = =^ = = = = = S p l  = = = = = = N F- 1  = = =
= = = O c t - l = = =
(B) - 7 4 7
TTTCTAGTTGCCCACTGTGTGTACAGCACCCTGGTAGGGACCAGAGCCATGACAGGGAAT
=: = = = S p l  = = = = = = N F - 1  = = =
= = = = A P - 1==
(C) - 8 4 5
ACAGCAGCTGAGGCACAGCCAAGAGCTCTGGCTGTATTAATGACCTAAGAAGTCACCAGA 
= = = A P - 4 = = =  = = C / EB P g= = == =HNF- 1==
= = C /EBP g= = = = C/EB Pg= =
= = = A P - 1===
Figure 5.1 Analysis of CYP3A4 wild type proximal promoter for potential 
transcriptional factor binding sites using AliBaba 2.1 online program.
The sequences neighbouring the mutation sites are shown compared the mutant 
sequences in Figure 5.2, (A-C) Indicate the sites for wild type sequences of the 
corresponding mutation sites.
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(A) - 3 9 2  - 3 5 9
GGACAGCCATAGAGACAAGGGCAGGAGAGAGGCGATTTAATAGATTATATGCCAATGGCT 
NFSE CAATbox
= = = = S p l = = =  = = = = S p l = = =  = = = O c t - l = = =
= = =NF- 1  = = =
(B) - 7 4 7
TTTCTAGTTGCCCACTGTGTGTACAGCACGCTGGTAGGGACCAGAGCCATGACAGGGAAT
= = = N F - 1 = = =
= = = = A P - 1 = =
(C) - 8 5 4
ACAGCAGCTGAGGCACAGCCAAGAGCTCTGGCTGTATTAATGACCTAAGAAGATGGAGTGATCACCAGA 
= =z= A P - 4  = = = = = C/ E B P g = =  = = =HNF-1 = =
= = C/ E B P g = =  == C /E BP g ==
= = = A P - 1 = = =
Figure 5.2 Analysis of CYP3A4 mutant proximal promoters for potential 
transcriptional factor binding sites.
(A) Indicates the sites for -369 A ^ T  transversion and -392 A ^ G  transition.
(B) Indicates the site for -747 C ^ G  transversion. (C) Shows the site for nine 
nucleotide insertion (underlined) after -845 G.
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5.4 Transcriptional regulation of CYP3A4 gene expression: basal 
expression versus xenobiotic modulation
The role of PXR as a xenobiotic-responsive mediated transcriptional modulator of 
CYP3A4 gene expression has been established (Bertilsson et al, 1998; Blumberg et al, 
1998; Kliewer et al, 1998; Lehman et al, 1998). Moreover, in studies earned out in 
vitro, without co-transfection with hPXR expressing vectors, no induction of CYP3A4 
reporter constructs was observed (Goodwin et al, 1999). The same results were also 
observed during this project (section 4.4.2). However, it has been shown that the loss 
of the expression of PXR protein inereases the constitutive expression of the murine 
CYP3A proteins (Xie et al, 2000b). Therefore, a transcription factor(s) other than 
PXR is assumed to contribute to the constitutive expression of the CYP3A gene in 
mammals (Saito et al, 2001).
A general model (Figure 5.3) for the constitutive transcriptional regulation of the 
CYP3A7 and CYP3A4 genes in HepG2 cells has been proposed (Saito et al, 2001). 
Using gel mobility shift assays, site-directed mutagenesis and transfection of HepG2 
cells with reporter constructs in which 5' flanking regions of the CYP3A7 or the 
CYP3A4 gene were fused to the luciferase gene, they have identified the binding sites 
for transcription factors such as Spl/Sp3, USFl (upstream stimulatory factor 1), YYl 
(ying yang 1), NFl and/or HNF-3p in the proximal promoters between nucleotides 
-140 and -35 of the CYP3A7 and CYP3A4 genes (Figure 5.4). In this report a novel 
NF-KB-like enhancer has also proposed in ~ 2300 bp of the promoters. There is only 
one bp mismateh between the sequences of this element in both genes. However, 
binding of Spl/Sp3 to the CYP3A7 (but not CYP3A4) NF-tcB-like element could be 
documented. It is proposed that an unknown factor(s), so called complex D, also acts 
as a transcriptional activator of the CYP3A4 gene (Figure 5.3).
Other interesting result reported by these investigators is that the deletion of PXR- 
responsive elements (PXR-RE) of the two genes increased lueiferase activity by -1.5 
fold in HepG2 cells. Thus, it was assumed that PXR-RE may function as a negative 
regulatory element in constitutive transcription. Although a constitutive factor(s) that 
interacts with the PXR-RE remains to be identified, an orphan receptor COUP-TF
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Figure 5.3 Proposed model for constitutive transcriptional regulation of the 
CYP3A7 and CYP3A4 genes (Saito et al, 2001). Transcriptional factors D  and E  
have not yet b een  id en tified .
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TGTTTATGATACCTCATAGAATATGAACTCAAAGGAGGTCAGTGAGTGGTGTGTGTGTGA
ER6/PXR-RE
= = C / E B a = =  = = = O c t - l = =  =COUP-TF==
- 1 32
TTCTTTGCCAACTTCCAAGGTGGAGAAGCCTCTTCCAACTGCAGGCAGAGCACAGGTGGC 
=C/EBPg== YYl E box
- 7 2
CCTGCTACTGGCTGCAGCTCCAGCCCTGCCTCCTTCTCTAGCATATAAACAATCCAACAG
BTE '  '  TATA box
= = - N F - K= = = = = = = = = = S p l == ==== ====TBP===
■12 I t r a n s c r i p t i o n a l  s t a r t
CCTCACTGAATCACTGCTG
Figure 5.4 Proposed binding sites of Spl/Sp3 (BTE), USFl (E-box), YYl, 
N Fland/or HNF-3p in the CYP3A4 proximal promoter (Saito et al, 2001).
S o m e putative b in d in g  sites id en tified  by the A liB ab a  program m e are a lso  sh ow n .
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(chicken ovalbumin upstream promoter transeription factor) known to be a 
transcriptional repressor, is one of the candidates that constitutively bind to the PXR- 
RE (Figure 5.4). In fact, COUP-TF is reported to interact with the PXR-RE of the rat 
CYP3A genes, which contain the direct repeat of an AGGTCA motif separated by 
three nucleotides. Because COUP-TF is capable of recognising the divergent types of 
the AGGTCA repeat, it may also interact with the ER6-type motif seen in the human 
CYP3A genes (Saito et al, 2001 and references therein).
5.5. Genetic variation in the PXR gene
Variant CYP3A4 allelic frequencies and /or the available funetional data indicate a 
limited role of these variants in the inter-individual variability of CYP3A4 expression 
and activity (Rebbeck et al, 1998; Ball et al, 1999; Westlind et al, 1999; Sata et al, 
1999, Eiselt et al, 2001; Hsieh et al, 2001). The good correlation between hepatic 
CYP3A4 protein and mRNA expression suggests variation in CYP3A expression may 
be under transcriptional control. Because no SNPs in either the proximal or distal 
PXR cognate binding sequences in CYP3A4 5' flanking region were so far reported, it 
can be hypothesised that sequenee variations in PXR exist and could contribute to 
variation in expression of a target gene, CYP3A4 (Kuehl et al, 2001). Although 
hepatic CYP3A activity is the sum activity of the CYP3A4 and CYP3A5 gene products 
in most individuals, only CYP3A4 is significantly induced by PXR ligands. The 
CYP3A5 gene has a consensus proximal PXR-RE identieal to that in CYP3A4 but 
lacks the distal PXR-RE cluster found in CYP3A4. This may be why CYP3A5 is not 
significantly up regulated by PXR ligands (Zhang et al, 2001).
Two independent groups (Hustret et al, 2001; Zhang et al, 2001) have reported PXR 
protein variants (R122Q, V140M, D163G and A370T) with altered regulatory activity 
toward CYP3A4. However, in both studies no conclusive results have been obtained 
in relation to the CYP3A4 expression. For example, the variant protein R122Q had 
significantly decreased affinity for the PXR binding sequenee in electromobility shift 
assays and attenuated ligand activation of the CYP3A4 reporter plasmids in transient 
transfection assays. However, the individual heterozygous for this variant had a 
normal CYP3A4 metabolism phenotype. Therefore it has been suggested that further
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studies are needed to elucidate whether these PXR variants may represent reliable 
predictors of in vivo CYP3A metabolism.
5.6 Conclusions
In this project a population screening for novel mutations in CYP3A4 5' regulatory 
region produced interesting results. As described before, in addition to the 
CYP3A4^1B allele (discovered in 1998) three new CYP3A4 alleles designated 
CYP3A4'^1E, CYP3A4^1F and CYP3A4"^15B were identified. Although the 
CYP3A4^1E and CYP3A4*15B alleles could be considered as rare alleles, 
CYP3A4^1F has a high frequency in both Iranian and British populations, and 
homozygotes could be more common. Therefore, its impact on CYP3A4 regulation 
could be more important. In fact this is the first time that mutation detection 
experiments have been extended to -1100 bp of the proximal and also the distal 
XREM sections of CYP3A4 promoter. However, regarding reeent reports on the role 
of regulatory elements beyond these sections it seems that upstream sequences up to 
10 kb should also be considered in the study of regulatory elements and mechanisms.
Based on previous experiments and published literature I was able to design and 
construct an in vitro reporter gene system to evaluate the functional impact of these 
mutations. The evidenee presented in this report suggests that inherited mutations in 
the CYP3A4 gene 5' regulatory region can significantly affect in vitro transcriptional 
responses to different xenobiotic inducers. The relative increased activation of all 
mutant promoters by several CYP3A4 inducers which was observed in two hepatoma 
cell lines (except F-27 in HepG2) as well as increased aetivation of only one mutant 
(M-42) in Caco-2 cell, suggests that these effects could be as a result of possible 
occurrence of mutations at some yet unknown cell-specific repressor binding sites. 
Indeed, it has been recently reported that a single nueleotide polymorphism (-308 
A ^G ) in the promoter of the tumour necrosis factor a  gene inereased its transcription 
6 to 7 fold (Fernandes et al, 2002). Also, it has been shown (Saito et al, 2001) that 
basal expression in both CYP3A4 and CYP3A7 of genes is inhibited by sequence 
motifs present between -140 and -1000 bp, presumably due to binding of repressor 
proteins. Conversely, it is possible that a mutation in an activator protein binding site 
may increase the binding affinity for the activator and hence lead to higher levels of
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expression. Therefore, considering the different activation profiles of the mutant 
alleles in different cell types, it can be deduced that these responses are dependent on 
the cellular environment, the availability of the transcription factors governing the 
expression of a specific gene in a specific tissue and the presenee of endogenous or 
xenobiotic ligands and their coneentrations.
Finally, in spite of a great deal of effort to search for genetic factors governing 
the inter-individual variability in CYP3A enzyme expression during last four 
years and the identification of a long list of mutations in both coding and regulatory 
regions of the CYP3A4 gene (http://ww.imm.ki.se/CYPalleles/cyp3a4.htm), a genetic 
polymorphism with a conclusive and clear functional effect on CYP3A4 activity 
in vivo has yet to be identified. Very recent studies have also focused on the possible 
impaets of the polymorphisms in CYP3A5 and genes encoding the transeriptional 
faetors responsible for CYP3A regulation such as PXR. To date these studies have 
been inconclusive.
5.7 Future work
(1) Screening of additional populations should be done to determine the allele 
frequencies and search for homozygous subjects who can be analysed with 
in vivo probes of CYP3A activity.
(2) Electrophoretic mobility shift assays could be performed to elucidate any 
difference in protein binding properties of the mutant alleles compared to the wild 
type sequenee and the nature of the elements that interaet with them.
(3) It would be interesting to expand mutation deteetion experiments to the whole 10 
kb upstream region of the CYP3A4 gene.
(4) Use of primary cultures of human hepatocytes instead of cancer cell lines for 
transfection studies may also be useful in evaluating the impact of the CYP3A4 
novel alleles.
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(5) Further expansion of mutation analysis to other nuclear receptors which have a 
role in CYP3A4 regulation such as CAR, GR and other possible elements.
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APPENDIX I 
SOLUTIONS, MEDIA AND BUFFERS
Ammonium persulphate stock solution (10% w/v)
0 . 1  g ammonium persulphate 
1 ml distilled water 
Prepare fresh and mix well.
Ampicillin stock solution
1 0 0  mg/ml ampicillin in dissolved in distilled water.
The solution is filter sterilised.
Store at -20°C.
Use at 100 pg /ml in growth media for selection of ampicillin resistant bacteria.
Calcium chloride stock solution (2M) for transfection experiments
Dissolve 10.8 g of CaCU. 6 H2 O in 20 ml distilled water.
Sterilise by filtration; store in 1ml aliquots at -20°C.
EDTA stock solution (0.5 M)
186.1 g EDTA 
20 g NaOH pellets
Add 800 ml distilled water, adjust the pH to 8.0 
Make up to 1 L with distilled water.
Ethidium Bromide
Stock solution of 10 mg/ml in TAB buffer.
HBS (2x) (HEPES-buffered saline) for transfection experiments
1.6 g NaCl (280 mM)
0.074 g KCl (10 mM)
0.027 g Na2 HPO4 .2 H2 0  (1.5 mM)
0.2 g dextrose (12 mM)
1 g HEPES (50 mM)
pH to 7.05 with NaOH; make up to 100 ml with distilled water.
Sterilise by filtration; store in 5 ml aliquots at -20°C.
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LB medium
10 g trypton 
5 g yeast extraction 
10 g NaCl
Add distilled water to 1 L.
Sterilise by autoclaving.
LB agar
15 g agar/L of LB medium 
Sterilise by autoclaving.
Cool to 50°C before addition of ampicillin (if required).
Poor into petri dishes.
Phosphate buffered saline (PBS pH 7.5)
1 tablet (Dulbecco ‘A’ Oxoid) dissolved in 100 ml distilled water. 
Sterilised by autoclaving.
TAE electrophoresis buffer (lOx)
48.4 g Tris base 
40 ml 0.5 M EDTA pH 8.0
11.42 ml glacial acetic acid 
Add distilled water to 1 L
TBE electrophoresis buffer (lOx) for SSCP
108gTris.Cl
55 g boric acid
20 ml 1 M EDTA
Make up to 1 L by distilled water.
TE buffer (Tris-EDTA)
10 mM Tris.Cl, pH 7.5 
1 mM EDTA 
Sterilise by filtration.
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Abstract
Human CYP3A4 is the major cytochrome P450 isoenzyme in adult human liver and is known to metabolise many xenobiotic 
and endogenous compounds. There is substantial inter-individual variation in the hepatic levels o f CYP3A4. Although, 
polymorphic mutations have been reported in the 5' regulatory region o f the CYP3A4 gene, those that have been investigated 
so far do not appear to have any effect on gene expression. To determine whether other mutations exist in this region o f  
the gene, w e have performed a new population screen on a panel o f 101 human D N A  samples. A  1140 bp section o f the 5' 
proximal regulatory region o f the CYP3A4 gene, containing numerous regulatory motifs, was amplified from genomic DNA  
as three overlapping segments. The 300 bp distal enhancer region at —7.9 kb containing additional regulatory motifs was also 
amplified. Mutation analysis o f the resulting PCR products was carried out using non-radioactive single strand conformation 
polymorphism (SSCP) and confirmatory sequencing o f both DNA strands in those samples showing extra SSCP bands. In 
addition to detection o f the previously reported CYP3A4* IB  allele in nine subjects, three novel alleles were found; CYP3A4* IE  
(having a T A  transversion at —369 in one subject), CYP3A4*1F (having a C -»  G tranversion at —747 in 17 subjects) 
and CYP3A4* 15B containing a nine-nucleotide insertion between —845 and —844 linked to an A  ^  G transition at —392  
and a G ^  A  transition in exon 6 (position 485 in the cDNA) in one subject. A ll the novel alleles were heterozygous. No  
mutations were found in the upstream distal enhancer region. Our results clearly indicate that this rapid and simple SSCP 
approach can reveal mutant alleles in drug metabolising enzyme genes. Detection and determination o f  the frequency o f novel 
alleles in CYP3A4 w ill assist investigation o f the relationship between genotype, xenobiotic metabolism and toxicity in the 
CYP3A family o f isoenzymes. © 2002 Elsevier Science B.V. A ll rights reserved.
Keywords: Cytochrome p450; CYP3A; CYP3A4 gene; CYP3A4 mutations; Single strand conformation polymorphism
1. Introduction
CYP3A isoenzymes are the most abundantly 
expressed cytochrome P450s in human liver, account­
ing for up to 60% of the total hepatic cytochrome 
P450 activity in some individuals [1]. However, the 
expression and activity of the CYP3A isoenzymes
* Corresponding author. Tel.: +44-1483-876456; 
fax: +44-1483-300374.
E-mail address: p.goldfarb@surrey.ac.uk (P.S. Goldfarb).
show wide inter-individual variation, influencing both 
drug responses and disease susceptibility [2]. Four 
human CYP3A genes have been identified, CYP3A4, 
CYP3A5, CYP3A7[2>] and most recently CYP3A43 [4].
CYP3A4 is the major cytochrome P450 isoenzyme 
in adult human liver and is known to metabolise a large 
variety of xenobiotic and endogenous substrates [5]. 
Inter-individual variation in hepatic CYP3A4 levels of 
up to 40-fold (based on the metabolism of specific sub­
strates such as triazolam, midazolam or cyclosporine) 
has been observed [6]. The basis of this variation is
0027-5107/02/$ -  see front matter © 2002 Elsevier Science B.V. All rights reserved. 
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not yet understood but may be due to genetic, environ­
mental, pathological, hormonal or dietary factors [7].
The CYP3A4 gene and its 5' flanking region has 
been isolated and sequenced [8]. The gene is approx­
imately 27 kb long with a coding region composed 
of 13 exons located on chromosome 7q22.1 [8,9]. 
Although there had been no indication o f genetic poly­
morphism in the CYP3A4 gene until 1997 [10-12], 
investigations since then have reported inherited vari­
ation in both the promoter [13,14] and coding region 
of the gene [15-18]. However, the impact o f these 
mutations on mRNA expression or enzyme activity 
has not been extensively investigated. Also the pro­
posed relationship between the CYP3A4* IB allele 
(—392 A -A- G) and an increased incidence of prostate 
cancer was not confirmed in later studies [19,20]. 
However, Sata et al. [15] showed that the CYP3A4*2 
allele (Ser222Pro) produces a lower in vivo intrinsic 
clearance of nifedipine, but no significant difference 
from the wild-type enzyme activity for testosterone 
6-3-hydroxylation. In addition Hsieh et al. [16] have 
recently reported three further mutations in the coding 
region of the CYP3A4 gene and related them to a dec­
reased urinary 6-^-hydroxycortisol/cortisol ratio in 
heterozygotes. In a further study of 213 subjects Eiselt 
et al. [17] have identified 18 new CYP3A4 variants 
of which several showed altered enzyme activity.
In the case of CYP3A5, there is also evidence of 
polymorphism in the coding [21] and promoter re­
gions [22] which may contribute to variation in the 
overall hepatic metabolism of CYP3A substrates. All
the recognised CYP3A alleles are now listed on in the 
Human Cytochrome P450 (CYP) Allele Nomenclature 
Committee home page [18].
In order to identify novel mutations in the 5' prox­
imal and distal regulatory regions of the CYP3A4 
gene we have performed a new population screening 
study. Linkage of new regulatory region mutations to 
mutations in the coding region was also examined by 
sequencing all 13 exons of the CYP3A4 gene in those 
individuals carrying the new mutations. We report 
here the discovery of three new CYP3A4 alleles des­
ignated CYP3A4*1E, CYP3A4*1F and CYP3A4*15B.
2. Materials and methods
2.1. Subject recruitment and genomic 
DNA isolation
Blood samples were obtained by phlebotomy from 
healthy subjects (41 females and 60 males) o f mainly 
Caucasian or Iranian origin. Genomic DNA was iso­
lated from whole blood using the Wizard® genomic 
DNA purification kit (Promega, UK) and used directly 
for PCR amplifications.
2.2. PCR amplifications
The specific primers used to amplify the proximal 
regulatory and distal enhancer regions of the CYP3A4 
gene are shown in Table 1. The proximal 1140 bp 5'
Table 1
Primer pairs used for PCR amplification of the CYP3A4 5' regulatory and XREM regions
Region Sequence Position^ Size (bp)
5' Proximal region
PI: 5'-GACCACTGCCCCATCATTGC-3' 
P2: 5'-GCTGGTGGAGTTGACTTAGC-3'
1201/-778 423
P3: 5'-GCACAGCCAAGAGCTCTGGC-3' 
P4: 5'-CrrGCCCTTGTCTCTATGGC-3'
-8 8 4 /-3 9 1 493
Modified PI and P6
P5: 5'-GGCACAGGCACACTCCAGGC-3'
P6: 5'-TGCTGGGCTATGTGCATGGAGC-3'
5'-cccaagcttGACCACTGCCCCATCArrGC-3'
5'-ccggaattcTGCTGGGCTATGTGCATGGAGC-3'
-4 9 3 /-6 1 433
Distal XREM
P7: 5'-ACTTCATGCAAAAATGCTGG-3' 
P8: 5'-GTTCTrGTCAGAAGrrCAGC-3'
-79 7 2 /-7 6 7 1 300
'Numbering system defines the first coding ATG as position +1.
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regulatory region was amplified as three short overlap­
ping segments to aid the single strand conformation 
polymorphism (SSCP) analysis. All PCR amplifica­
tions were carried out in a 50 p-1 reaction volume, using 
the Advantage-HF2 (high fidelity) PCR kit (Clontech, 
Palo alto, CA, USA). Each reaction contained 5 p,l of 
10 X HF2 PCR buffer, 5 p.1 of 10 x  HF2 dNTP mixture, 
1 p.1 of 50 X Advantage-HF2 polymerase mixture, 
6 pul o f relevant primer mixture (15pm ol each) and 
100-200 ng o f genomic DNA template. The reaction 
conditions for the CYP3A4 proximal 5' regulatory 
region segments were: 1 min at 94 °C for 1 cycle; 30 s 
at 94 °C, 30 s at 65 °C and 1 min at 72 °C for 30 cy­
cles; 7 min at 72 °C for 1 cycle. The same conditions
(except for the annealing temperatures) were used to 
amplify the distal XREM region and the coding ex­
ons. The annealing temperature used for amplification 
of the distal XREM region was 60 °C. PCR primers 
and annealing temperatures used for amplification of 
the individual CYP3A4 exons are shown in Table 2.
2.3. Non-radioactive Cold-SSCP analysis
An efficient Cold-SSCP technique was developed 
empirically for analysis of PCR products of up to 
500 bp in length. Previous methods had only been 
able to use the technique for analysis o f PCR prod­
ucts up to 300 bp [23-27]. Five microliters of PCR
Table 2
Primers used for PCR amplification of the CYP3A4 exons^
Primer pairs Sequence Size cDNA position PCR aimealing 
temperature (°C)
Exon 1-A* 
Exon 1-B*
5'-GTGGAGAAGCCTCTTCCAACTG-3'
5'-GGGAAAGAGAGGCCTGATTAGC-3'
357 -216/71 62
Exon 2-A 
Exon 2-B
5'-CATTGCCGTCAGAGTTACTG-3'
5'-CTGAGGCAAACCTGAGGTTC-3'
439 72/165 60
Exon 3-A 
Exon 3-B*
5'-GCTTCCTCTAACTGCCAGCAAG-3'
5'-GGCATGCAGATTCCCATTGC-3'
365 166/218 62
Exon 4-A* 
Exon 4-B
5' -GTGTC AGACTCTTGCTGTGTG-3' 
5'-GAAGTGGACGTGGAACCTTC-3'
387 219/318 60
Exon 5-A 
Exon 5-B
5'-CATCACCCAGTAGACAGTCAC-3'
5'-GGCAGCTCAAATTCAGTGGAC-3'
351 319/432 60
Exon 6-A* 
Exon 6-B*
5'-TGTCCTTCTGGGACTAGAGTC-3'
5'-GGGAGAAGATCCTTTTCCTCC-3'
351 433/521 60
Exon 7-A 
Exon 7-B
5'-CCTGTTGCATGCATAGAGG-3'
5'-GATGATGGTCACACATATC-3'
366 522/670 58
Exon 8-A 
Exon 8-B*
5'-GCrrCCAGTTGAGAACCTTG-3'
5'-CTCTTGCTCTAAACATGAGCAG-3'
393 671/798 60
Exon 9-A* 
Exon 9-B
5'-ACATCCTGCnTCCAAGGA-3'
5'-CCTGCATGCCTCTAGAAAGTG-3'
419 799/865 60
Exon 10-A 
Exon 10-B
5'-CCAGTGTACCTCTGAATTGC-3'
5'-CAGAGCCrrCCTACATAGAG-3'
430 866/1027 60
Exon 11-A* 
Exon 11-B*
5'-CCAGTATGAGTrAGTCTCTGGA-3'
5'-TGTCCTGTAGArrAAGAGAGGC-3
416 1028/1253 60
Exon 12-A* 
Exon 12-B
5'-AGGGGTGGCCCTAAGTAAG-3'
5'-GATCACAGATGGGCCTAATTG-3'
396 1254/1416 62
Exon 13-A* 
Exon 13-B*
5'-TGAAGGAGTGTCTCACTCAC-3'
5'-ACGCCAACAGTGATTACAATG-3'
735 1417/2065 60
'(*): Indicates primers modified from Sata et al. [15].
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product was mixed with 10 |xl of a denaturing-loading 
dye (95% formamide, 4M  urea, 0.1% bromophenol 
blue, 0.1% xylene cyanol FF and 0.5 p.1 15% Ficoll). 
The mixture was heated to 94 °C for 10 min and 
loaded into the wells of a 15% polyacrylamide 
(39:1 acrylamide/bis-acrylamide) gel. Each gel 
(8 cm X 7.3 cm x  1 mm) was cast using the Bio-Rad 
mini Protean set and pre-run in I x  TBE buffer 
for 1 h before loading the samples. The electrophore­
sis was carried out in a 4 °C cold room at 15 V/cm for 
65-70 h for 5' regulatory region PCR products or for 
48 h for the XREM region PCR products. After elec­
trophoresis the gels were stained with SYBR® Gold 
nucleic acid stain (Molecular Probes, Oregon, USA), 
for 30-40 min and photographed under UV light 
using a SYBR® gel stain photographic filter [28].
2 .4 .  D N A  s e q u e n c i n g
PCR products showing altered SSCP patterns were 
re-amplified from genomic DNA then purified with 
the Ultra Clean  ^^ 15 DNA purification kit (MO BIO, 
Solana beach, CA, USA). The purified samples were 
then used directly for DNA sequencing of both strands 
without any further treatment. Where a variation in 
DNA sequence from the wild-type was found, the orig­
inal PCR product was also sequenced for confirma­
tion. In the case of novel mutations, additional repeat 
amplification and sequencing was performed. In all 
samples where novel 5' regulatory region mutations 
were found, direct sequencing of PCR products from 
the 13 C Y P 3 A 4  exons was also performed to iden­
tify any linked coding region mutations. Numbering 
of nucleotides has been carried out by assigning the 
figure +1 to the base A in the translation ATG initia­
tion codon and —1 to the base before the A [18].
2 .5 .  L i n k a g e  a n a l y s i s  o f  m u t a t i o n s  
in  . s a m p le  M - 4 2
In order to determine whether the three heterozy­
gous mutations found in genomic DNA amplifica­
tions from subject M-42 were in the same allele, 
linkage analysis was performed. An initial amplifica­
tion and cloning of the 5' proximal promoter region 
(—1201/—61) was used to separate the alleles and 
determine if the 9 bp insertion at —845 was linked to
the —392 A -A- G mutation. Subsequently, long-range 
allele-specific PCR products (-858/4-14536) were 
used as templates to amplify each corresponding exon 
6 and determine whether the 5' regulatory region 
mutations were linked to the exon 6 mutation.
First the C Y P 3 A 4  proximal regulatory region in 
M-42 was amplified using modified PI and P6 primers 
(Table 1) creating H i n d l l l  and EcoRI sites at the 5 '  and 
3 ' ends of the PCR product, respectively. The restric­
tion digested and purified PCR products (PCR prod­
uct purification kit, QIAGEN, Germany) were then 
cloned into plasmid pSEAP2-Basic (Clontech, Palo 
alto, CA, USA). The recombinant plasmid DNA was 
transformed into E . c o l i  TOPI OF' (Invitrogen, CA, 
USA) cells and transformed colonies were isolated. 
Sequencing of DNA from plasmid minipreps was used 
to identify the mutant and wild-type alleles.
Secondly, 15.5 kb products from —858 bp of the 5' 
proximal regulatory region to the end of exon 6, were 
amplified from M-42 genomic DNA using a long- 
range PCR kit (TripleMaster PCR system, Eppendorf 
AG, Germany) and allele-specific forward primers 
5 -AATGACCTAAGAAGTCACCAGAA-3' (wild- 
type) or 5-AATGACCTAAGAAGATGGAGT-AG-3' 
(insertion-mutant) with a common exon 6 reverse 
primer 5 -TGGATATGTAAACCCTGGCCC-3'. The 
reaction conditions were: 2 min at 94 °C for 1 cycle; 
25 s at 94 °C, 30 s at 62 ° C  and 12 min at 68 °C for 28
23.1 kb 
9.4 kb 
6.6 kb
4.3 kb
2.3 kb ->  
2.0 kb —>
<—15.5 kb
Fig. 1. Allele-specilic long-range-PCR of the wild-type and mutant 
alleles of sample M-42 using genomic DNA as template and 
the primers described in Section 2.4. Arrow indicates the 15.5 kb 
desired PCR product. (A) Lambda DNA///mdIlI DNA marker. (B) 
Negative PCR control. (C) M-42 mutant allele PCR product. (D) 
M-42 wild-type allele PCR product.
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cycles; 10 min at 68 °C for 1 cycle. Following elec­
trophoresis, the 15.5 kb bands (Fig. 1) were extracted 
from the gel, purified with the Ultra Clean 15 DNA 
purification kit (MO BIO, Solana beach, CA, USA) 
and used as templates to re-amplify exon 6. The exon 
6 PCR products were then sequenced to identify on 
which allele the exon 6 mutation was present.
3. Results
All PCR primers were checked initially for speci­
ficity by sequencing of the PCR products. No evidence 
was found to indicate non-specific cross-amplification 
of the C Y P 3 A 5  or C Y P 3 A 7  5' regulatory regions. For 
amplification of the C Y P 3 A 4  exons the primers and 
conditions in Sata et al. [15] were used initially. In 
some instances, however the primers and annealing 
temperatures were modified to optimise the amplifi­
cations (Table 2). In the case of the primers for exons 
I and 2 these did not distinguished between C Y P 3 A 4  
and C Y P 3 A 7 ,  causing double sequence readings for 
the PCR products. However, the two sequences could 
be read manually from the sequencer printout and 
analysed for mutations by inspection.
SSCP analysis of PCR products from the —493/—61 
section of the promoter region revealed 10 samples 
with an altered electrophoresis pattern indicating 
likely mutations (Fig. 2A). These samples were re­
amplified and the PCR products were sequenced in 
both directions. The previously described C Y P 3 A 4 * 1 B  
allele (—392 A G) [13] was found to be
heterozygous in 9 out of 10 samples. A new allele 
(designated C Y P 3 A 4 * 1 E  [18]) containing a -3 6 9  
T -»  A transversion was found in sample F-14 
(Fig. 3A). The SSCP pattern of this mutation was 
not distinguishable from that of the other nine sam­
ples. In the —884/—391 section 18 samples showed 
altered SSCP patterns indicating possible mutations 
(Fig. 2B). Subsequent sequencing revealed 17 sam­
ples with a novel allele (designated C Y P 3 A 4 * I F  [18]) 
containing a —747 C ^  G transversion (Fig. 3B). The 
remaining sample (M-42) showed a nine-nucleotide 
heterozygous insertion (ATGGAGTGA) after —845 
G (Fig. 3D). This sequence has close similarity to the 
‘HFL-a’ motif in the C Y P 3 A 7  promoter region [8] 
and may have arisen by recombination. The insertion 
was also detected in the SSCP and sequencing anal­
ysis of the overlapping —1201/—778 segment of the 
M-42 promoter and was the only sample from this 
segment with an altered SSCP pattern (Fig. 2C). All 
DNA samples containing novel mutations were sub­
ject to confirmatory PCR and sequencing to eliminate 
the possibility of PCR artefacts.
Sequencing results for the 13 exons of the C Y P 3 A 4  
gene for samples with new mutations in the 5' regula­
tory region showed no mutations in the coding region 
except in the case of sample M-42 where a heterozy­
gous G ^  A transition in exon 6 (cDNA position 
485), creating R162Q in the protein structure, was 
found (Fig. 3D). It should be noted that in addition to 
the insertion at —845 this sample also contained het­
erozygous ly a —392 A ^  G transition [13]. Results of 
the linkage analysis revealed that the three mutations
(A) (B)
1
B
Q
M WT M WT
(C)
WT
F'ig. 2. Representative non-radioactive SSCP of CYP3A4 5' regulatory region PCR products. M and WT indicate mutant and wild-type 
samples. (A-C) Indicate SSCP patterns for mutant and wild-type samples in the -4 9 3 /-6 1 , -8 8 4 /-3 9 1  and -1 2 0 1 /-7 7 8  sections of the 
5' regulatory region, respectively. Arrows show the site of appearance of extra SSCP bands indicating likely mutations.
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-3 6 9
(A)
-747
100 v  n o
0 T OT OT O T A C A  O C A C g C T O O T A G O O A
(B)
-8 4 5
310 320 ^  330 340
T T A  A T G A C  C T A A G A A G  A ■ C C G A G A G  A C  C AG  G
350 360 370
C A G GC A . G G C  • C A G - C - C A G C  1
TCACCAGAAAGTCAGAAGGGATGACATGCAGAGGCCCAGCAATCTCAGC
ATGGAGTAGTCACCAGAAAGTCAGAAGGGATGACATGCAGAGGCCCAGC
(C)
485 (cDNA)
80 90 100
A A A T C T  G A G G C A G O O A A O C A G A O
(D)
-845 -392 485 (cDNA)
50 ^ 9 0  100
A T C T  O A G O C A G G A A G C A G A G A C . i
500 310
G A G A Ç A  A 0 0 0  C A G O  AO A G A O O C  G A I
520
\ C  CT AA G  AAG AT 0  0  . -.OTA G TCAC
(E)
Fig. 3. Sequence confirmation of novel mutations identified by SSCP. (A-C) Indicate tlie heterozygous —369 T A, —747 C ^  G 
and nine-nucleotide insertion (after -8 4 5  G, underlined) mutations respectively. In (C) the double sequence read out due to the insertion 
and its normal interpretation are demonstrated. (D) Indicates the heterozygous G ^  A mutation in exon 6 of sample M-42. (E) Shows 
sequence data from the CYP3A4* I5B  allele in sample M-42 containing the three linked mutations.
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identified in sample M-42 were located on the same 
allele, designated CYP3A4*15B [18], (Fig. 3E).
No mutations were found in the CYP3A4 distal 
XREM enhancer region indicating high sequence con­
servation in this essential regulatory element.
4. Discussion
The discovery of variant alleles for the enzymes 
CYP2D6, CYP2C19, CYP2C9, CYP2A6 and 
CYP3A5 which markedly influence the activity or 
expression of these enzymes [22] has added impe­
tus to the search for CYP3A4 variants which may 
similarly affect the hepatic CYP3A4 phenotype.
A report by Rebbeck et al. [13] that a —392 A  
G transition in the CYP3A4 promoter may be associ­
ated with a higher clinical stage and grade of prostate 
tumours challenged investigators to determine if  this 
variant indeed had any impact on CYP3A4 activity. It 
also greatly encouraged population-screening efforts 
to investigate the frequency of this variant and to iden­
tify other mutations in the promoter or coding regions 
of CYP3A4. Our results for this mutation indicated a 
frequency o f 9.6% in the Caucasian population, a fig­
ure in agreement with previous authors [20]. In the 
Iranian samples the frequency was lower at 6%.
The initial goal of this study was the identification 
of novel mutations in the promoter of the CYP3A4 
gene and determination o f their frequencies. In fact we 
have extended the work of previous authors by scan­
ning the 5' proximal regulatory region up to —1140 bp 
and including the XREM at —7.9kp. We have identi­
fied three new mutations in the 5' proximal regulatory 
region. The —369 T ^  A transversion which was 
found only in one Caucasian subject may have some 
effect on enzyme expression because of its proxim­
ity to the CAAT box and other regulatory motifs. The 
—747 C -A- G transversion is a mutation with rela­
tively high frequency, i.e. 20% in Caucasian and 18% 
in Iranian populations. This mutation is not located 
in or near a known transcriptional element and might 
thus have little or no effect on gene expression.
Perhaps the most surprising of our findings is the 
genotype of subject M-42. This Caucasian male has 
inherited an allele containing a nine-nucleotide inser­
tion after —845 G, a —392 A ^  G transition [13], 
and a G ^  A transition in exon 6 (resulting in
R162Q). There has been a substantial debate regard­
ing the effects o f the —392 A ^  G transition on 
enzyme level [19,20] and this issue has yet to be 
resolved. However, an insertion of nine nucleotides at 
position —845 (which is identical in eight out of nine 
nucleotides to the ‘HFL-a’ response element in the 
CYP3A7 promoter) makes this region of the CYP3A4 
gene in this allele similar to CYP3A7. Since, CYP3A7 
expression is repressed in adult liver and ‘HFL-a’ is 
one of the few substantial differences between the 
CYP3A4 and CYP3A7 promoter regions this insertion 
may cause down-regulation of CYP3A4 expression 
from this allele, hi the case of the linked mutation in 
M-42 exon 6 the conservative substitution of arginine 
for glutamine may not have a substantial effect on 
enzyme activity [29-31]. We are presently investigat­
ing in vitro the possible impact of the novel alleles 
on hepatic CYP3A4 gene expression.
In summary, we have further developed a simple, 
non-radioactive SSCP analysis method so that it can 
reliably detect single nucleotide changes in PCR prod­
ucts of up to 500 bp in length. We have utilised this 
system to identify novel mutations in the 5' promoter 
region of the human CYP3A4 gene.
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POLYMORPHIC VARIATION IN THE CYP3A4 GENE 5' REGULATORY REGION: 
EFFECT ON XENOBIOTIC TRANSCRIPTIONAL INDUCTION.
Hossein Ham zeiy, Nasser Vahdati-M ashhadian, Helen J. Edwards, G em m a L  S w a is land , Peter S. Goldfarb I 1 I
Toxicology Group, School of Biomedical and Life Sciences, University of Surrey, Guildford, Surrey G U 2 7XH, UK  ^ I
iduction
A4 is usually the major cytochrome P450 enzyme in adult 
1 liver. It is known to metabolise a wide variety of xenobiotic 
idogenous compounds. Substantial inter-individual variation 
)atic levels of CYP3A4 has been observed and although 
orphIc mutations have been reported in both the 5‘ 
tory and coding regions of the CYP3A4 gene, those 
gated [1] so far do not appear to make a major contribution 
P3A4 variation in the population as a whole. To determine 
sr regulatory mutations might occur in more distal regions of 
jmoter, we have performed a new population screening on a 
of 101 human DNA samples.
llts
)p of the proximal 5' regulatory region of the CYP3A4 gene 
00 bp of the distal enhancer region at -7 ,9  kb, both 
ling numerous regulatory motifs, were amplified from 
lie DNA, Screening for mutations in the resulting PCR 
Its was carried out using non radioactive single strand 
mation polymorphism (SSCP), Analysis of PCR products 
the proximal 5' regulatory region (amplified as three 
iping segments) revealed several samples with altered 
phoretic patterns (Fig 1),
lepresentative non-radioactive SSC P of the CYP3A4  gene regulatory 
^CR products, (A-G) patterns for mutant (M) and wild-type (WT) 
1 in the -4 9 3 /-6 1 ,-8 8 4 /-3 9 1  and -1 2 0 1 /-7 7 8  segm ents respectively, 
ndicate the p resence of additional bands In the S SC P  pattern,
iant electrophoretic pattems were found in PCR products 
le  distal enhancer region (amplified as two overlapping 
nts) indicating extensive consen/ation of sequence in this 
al regulatory region. The presence of proximal 5' regulatory 
mutations was confirmed by sequencing of both DNA 
! in the original and freshly amplified PCR products (Fig 2),
ilM'M/Lk,
485 (cDNA)
W '
485 (cDNA)
/m illA , û ü
)NA seq u en ce  confirmation of novel m utations identified by SSCP, 
licatethe heterozygous -3 6 9  T ^ A , -7 4 7  C -^ G  and, 9 nucleotide 
(after -8 4 5  G,underlined) respectively, (D) indicates the 
jous G—>A mutation in exon 6 ofsubject IVI42, (E) show s seq u e n ce  
I the novel CYP3A4'15B  allele from subjectM 42 containing the three 
rtations.
In addition to detection of the previously reported 
CYP3A4*1B allele [2] in ninesubjects, three novel 
alleles were found: CYP3A4*1E (having a T ^ A  
transversion at -369 in one subject), CYP3A4*1F 
(having a C->G transversion at -747 in 17 subjects) 
and CYP3A4*15B having a nine-nucleotide insertion 
between -845 and -844linked to an A->G transition 
at -392 and a G ^ A  transition in exon 6 (position 485 
in the cDNA) in one subject [3], In all samples where 
novel CYP3A4 regulatory region mutations were 
found, direct sequencing of PCR products from all 13 
exons was performed to identify any linked coding 
region mutations. As indicated in Fig 2 one such 
mutation was found in subject M42, Linkage of the 
three mutations in M42 was confirmed using cloning 
and long range PCR to separate the alleles.
Functional analysis of the regulatory region mutants 
was performed in vitro using reporter DNA constructs 
in wfiich the whole 1140 bp proximal promoter region 
from each mutant allele was inserted between a 
single copy of the 300 bp core distal enhancer 
sequence and the cDNA for human secreted 
alkaline phosphatase (SEAP), The individual reporter 
constructs were co-transfected with an hPXR 
expression vector into human liver (HepG2, HuH7) 
and intestinal (Caco-2) cell lines, Xenobiotic 
modulation of CYP3A4 promoter activity was 
measured by chemiluminescent SEAP assay (Fig 3),
Fig 3. Dose response curve for rifampicin induction of SEAP 
expression from the wild-type and IVI42 CYP3A4  prom oters in 
hPXR co-transfected HepG2 cells (n=6, P<0,01 at 10-40 piM),
While there was close similarity between the xenobiotic 
induction patterns for wild type and mutant promoters in 
HepG2 and HuH7 cells, the pattern in Caco-2 cells was 
substantially different (Fig 4), Significant variation in 
promoter strength was found among the mutant 
CYP3A4 alleles depending on the Inducer used and the 
recipient cell line. Also different induction pattems were 
observed in different cell lines with different CYP3A4 
inducers (most notably by phénobarbital and 
mifepristone). This indicates the role of endogenous 
transcription factors (such as CAR and PXR) and their 
concentration relative to each other.
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Transfection of wild type and mutant containing reporter 
constructs in HepG2, HuH7 and Caco-2 cells, in 
general, produced similar pattem of Induction by the 
same drugs. The only exception was phénobarbital 
which produced more induction with all CYP3A4 alleles 
in HuH7 and Caco-2 cells compared to FlepG2 cells,
Flowever, the Induction pattern of the CYP3A4 alleles 
was substantially different in Caco-2 cells. Only the 
M-42 reporter construct showed a significantly different 
(increased) activity in comparison to the wild type 
promoter in this cell line. This may suggest the 
possibility of binding of a specific transcription factor to 
the nine-nucleotide insertion site in the M-42 promoter in 
these cells. Further studies are required to evaluate this 
assumption,
UNIVBffiSiTV OF îaiRR FV
W T M -42  M -18 F -27  F-14
Fig 4, Xenobiotic induction of SEAP expression from wild-type and  m utant 
CY3A4 promoters in different cell lines, M 42:CYP3A4‘15B, ^^^3:CYP3A4*1F, 
F 27:C Y P 3A riB , F14:CYP3A4*J£, □  DMSO; H D E X  10 ,utV I;D PB 1 mlVl; 
□  CLTZ, ■  MIF, □  RIF and ■  RIF without hPXR 10 p.lVt,
Conclusions
The evidence presented in this report suggests that inherited 
mutations in the CYP3A4 gene 5' regulatory region can 
significantly affect in vitro transcriptional responses to different 
xenobiotic inducers. However, considering the different activation 
profiles of the mutant alleles In different cell types, it can be 
deduced that these responses are depend on the cellulat 
environment, the availability of the transcription factors goveming 
the expression of a specific gene in a specific tissue and the 
presence of endogenous or xenobiotic ligands and theii 
concentrations.
Finally, in spite of a great deal of effort to search for genetic 
factors goveming the inter-individual variability in CYP3A enzyme 
expression during last four years and the identification of a long 
list of mutations in both coding and regulatory regions of the 
CYP3A4 gene (http://ww,imm,ki,se/CYPalleles/cyp3a4,htm), a 
genetic polymorphism with a conclusive and clear functional effeci 
on GYP3A4 activity has yet to be identified.
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